Assessment of potential antibacterial drug targets by Diaz Saez, Laura
 
 
A thesis submitted for the degree of Doctor of Philosophy 
 
 
 
 
ASSESSMENT OF POTENTIAL 
ANTIBACTERIAL DRUG TARGETS 
 
Laura Díaz Sáez 
 
Supervisor:  
Professor William N. Hunter 
 
 
 
 
 
 
 
School of Life Sciences 
University of Dundee  
November 2015 
 
Table of contents 		 I 
TABLE OF CONTENTS 
 
Table of contents ............................................................................................................ I 
List of figures .............................................................................................................. VII 
List of equations and tables ........................................................................................ XI 
List of abbreviations ................................................................................................. XIII 
Acknowledgments ..................................................................................................... XVI 
Declaration ............................................................................................................... XVII 
Abstract ................................................................................................................... XVIII 
Part One: Introduction 
1.1 Antibacterial drugs and resistance ............................................................................. 1 
1.2 Strategies for antibacterial drug development ........................................................... 2 
1.2.1 The Past .............................................................................................................. 2 
1.2.2 The present ......................................................................................................... 3 
1.2.2.1 The Void Age ........................................................................................... 3 
1.2.2.2 Drug discovery strategies ......................................................................... 5 
1.2.2.3 Target selection approaches ..................................................................... 8 
1.2.3 The future ......................................................................................................... 11 
1.3 Biowarfare agents .................................................................................................... 12 
1.4 Aim and objectives .................................................................................................. 14 
Part Two: Selection and prioritisation of potential targets 
2.1 Target selection strategy .......................................................................................... 15 
2.1.1 Candidates for target selection ......................................................................... 15 
2.1.2 Assessment of selection criteria ....................................................................... 16 
2.1.2.1 Traffic light score ................................................................................... 17 
Table of contents 		 II 
2.2 Selected targets ........................................................................................................ 18 
2.2.1 First selected targets ......................................................................................... 19 
2.2.2 Second selected targets .................................................................................... 20 
2.3 Target prioritisation ................................................................................................. 23 
Part Three: Kynurenine formamidase 
3.1 Introduction ............................................................................................................. 24 
3.2 Experimental procedures ......................................................................................... 28 
3.2.1 Recombinant protein production ..................................................................... 28 
3.2.2 Crystallographic analysis ................................................................................ 30 
3.2.2.1 Crystallisation and diffraction measurements ....................................... 30 
3.2.2.2 Structure determination ......................................................................... 33 
3.2.2.3 Cation identification .............................................................................. 34 
3.2.2.4 Purification and structure determination of BaKynB in the presence of 
EDTA ..................................................................................................... 36 
3.2.2.5 Analysis of models and structure comparisons ..................................... 38 
3.2.3 Enzymatic assay .............................................................................................. 38 
3.2.4 Tryptophan fluorescence: fluorescence spectroscopy ..................................... 39 
3.3 Results and discussion ............................................................................................ 40 
3.3.1 Recombinant protein production ..................................................................... 40 
3.3.2 Crystallisation and structure determination .................................................... 41 
3.3.3 KynB structure ................................................................................................ 44 
3.3.3.1 Overall structure and dimer formation .................................................. 44 
3.3.3.2 The KynB active site ............................................................................. 46 
3.3.3.3 Reaction mechanism ............................................................................. 50 
3.3.4 Enzyme kinetics .............................................................................................. 51 
Table of contents 		 III 
3.3.5 Fluorescence spectroscopy of BaKynB ........................................................... 55 
3.4 Conclusions ............................................................................................................. 56 
Part Four: D-alanine—D-alanine ligase  
4.1 Introduction ............................................................................................................. 58 
4.2 Experimental procedures ......................................................................................... 65 
4.2.1 Recombinant protein production ..................................................................... 66 
4.2.2 Crystallographic analysis ................................................................................. 67 
4.2.2.1 Protein crystallisation ............................................................................ 67 
4.2.2.2 Diffraction and structure determination ................................................ 68 
4.2.2.3 Ligand identification ............................................................................. 70 
4.2.2.4 Further structural analysis ..................................................................... 72 
4.2.3 AMP detection ................................................................................................ 73 
4.2.4 Enzyme kinetics: coupled enzymatic assay .................................................... 75 
4.2.4.1 D-alanine Km determination .................................................................. 76 
4.2.4.2 ATP Km determination .......................................................................... 77 
4.2.4.3 D-cycloserine and fosmidomycin inhibition assays .............................. 78 
4.2.4.4 Ddl activity at different pH values ........................................................ 79 
4.2.5 Enzyme kinetics: malachite green assay and high-throughput assay 
development .................................................................................................... 80 
4.2.5.1 Optimisation of enzyme concentration ................................................. 81 
4.2.5.2 D-alanine Km determination .................................................................. 82 
4.2.5.3 ATP Km determination .......................................................................... 84 
4.2.5.4 Time course experiment ........................................................................ 85 
4.2.5.5 Determination of DMSO tolerance and D-cycloserine IC50 ................. 85 
4.2.6 ELF library screen ........................................................................................... 87 
Table of contents 		 IV 
4.2.6.1 Validation of hits ................................................................................... 87 
4.2.7 Small diversity set screen ................................................................................ 89 
4.2.7.1 Assay development and screening ........................................................ 89 
4.2.7.2 Validation of hits ................................................................................... 89 
4.2.8 Biolayer interferometry and a fragment library screen ................................... 90 
4.2.8.1 Experimental set up ............................................................................... 92 
4.2.8.2 Validation of hits ................................................................................... 93 
4.3 Results and discussion ............................................................................................ 95 
4.3.1 Recombinant protein production ..................................................................... 95 
4.3.2 Crystallisation and structure determination ..................................................... 97 
4.3.3 Ddl structure  ................................................................................................. 100 
4.3.3.1 Overall structure .................................................................................. 100 
4.3.3.2 Co-factor and substrate pockets .......................................................... 105 
4.3.3.3 Conformational change ....................................................................... 108 
4.3.3.4 Druggability ........................................................................................ 110 
4.3.4 Biochemical characterisation ........................................................................ 111 
4.3.4.1 Enzyme kinetics .................................................................................. 111 
4.3.4.2 AMP detection .................................................................................... 115 
4.3.5 BLI: Fragment library screen ........................................................................ 117 
4.3.6 HTP screens ................................................................................................... 121 
4.3.6.1 EFL library screening .......................................................................... 121 
4.3.6.2 DDU small diversity set screening ...................................................... 125 
4.4 Conclusions ........................................................................................................... 127 
Part Five: Caseinolytic protease subunit P 
5.1 Introduction ........................................................................................................... 129 
Table of contents 		 V 
5.2 Experimental procedures ....................................................................................... 131 
5.2.1 Recombinant protein production ................................................................... 131 
5.2.2 Crystallographic analysis .............................................................................. 132 
5.2.2.1 Crystallisation ..................................................................................... 132 
5.2.2.2 Diffraction measurements and structure determination ...................... 132 
5.2.2.3 Further structural analysis ................................................................... 134 
5.3 Results and discussion .......................................................................................... 135 
5.3.1 Recombinant protein production ................................................................... 135 
5.3.2 Crystallisation and diffraction ....................................................................... 137 
5.3.3 ClpP structure ................................................................................................ 139 
5.3.3.1 ClpP complex analysis ........................................................................ 141 
5.4 Conclusions ........................................................................................................... 143 
Part Six: Dihydrofolate synthase:folyl-poly-glutamate synthase 
6.1 Introduction ........................................................................................................... 145 
6.2 Experimental procedures ....................................................................................... 148 
6.2.1 Recombinant protein production ................................................................... 148 
6.2.2 Differential scanning fluorimetry .................................................................. 149 
6.2.3 Crystallisation and diffraction ....................................................................... 149 
6.2.4 Enzyme kinetics ............................................................................................ 151 
6.2.4.1 Coupled spectrophotometric assays .................................................... 152 
6.2.4.2 Malachite green assay ......................................................................... 153 
6.2.5 Tryptophan fluorescence ............................................................................... 153 
6.3 Results and discussion .......................................................................................... 154 
6.3.1 Recombinant protein production ................................................................... 154 
6.3.2 Differential scanning fluorimetry .................................................................. 154 
Table of contents 		 VI 
6.3.3 Crystallisation and diffraction ....................................................................... 155 
6.3.4 Enzyme kinetics ............................................................................................ 157 
6.3.5 Tryptophan fluorescence ............................................................................... 158 
6.4 Conclusions ........................................................................................................... 159 
Part Seven: Conclusions ........................................................................................... 160 
Appendix A: Results from TraDIS and the target selection criteria analysis has been 
added for the 75 considered candidates ............................................................. 164 
Appendix B: Structural comparisons of KynB monomers and dimers ...................... 170 
Appendix C: Resume of the work carried out with other potential targets; FabZ, FtsZ, 
MsbA, RsmH, PyrG and NorM 
C.1 Introduction .......................................................................................................... 172 
C.1.1 FabZ .............................................................................................................. 172 
C.1.2 FtsZ ............................................................................................................... 173 
C.1.3 MsbA ............................................................................................................ 173 
C.1.4 RsmH ............................................................................................................ 174 
C.1.5 PyrG ............................................................................................................. 174 
C.1.6 NorM ............................................................................................................ 175 
C.2 Experimental procedures ...................................................................................... 175 
C.3 Results .................................................................................................................. 179 
References .................................................................................................................. 182 
Publication ................................................................................................................. 228 
 
 
List of figures  	 VII 
LIST OF FIGURES 	
1.1 Chart showing the number of new antibacterial classes over time and 
different strategies used for drug search. 
 
3 
2.1 Schematic of TraDIS method. 15 
2.2 Prioritisation of the targets during the course of the project. 23 
3.1 Tryptophan degradation pathway via L-kynurenine. 25 
3.2 Cartoon representation of DmKFase. 26 
3.3 PaKynB crystals. 41 
3.4 BaKynB diffracting crystals. 41 
3.5 Cartoon representation of BaKynB dimer. 44 
3.6 Alignment of BaKynB, PaKynB and BcKynB amino acid sequences. 45 
3.7 (A) Overlay of the Cα atoms from BaKynB, PaKynB and BcKynB. (B) 
Surface representation of the BaKynB dimer. 
 
46 
3.8 KynB active site. 47 
3.9 XANES spectra. 48 
3.10 Anomalous difference Fourier map for BcKynB. 48 
3.11 2-aminoacetophenone in the BaKynB active site. 49 
3.12 (A) Cartoon representation of the Cα overlay of BaKynB and isatin 
hydrolase. (B) Sticks representation of the active sites pockets. 
 
50 
3.13 Proposed reaction mechanism. 51 
3.14 (A) Initial velocity plotted against substrate concentration. (B) Initial 
velocity against substrate concentration at three different pH values. 
 
53 
3.15 Difference Fourier peaks for metal sites. 55 
3.16 Emission spectra from BaKynB using an excitation wavelength of 290 nm. 55 
3.17 Plot of the percentage of enzyme saturation against L-kynurenine and   
List of figures  	 VIII 
2-aminoacetophenone concentration. 56 
4.1 Schematic of the peptidoglycan layer. 59 
4.2 A proposed mechanism for Ddl. 61 
4.3 Examples of Ddl inhibitors. 63 
4.4 Experimental flow chart. 65 
4.5 Microseeding procedure scheme. 67 
4.6 AMP-Glo kit reactions. 73 
4.7 Plate layout for the AMP detection experiment. 74 
4.8 Enzymatic assay scheme. 75 
4.9 Layout of the plate for the enzyme titration experiment. 82 
4.10 Plate layout for the Km determination experiments. 83 
4.11 Plate layout for the Km determination experiments. 84 
4.12 Time course experiment plate layout. 85 
4.13 The dose-response experiment plate layout. 86 
4.14 Dose-response experiment plate layout. 90 
4.15 A scheme of BLI signal detection. 90 
4.16 (A) SEC chromatogram for FtDdl and BpDdl. (B) Equilibration curves 
with FtDdl and BpDdl peaks plotted. 
 
95 
4.17 Native-PAGE 3-12%. 97 
4.18 (A) BpDdl crystals. (B) FtDdl crystals. (C) Optimised BpDdl crystals. 98 
4.19 Cartoon representation of the BpDdl:AMP-2 structure. 100 
4.20 Alignment of BpDdl, FtDdl, BaDdl, EcDdl and MtDdl. 101 
4.21 Stereo view of the Cα overlay of subunit A and B from BpDdl:D-Ala—D-
Ala. 
 
102 
4.22 Structural comparisons. 102 
List of figures  	 IX 
4.23 Stereo view of the overlay of BpDdl:AMP-2 and glycinamide 
ribonucleotide synthetase. 
 
105 
4.24 (A) ATP binding pocket. (B) D-Ala binding pocket. 106 
4.25 Overlay of BpDdl:D-Ala—D-Ala and EcDdl. 107 
4.26 (A) Ribbon diagram of the superposition of the apo-BpDdl and 
BpDdl:AMP-2. (B) Residues implicated in co-factor binding. 
 
108 
4.27 Electrostatic surface representation of (A) apo-BpDdl and (B) 
BpDdl:AMP-2 structures. 
 
110 
4.28 BpDdl pockets. 111 
4.29 pH effect on the reaction velocity. 114 
4.30 (A) Double reciprocal plot for the DCS inhibition. (B) Plot of the slopes 
from the reciprocal plot against the concentration of DCS. 
 
115 
4.31 AMP detection result. 116 
4.32 Spectrophotometric assay. 117 
4.33 Enzyme titration experiment. 122 
4.34 (A) DMSO dose-response curve to determine DMSO tolerance. (B) DCS 
dose-response curve. 
 
122 
4.35 (A) Result of the ELF library screening represented as the percentage of 
inhibitory effect against the plate number. (B) Result of the ELF library as 
the compounds distribution along the percentage of effect. 
 
 
123 
4.36 Dose-response curves and structures of hit compounds for the ELF screen. 125 
4.37 (A) Result of the DDU diversity set represented as the percentage of 
inhibitory effect against the compound ID. (B) Result of the DDU diversity 
set represented as the compounds distribution along the percentage of 
effect. 
 
 
 
127 
List of figures  	 X 
5.1 Scheme of Clp protease function. 129 
5.2 (A) SEC results in the absence and presence of 10% glycerol. (B) Native-
PAGE 3-12%. 
 
135 
5.3 MALDI-TOF mass spectrometry result for FtClpP. 136 
5.4 FtClpP crystals and diffraction pattern. 137 
5.5 (A) Cartoon representation of the Cα alignment of monomers from 
FtClpP:open and FtClpP:compressed. (B) Active site pocket showing the 
catalytic triad residues. 
 
 
140 
5.6 Sequence alignment of FtClpP, BsClpP, EcClpP and MtClpP. 140 
5.7 Structural insights into FtClpP:Form-II, and FtClpP:Form-I. 142 
6.1 Schematic of the folyl-poly-glutamate biosynthesis pathway. 146 
6.2 Scheme of the assays tried for measuring FolC activity. 155 
6.3 Results of YpFolC DSF represented by the Tm (ºC). 155 
6.4 (A) YpFolC optimised crystal. (B) Diffraction pattern from collected data 
on the in-house X-ray generator. (C) Electron density and difference maps 
at the ATP binding pocket of YpFolC. 
 
 
156 
6.5 (A) Result from YpFolC enzyme titration experiment. (B) Plot 
representation of YpFolC results in A. 
 
158 
6.6 YpFolC tryptophan fluorescence result. 158 	
List of equations and tables 		 XI 
LIST OF EQUATIONS AND TABLES 
 
Equations 
4.1 General equation for Ddl mechanism. 76 
4.2 (A) Michaelis-Menten equation. (B) Double reciprocal equation for Km1 
calculation. 
 
76 
4.3 Substrate inhibition. 78 
4.4 (A) Double reciprocal equation for competitive inhibition. (B) Secondary 
representation for inhibitory data. 
 
78 
4.5 Z’ score equation. 85 
4.6 Percentage of effect equation. 87 
 
Tables 
1.1 Summary of B. anthracis, Y. pestis, B. pseudomallei and F. tularensis 
characteristics. 
 
13 
2.1 Traffic light score definitions for criteria classification. 18 
2.2 Target selection criteria and traffic light score. 22 
3.1 Protein production details for KynB. 30 
3.2 Analysis of the metal ion sites in BaKynB-EDTA and BaKynB-EDTA-
Cd2+ structures. 
 
37 
3.3 Crystallographic statistics. 42 
3.4 Crystallographic statistics. 43 
3.5 Kinetic parameters of KynB samples. 52 
3.6 Summary of the EDTA experiment results. 54 
4.1 Crystallographic statistics summary of data sets from the Diamond Light 
Source beamline I04-1. 
 
69 
List of equations and tables 		 XII 
4.2 Buffers used for the determination of the pH effect curve. 79 
4.3 Assay plate time points. 81 
4.4 Assay plate time points. 83 
4.5 Information on compounds tested as potential inhibitors. 94 
4.6 Crystallographic statistics. 99 
4.7 Comparison of BpDdl with orthologues. 104 
4.8 Ddl kinetic parameters. 113 
4.9 Fragment screening hit compounds and their binding signal. 119 
4.10 Results from the dose-response experiment for 13 hit compounds. 124 
5.1 Missing residues from models FtClpP:Form-I and FtClpP:Form-II. 134 
5.2 Crystallographic statistics. 138 
6.1 Crystallographic statistics. 156 
A.1 Target selection criteria and traffic light score. 165 
B.1 Results of the Cα overlay between BaKyB and BcKynB subunits. 170 
B.2 Results of the Cα overlay between PaKynB, BaKyB and BcKynB subunits. 170 
B.3 Results of the Cα overlay between PaKynB, BaKyB and BcKynB dimers. 171 
C.1 Material procedures information for FabZ, FtsZ, MsbA, RsmH, PyrG and 
NorM from B. anthracis, Y. pestis, B. pseudomallei, P. aeruginosa. 
 
178 
C.2 Results resume from work carried out on FabZ, FtsZ, MsbA, RsmH, PyrG 
and NorM from B. anthracis, Y. pestis, B. pseudomallei and P. aeruginosa. 
 
179 
C.3 Hits from YpPyrG fragment screening. 180 
 
List of abbreviations 		 XIII 
LIST OF ABBREVIATIONS 
 
Abbreviations were conducted following the International Union of Pure and Applied 
Chemistry (IUPAC, www.chem.qmul.ac.uk/iupac) and the International Union of 
Biochemistry and Molecular Biology (IUBMB, www.chem.qmul.ac.uk/iubmb) 
nomenclature. Proteins and compound abbreviations follow BRENDA (www.brenda-
enzymes.org) and Acronyms-Abbreviations (www.chemie.fu-berlin.de/cgi-
bin/acronym) databases. Amino acids are represented with the three or one letter 
identifier, and atoms as their elemental symbol. Standard SI abbreviations are used 
except Ångstrom (Å, 10-10 m). Additional abbreviations as follows: 
 
AAA+ ATPases associated with various cellular activities 
AChRs Acetylcholine receptors 
ACP Acyl-carrier-protein 
Ba Bacillus anthracis 
Bc Burkholderia cenocepacia 
Bce Bacillus cereus 
BLI Biolayer interferometry 
Bm Bombyx mori 
Bp Burkholderia pseudomallei 
Bs Bacillus subtilis 
Bt Bos taurus 
D-Ala:LA D-Ala bound to LA by an ester bond 
Cb Coxiella burneii 
CDC The U.S. centers for disease control and prevention 
List of abbreviations 		 XIV 
DCS D-cycloserine 
DDM n-dodecyl β-D-maltoside 
DDU Drug discovery unit 
DEG Database of essential genes 
DHF Dihydrofolate 
DHPPP 6-hydroxymethyl-7,8-dihydropterin pyrophosphate 
DLID Drug-like density score 
Dm Drosophila melanogaster 
DSF Differential scanning fluorimetry 
Dstl Defence science and technology laboratory 
Ec Escherichia coli 
ELF European lead factory 
FASI Fatty acid biosynthetic pathway type I 
FASII Fatty acid biosynthetic pathway type II 
FFT Fast Fourier transform 
gDNA Genomic DNA 
GSK GlaxoSmithKline 
Hp Helicobacter pylori 
H2Pte Dihydropteroate 
Hs Homo sapiens 
HTP High-throughput 
InF Intensity of fluorescence 
LA Lipoteichoic acid 
Lc Lactobacillus casei 
Lm Listera monocytogenes 
List of abbreviations 		 XV 
MALDI-TOF Matrix-assisted laser desorption/ionization time-of-flight. 
MATE Multidrug and toxic compounds extrusion 
mDAP meso-diaminopimelate 
MIC Minimum inhibitory concentration 
Ml Microcuccus luteus 
MRSA Methicillin-resistant Sa 
MS Mass spectrometry 
Mt Mycobacterium tuberculosis 
MTX Methotrexate 
N Number of molecules in the asymmetric unit 
NAcGlc N-acetyl-glucosamine 
NAcMur N-acetyl-muramic acid 
NCS Non-crystallographic symmetry 
NFK N-formyl-L-kynurenine 
Ng Neisseria gonorrhoeae 
Ni-NTA Tris-nitriloacetic acid (tris-NTA) charged with Ni2+ 
NMDARs N-methyl-D-aspartate glutamate receptors 
Pa Pseudomonas aeruginosa 
PDB Protein data bank 
PG Peptidoglycan 
Pf Plasmodium falciparum 
QED Quantitative estimate of drug-likeness 
Rm Ralstonia metallidurans 
r.m.s.d. Root mean square deviation 
Rn Rattus norveqieus 
List of abbreviations 		 XVI 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SPR Surface plasmon resonance 
rRNA Ribosomal RNA 
Sa Staphylococcus aureus 
Sc Saccharomyces cerevisiae 
s.d. Standard deviation 
Se Salmonella enterica 
SEC Size-exclusion chromatography 
Sf Streptococcus faecalis 
Sm Streptococcus mutants 
Sp Streptomyces parvulus  
Sp Streptococcus pneumoniae 
TEV Tobacco etch virus 
THF Tetrahydrofolate 
TKO Genome-transposon knock-outs 
TraDIS Transposon-directed insertion site sequencing 
Vm Matthews coefficient 
XANES X-ray absorption near-edge structure 
Xo Xantomonas oryzae 
Yp Yersinia pestis 
 
Acknowledgments  	 XVI 
ACKNOWLEDGMENTS 
 
I would like to express all my gratitude to the people without whom this research would 
not have been possible: 
First to Bill Hunter who welcomed me in his lab and whom I thank for all the 
mentorship, advice, motivation, teaching and patience during these three years. Also for 
recommendations of unforgettable Scottish wonders. 
To my labmates who always helped and taught me, and became valuable friends. 
My special thanks to Alice Dawson, who proof-read this thesis, and Paul Fyfe for their 
advice on X-ray diffraction data collection and structure determination. Also to 
Velupillai Srikannathasan for introducing me to the KynB project, Martin Zoltner for 
his teaching on membrane protein production and crystallisation, Thomas Eadsforth for 
advise on my first assay optimisation, and the Brazilian gang (Carla Gottschald, 
Gustavo Mercaldi and Renata Reis) for our science and life talks.  
To Stuart McElroy and his team at the ELF, and the DDU screening team, in 
particular Leah Torrie, who gave advice and support on HTP assays and compound 
library screens. Also, special thanks to the Dstl for funding and their strategic 
contributions. 
To Laura Riolobos (my first mentor), Mark van Raaij and Carmela García for 
showing me the fun of science when I was an undergraduate. 
Last but not least, I would like to thank my parents (Charo and Luis), sister 
(Julia) and friends, especially to Jana Alonso, for all the unconditional support received 
during these years in both thesis and personal life. Thank you! 
 
I will never forget your friendship and everything I have learnt. Thank you all for 
making these three years one of the greatest experiences I ever had. 
Declaration  	 XVII 
DECLARATION 
 
I thereby declare that the following thesis is based on the results of investigations 
conducted by myself, and that this thesis is of my own composition. This thesis has not, 
in whole or part, been previously presented for a higher degree. Work other than my 
own is clearly indicated in the text by reference to the relevant researchers or 
publications. I would like to thank those people who allowed me to refer to their 
unpublished observations and data, which are individually acknowledged where they 
occur. 
 
 
 
 
Laura Díaz Sáez 
 
 
 
The work presented in this thesis is the work of the candidate Laura Díaz Sáez. 
Conditions of the relevant Ordenance and Regulations have been fulfilled. 
 
 
 
 
Professor William N. Hunter 
Abstract  	 XVIII 
ABSTRACT 
 
The alarming increase in antibacterial drug resistance indicates an urgent need to 
develop new drugs. This project aimed to assess and select potential antibacterial targets 
and carry out initial biochemical characterisation concentrating on enzymes from 
biowarfare agents Bacillus anthracis, Burkholderia pseudomallei, Francisella 
tularensis and Yersinia pestis. The overall objective is to combine genetic and chemical 
studies to validate, or not, targets for early stage drug discovery. 
 
In collaboration with the Dstl (Defence Science and Technology Laboratory), a series of 
potential targets were selected. This was carried out using essentiality prediction data 
from the Dstl labs, information at AEROPATH and ChEMBL databases, and the 
literature. Once ten different targets were selected, recombinant protein production was 
carried out to support structural and biochemical characterisation. Seven proteins were 
successfully purified and four of them prioritised for further studies. These are 
kynurenine formamidase (KynB), D-alanine—D-alanine ligase (Ddl), caseinolytic 
protease subunit P (ClpP), and the dihydrofolate synthase:folyl-poly-glutamate synthase 
(bifunctional protein FolC). X-ray crystallography was used to determine protein 
structures of KynB, Ddl and ClpP from various bacteria. Additionally, different 
enzymatic and binding assays were applied to assess kinetic parameters of KynB, Ddl 
and FolC, and compound library screenings were carried out for Ddl. In parallel, the 
genetic validation of these targets was being carried out by the Dstl. 
 
KynB is an important enzyme in tryptophan metabolism and predicted to be essential in 
Pseudomonas aeruginosa. The B. anthracis, B. cenocepacia and P. aeruginosa KynB 
structures showed an amidase fold not previously described, with a distinctive binuclear 
Abstract  	 XIX 
Zn2+ catalytic site that indicated a distinct reaction mechanism. Whilst the 
characterisation of the enzyme was ongoing, the Dstl lab reported the gene as non-
essential and so no additional chemical validation was pursued. Ddl generates a 
precursor for the peptidoglycan layer and appears to be an essential protein in several 
Gram-negative bacteria. The structure of B. pseudomallei Ddl (BpDdl) in the presence 
of the co-factor and the reaction product D-alanyl-D-alanine (1.5 Å resolution) gives 
information about the substrate-binding site. Biolayer interferometry (BLI) and high-
throughput (HTP) assay protocols were developed and applied. Despite testing around 
22,000 compounds no inhibitors or suitable hits were found. This suggests BpDdl is a 
challenging target and a different approach for drug discovery might have to be 
considered. Fourteen ClpP subunits form a proteolytic complex which presents two 
different conformations; open and compressed. Structures of F. turalensis ClpP 
(FtClpP) with open and compressed conformations have been determined indicating 
this major conformational change is caused by a loop rearrangement at the proteasome 
inner canal that leads to the protease active site. FolC is an essential protein for the 
synthesis of folyl-poly-glutamates, a reference pathway for drug development. A new 
enzymatic assay, using malachite green, has been identified and used to confirm Y. 
pestis FolC activity. Such an assay could be used to determine kinetic parameters and to 
develop a HTP assay. 
 
The studies carried out informed about potential antibacterial target structures and 
biochemical properties. Protocols have been developed for protein recombinant 
expression, purification, crystallisation and structure determination as well as enzymatic 
assay development and compound library screens.  
Part One: Introduction  	
	
1 
PART ONE 
INTRODUCTION 
 
1.1 Antibacterial drugs and resistance 
 
During the last century important discoveries have been made in the development of 
antibacterial drugs and different classes of antibiotics have been successfully used (Fair 
and Tor, 2014). These include aminoglycosides (e.g. streptomycin, gentamycin and 
kanamycin), amphenicols (e.g. chloramphenicol), β-lactams (e.g. penicillin G, 
ampicillin and amoxicillin), glycopeptides (e.g. vancomycin and telavancin), 
lipopeptides (e.g. daptomycin), macrolides (e.g. erythromycin and azithromycin), 
quinolones (e.g. ciprofloxacin and levoflaxacin), rifamycins (e.g. rifampicin), 
streptogramins (e.g. dalfopristin), sulphonamides (e.g. trimethoprim) and tetracyclines 
(e.g. tetracycline and doxycycline). However, the alarming increase of (multi)drug 
resistance to these commonly used treatments is a major global healthcare problem 
(Silver, 2011; Chopra, 2013; Fair and Tor, 2014). The natural occurrence of drug 
resistance mechanisms plus the inappropriate use of antibiotics, for example by over-
prescription, patients failing to complete treatments or use in agriculture growth 
promotion, are the main causes of the increase in antibacterial resistance (Chopra, 2013; 
Done et al., 2015). This is reflected in increasing clinical isolates presenting drug 
resistance (Brooks and Brooks, 2014; Matthew et al., 2015).  
 
A wide range of drug resistance mechanisms, constitutively present or induced under 
stress conditions, have been described and the set of components involved is called the 
resistome (Silver, 2011). These mechanisms include chemical modification of the drug 
or sequestration (a non-essential protein binds to the drug), mutation of the targeted 
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protein or increasing its expression level, modification of the enzyme (e.g. methylation) 
to hinder drug binding, reduction of drug uptake (e.g. down regulation of porin 
expression), and increasing the efflux (e.g. overexpression of efflux pumps) (Li et al., 
2005; Li and Nikaido, 2009; Silver et al., 2012; Torok et al., 2012). Specifically in 
Gram-positive bacteria, modification of the properties of the peptidoglycan layer 
triggers a change in susceptibility to drugs. Resistance mechanisms can be transferred 
among bacteria by horizontal gene transmission, transformation (exogenous DNA), 
transduction (via bacteriophages) or conjugation (Culyba et al., 2015). In some cases, a 
combination of such mechanisms results in multidrug resistance (Li et al., 2005). In 
order to address the complex issue of drug resistance it is important to find new 
antibacterial compounds.  
 
1.2 Strategies for antibacterial drug development 
 
1.2.1 The past 
An early approach in antibiotic discovery was based on screens testing a collection of 
dyes and other chemicals. Paul Ehrlich defined the term chemotherapy as the use of 
synthetically produced chemicals to destroy pathogenic microorganisms, and worked on 
the development of selective biologically active compounds harmless for the host (Gelpi 
et al., 2015). His studies resulted in the discovery of salvarsan (in 1907, Bosh and 
Rosich, 2008), an antibiotic against syphilis (Reithmiller, 2005; Gelpi et al., 2015). 
Following the discovery of penicillin (Fleming, 1929), natural products from 
fermentation broths and extracts of microorganisms were introduced in screening. This 
became the start of the “Golden Age” in drug discovery (from about 1940 to 1970), 
characterised by the description of a high number of new antibacterial classes (Silver, 
2012; Figure 1.1). In the early 1960s, compound libraries were modified to detect 
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pathway-specific and intensive screens searching for inhibitors targeting the cell wall 
biosynthetic pathway produced three new classes of antibiotics; monobactams, 
carbapenems and fosfomycin (Silver, 2011). The single-component directed screening 
approach was proposed in 1977 (Cohen, 1997) and turned drug discovery into what it is 
implemented nowadays (Silver, 2011).  
 
1.2.2 The present 
1.2.2.1 The Void Age 
Despite improvements in technologies associated with drug discovery, the accessibility 
of protein structures and large-scale genomic and chemical data, no new drug class has 
been developed over the past 25 years, the so-called “Void Age” (Silver, 2011; Chopra, 
2013). The lack of new drug classes has been reviewed and attributed mainly to the lack 
of investment from the pharmaceutical industry and funding bodies, decisions likely 
influenced by high cost, timescales and high risk (Gwynn et al., 2010; Silver, 2011; 
Figure 1.1: Chart showing the number of new antibacterial classes over time and 
different strategies used for drug search. SC is the abbreviation for screening. The 
Golden Age is coloured in yellow and the Void Age in purple. Information from 1908 
until 2012 has been obtained from Adamczyk-Woźniak et al., 2009; Silver, 2012. 
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Chopra, 2013). The emerging antibacterial drug resistance crisis highlights the need for 
new drugs and to exit the Void Age. 
 
Initiatives are being implemented seeking to increase social awareness, introducing new 
procedures to avoid the misuse of antibiotics (ReAct initiative by Europe by the British 
Society for Antimicrobial Chemotherapy, www.bsac.org.uk) and improving the current 
technologies to find 10 new antibacterial drugs by 2020 (10x20 initiative by the 
Infectious Diseases Society of America, www.idsociety.org). European organisations 
are working together and have created the Innovative Medicines Initiative (IMI, 
www.imi.europa.eu), a collaborative partnership between private and public 
organisations to focus efforts investigating the mechanisms of drug transport and to 
apply the findings to improve antibacterial drug development (Tommasi et al., 2015). 
 
Having recognised deficiencies in antibiotic discovery (see also section 1.2.2.2), the 
situation has improved with four new classes of compounds identified recently. These 
include aryl isonitrile (Davis et al., 2015), ramizol (Iscla et al., 2015), lysocin E 
(Hamamoto et al., 2015) and teixobactin (Ling et al., 2015). A small library of aryl 
isonitrile derivatives was used in a phenotypic screen and this helped identify a potential 
antibiotic for skin infections of MRSA (Methicillin-resistant Staphylococcus aureus). 
Ramizol (1,3,5-tris[(1E)-2’-(4’’-benzoic acid)vinyl]benzene) is the result of an in silico 
compound design process targeting the ion channel MscL of MRSA, and lysicin E has 
been obtained from an empirical screen using bacterial supernatants and seems to bind 
menaquinone (vitamin K), a component of the electron transport system. Texiobactin, a 
cell wall biosynthesis inhibitor, was also obtained from a phenotypic screen. In this 
case, soil bacteria were isolated and grown using a multichannel device, called iChip, to 
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find new antibiotic compounds from growth extracts. These new classes are in the early 
stage of development.  
 
1.2.2.2 Drug discovery strategies 
Different strategies are used to search for new antibacterial drugs, and these can be 
classified depending on the screening method (phenotypic or single-target), and the 
nature of the chemical library (diverse or target-based synthetic compounds, and natural 
products) (Copeland, 2005). Drug development can be focused on the determination of 
new active compounds for known targets (a protein which has its activity modified by 
the drug, that hinders cell growth or promotes cell death) or the search for compounds 
active against new antibacterial targets. Drug discovery targeting new systems is more 
likely to yield novelty in terms of chemical structure and mechanism of action. The 
benefits of such a development could be the absence of resistance mechanisms in the 
clinically relevant bacteria (Silver, 2011). 
 
To select new potential targets, the most common approach is to consider gene 
essentiality experiments (further discussed in section 1.2.2.3). The potential targets then 
need to be validated employing two approaches: genetic and chemical (Frearson et al., 
2007). Genetic validation confirms the essentiality of the target for bacterial growth 
and/or survival using methodologies such as knock-outs and deleterious mutation 
generation (Freiberg and Brötz-Oesterhelt, 2005). Chemical validation involves the use 
of a compound capable of binding with high affinity to the target and producing 
concentration dependent cell death or inhibition of growth (Wyatt et al., 2011).  
 
Once the target has been selected, compounds that interact have to be found. High-
throughput (HTP) assays are being developed to screen libraries to obtain leads, which 
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are a starting point for generating target-specific (or single-target) compounds for 
further development. This approach has not been very successful in the development of 
new classes of antibiotics, and an issue that has been recognised is the lack of chemical 
diversity in compound libraries (Payne et al., 2007; Tommasi et al., 2015). Attempts 
have been made to improve libraries with broader chemical space representatives 
(Gwynn et al., 2010; Silver, 2011; Chopra, 2013). These improvements include the 
incorporation of new scaffolds with different chemical properties, and the development 
of pathway-specific libraries. Another approach is the search for a lead compound using 
fragment screens (Erlanson, 2006). In a more sophisticated way, phage display (Løset 
and Sandlie, 2012), and DNA-encoded libraries (Franzini et al., 2014) can also be used. 
The former has been used for creating biomacromolecule libraries (e.g. peptides, 
proteins, antibodies and nucleic acids). DNA-encoded libraries present a new way of 
synthesis and display of organic compound libraries. Lead compounds have been 
identified using DNA-encoded libraries for various eukaryotic targets (Franzini et al., 
2014), however in this approach a pool of different compounds are tested at once and 
this hinders the identification of the hits. Compound, fragment, phage display and 
DNA-encoded libraries can be screened against the whole-cell (phenotypic screen), an 
approach that might inform about which compounds can enter the cell. However, the 
identification of the drug target(s) is challenging and without this information, the 
optimisation of the compounds could be difficult and more time-consuming than in the 
single-target approach. 
 
Despite extensive HTP screening against specific targets, only a few leads have been 
identified for further development. This has lead to questions on how appropriate the 
compound libraries are for antibacterial drug discovery (Payne et al., 2007; Gwynn et 
al., 2010). The failure rate in the lead compound search has been assessed by GSK 
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(GlaxoSmithKline, Payne et al., 2007) and AstraZeneca (Tommasi et al., 2015) using 
different libraries and targets. The GSK program obtained 5 lead compounds from 70 
screening campaigns carried out between 1995 and 2001. Payne et al., (2007) suggested 
that their library was not appropriate for antibacterial development and the use of more 
chemically diverse compounds might be an improvement. AstraZeneca reported results 
of 65 screening campaigns (between 2001 and 2010), containing 8 targets in common 
with the GSK program. Fifteen lead compounds were obtained, however further 
investigations have not resulted in potential drugs, showing problems in terms of cell 
penetration (Tommasi et al., 2015).  
 
The first leads provide chemical information on what might form the basis for drug 
discovery. To progress to the synthesis of active compounds it is important to have 
accurate structural data. Target structures, including apo-form and with relevant ligands 
(e.g. substrates) or lead compounds, give information about binding modes as well as 
the physical and chemical properties of the ligand environment providing data for lead 
optimisation and rational drug design. In addition, protein-ligand complexes contribute 
to validation of hits obtained from HTP assays. In theory, it is possible to use structures 
as templates for developing in silico inhibitors. Such information can be used to design 
specific single-target based libraries (Frearson et al., 2007; Gwynn et al., 2010). 
However, these compounds usually do not support translation to the whole-cell 
environment as they are not able to overcome the membrane barriers of the 
microorganism (Gwynn et al., 2010). 
 
It has been recognised that directing drug discovery towards a single target might not be 
the most appropriate strategy for developing antibiotics (Gwyn et al., 2010). A more 
promiscuous drug would, in principle, require a more complex resistance system. 
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Indeed, the already clinically implemented single-target drugs (e.g. fosfomycin, fusidic 
acid and rifampicin) have shown a higher tendency to generate resistance than 
antibiotics targeting several proteins (e.g. β-lactams, fluoroquinolones and vancomycin) 
(Gwynn et al., 2010; Silver, 2012). Combinatorial therapies, which combine various 
antibiotics to circumvent issues of drug resistance, are already in use. This is the case 
for treatment of infections caused by Plasmodium falciparum (the causative agent of 
malaria) and Mycobacterium tuberculosis (Fischbach, 2011; Tamma et al., 2012). 
Multidrug resistance in Gram-negative bacteria has been attributed to the drug extrusion 
activity of efflux pumps in many clinical isolates (Li et al., 2015; Chang et al., 2015). In 
this context, treatment using combinatorial therapies could include cytosolic-target 
drugs, newly developed or already approved, plus an inhibitor of the efflux pump 
systems. This could increase susceptibility and toxicity to the cytosolic drug and could 
be used to reverse antibiotic resistance (Lomovskaya and Watkins, 2001). 
 
Alternative strategies to conventional drug discovery have been proposed. These 
include phage therapy (Nobrega et al., 2015) and RNA interference-based therapy 
(Dyawanapelly et al., 2014). Despite the promise of such alternative treatments, there 
has been little progress. Conventional approaches are still considered the most likely to 
progress development to antibacterial drugs (Gwynn et al., 2010).  
 
1.2.2.3 Target selection approaches 
Genetic and chemical data are required to assess the potential of antibacterial targets 
(Monaghan and Barret, 2006; Frearson et al., 2007). To handle the large amount of 
information present in various databases, different target selection strategies can be 
combined to generate a list of candidates (Frearson et al., 2007). A common approach is 
the prediction or analysis of gene essentiality (Freiberg and Brötz-Oesterhelt, 2005). 
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This can either be carried out experimentally or inferred from phylogenetically related 
bacteria (White and Kell, 2004; Doyle et al., 2010; Monye et al., 2013). When genome-
scale transposon knock-outs are available this information is used to generate a probable 
essential genes list (Moynie et al., 2013). Another approach is to exploit known 
antibacterial drug targets in the bacteria of interest (Frearson et al., 2007; Doyle et al., 
2010), so that these proteins and the pathways to which they belong can became targets. 
Such approaches generate a large number of potential candidates that need to be further 
analysed and filtered. Various criteria are generally used to conduct the selection and 
prioritisation of potential antibacterial candidates including precedence, essentiality, 
druggability, structural biology feasibility, selectivity, assay feasibility and spectrum of 
action (Frearson et al., 2007). 
 
Druggability is an important feature for target selection, corresponding to the propensity 
of drug-like compounds to interact with the target. It can be analysed from the structure 
or from large-scale bioactivity databases. Drug-likeness of a compound was initially 
assessed by Lipinski’s Rule of Five (Ro5, Keller et al., 2006), which was derived from 
empirical data on oral neuroactive compounds. The Ro5 suggests that, for the purpose 
of bioavailability and usefulness in subsequent chemical modifications, drug-like 
compounds should have: 1) no more than 5 hydrogen bond donors, 2) no more than 10 
hydrogen bond acceptors, 3) molecular weight less than 500 Da and 4) an octanol-water 
partition coefficient (logP) below 5. More recently, the Quantitative Estimate of Drug-
likeness (QED) was established as an improvement of the Ro5 and to allow the 
assessment of large-scale chemogenomic data (Bickerton et al., 2012). This is based on 
eight criteria: molecular weight, octanol-water partition coefficient, molecular polar 
surface area, number of hydrogen bond donors, hydrogen bond acceptors, rotatable 
bonds, aromatic rings and structural alerts. The QED value ranges from 0 (non-drug-
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like) to 1 (drug-like). A protein target is considered druggable when it is able to bind 
drug-like compounds. In this case, QED values of published active compounds in 
ChEMBL (www.ebi.ac.uk, Bento et al., 2014) and the number of drug-like compounds 
for each target can be used for estimating target druggability. Additionally, if a protein 
structure is available, druggability can be further evaluated using software such as 
DrugPred (Krasowski et al., 2011) or the Molsoft ICM pocket finder tool 
(www.molsoft.com). These programs generate a drug-like density score (DLID, 
Sheridan et al., 2010) that considers volume, buriedness and hydrophobicity of the 
pockets. The DLID values range from -3 to 2 and a pocket is considered druggable 
when a value equal to or greater than 0.5 is obtained.  
 
A structure can inform about active site pocket properties, substrates or inhibitor 
binding, and therefore, the reaction mechanism. This can be used for structure based 
drug design and for validation of drug binding. Feasibility of the targets for 
crystallisation can be predicted using XtalPred (Slabinski et al., 2007). A crystallisation 
probability score is calculated using various criteria (protein length and molecular 
weight, pI, instability index, content of Cys/Met/Trp/Tyr, percentage of coiled-coil or 
membrane regions among others) and compared with data at TargetDB (which also 
contains failure crystallisation data, www.targetdb.pdb.org, Chen et al., 2004). For each 
target, structures of homologues in the PDB (Protein Data Bank, www.rcsb.org) are 
identified and considered. The presence of ligand-bound and high-resolution structures 
will inform about the feasibility of obtaining good-quality crystals to conduct inhibitor-
bound studies. 
 
Another feature to evaluate when considering antibacterials is the selectivity of the 
target between the pathogen and the host. Ideally, the target should provide 
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discrimination to selectively target the bacteria. This can be achieved by lack of an 
homologue in the host, binding site selectivity (different residues in the binding site 
pockets), differences in the kinetics and binding mechanisms, the target essentiality in 
bacteria and host, and differences in drug transport and efflux systems (Huggins et al., 
2012; Torok et al., 2012). Also, depending on the strategy chosen (broad-spectrum or 
selective targets), the presence of orthologues in other bacteria can be included in the 
criteria (spectrum of activity) (Frearson et al., 2007). Finally, information in the 
literature and the BRENDA database (Chang et al., 2015) concerning assay feasibility, 
the existence of HTP assays, and inhibitors are also considered. Two approaches are 
generally followed in the search for inhibitors (Gwynn et al., 2010; Silver, 2011; 
Chopra, 2013). On one hand, rational design for new inhibitors based on the reaction 
mechanism and the available structures are often used. To validate the compounds an 
activity assay is required. On the other hand, to investigate novel inhibitor scaffolds, 
compound library screens can be carried out and this may require the development of 
appropriate assays.  
 
1.2.3 The future 
Problems in the current approaches and libraries have been identified and issues are 
being addressed (Silver, 2012; Chopra, 2013; Tommasi et al., 2015). Improvements in 
compound library collections are being implemented (Silver, 2012; Tommasi et al., 
2015) and may result in more efficient lead searches. In this respect, the identification 
of new chemical classes (Davis et al., 2015; Hamamoto et al., 2015; Iscla et al., 2015; 
Ling et al., 2015) provides optimism to exit the Void Age. However, campaigns for 
social awareness to promote the correct use of antibiotics and, therefore, avoid their 
rapid failure should be carried out along with the development of new antibacterial 
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drugs (Chopra, 2013). Additionally, research to develop alternative therapies may help 
to diversify strategies against resistant bacteria infections (Chopra, 2013).  
 
1.3 Biowarfare agents 
 
Some bacteria and viruses have been used as biowarfare agents, or bioweapons (Barras 
and Greub, 2014). Among these are the pathogens causing anthrax, glanders, plague and 
tularaemia. The critical situation in antibacterial resistance intensifies the concern about 
the employment of multidrug resistance agents for criminal acts. The U.S. Centers for 
Disease Control and Prevention (CDC, www.cdc.gov) have categorised biowarfare 
agents into different priority groups. Category A agents can be easily spread within the 
population, cause disease with high mortality rates and generate panic. Examples would 
be Bacillus anthracis, Francisella tularensis and Yersinia pestis. Agents from Category 
B spread less easily than Category A agents and have lower mortality rates. A 
representative of these agents is Burkholderia pseudomallei. Category C agents are 
characterised as pathogens that could be engineered for mass spread, are easy to obtain 
and produce, and present high morbidity and mortality rates. Multidrug-resistant 
Mycobacterium tuberculosis is an example of a Category C agent (Anderson et al., 
2012). Characteristics of the Category A and B organisms mentioned above are 
summarised in Table 1.1. 
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1.4 Aim and objectives 
 
Together with the Dstl (Defence Science and Technology Laboratory) this project is 
designed to address the evaluation and initial validation of new antibacterial drug 
targets for the biowarfare agents B. anthracis, B. psesudomallei, F. tularensis and Y. 
pestis. To achieve this, the following objectives were defined: 
1. Selection of potential targets and prioritisation: Generate a list of candidates 
taking into account information in databases, the literature and additional 
data from the Dstl. 
2. Genetic validation of the targets: Confirmation of gene essentiality for cell 
growth or viability. This is being carried out by the Dstl. 
3. Early-stage chemical validation. This requires: 
− Recombinant protein production to support the program. 
− Structural characterisation of the potential targets using 
crystallography. 
− Biochemical characterisation/validation of the targets using different 
techniques for determining enzymatic parameters, ligand binding 
constants and their performance in chemical library screening 
campaigns. 
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PART TWO 
SELECTION AND PRIORITISATION OF POTENTIAL TARGETS 
 
In consultation with the Dstl (Defence Science and Technology Laboratory), ten 
potential targets in Bacillus anthracis, Burkholderia pseudomallei, Francisella 
tularensis and Yersinia pestis were selected based on the criteria detailed in section 
1.2.2.2 (precedence, essentiality, druggability, structural biology feasibility, selectivity 
and assay feasibility). In this chapter, the decisions that guided target selection and 
prioritisation are explained. 
 
2.1 Target selection strategy 
 
2.1.1 Candidates for target selection 
The first approach to generate a list of target candidates was based on transposon-
directed insertion site sequencing (TraDIS, van Opijnen and Camilli, 2013). Genome-
scale transposon knock-outs (TKO) of Y. pestis was carried out by the Dstl team. TKO 
clones showing defects in cell growth were selected and sequenced using TraDIS. The 
results provided information about potential essentiality of groups of genes, 
consequently, false positives are expected from this approach and for selected targets 
Figure 2.1: Schematic of the TraDIS method adapted from Opijnen and Camilli (2013). 
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direct genetic validation is then required. To assist the completion of TraDIS, it is 
necessary to produce a transposon insertion library. The genomic DNA (gDNA) is 
digested with random DNA restriction enzymes generating products carrying the 
transposon, used as the sequencing starting point, and variable-length ends containing 
gDNA. The DNA ends are repaired, a poly(A) tail added and an adaptor sequence 
included to facilitate sequencing (Figure 2.1). Sequenced data were compared to the 
wild-type Y. pestis gDNA and knocked-out genes identified to generate a list of 
potential essential genes (Appendix A).  
 
2.1.2 Assessment of selection criteria 
For the selection of targets for B. anthracis, B. pseudomallei and Y. pestis different 
datatabases were used. Firstly, AEROPATH (www.aeropath.eu) gave information about 
gene essentiality, druggability, presence of homologues in the host and/or other Gram-
negative bacteria, crystallisation feasibility, and published drug-like compounds that 
interact with the targets. AEROPATH is a database prepared for target assessment in 
Pseudomonas aeruginosa and was developed at the University of Dundee. Essentiality 
information in AEROPATH and DEG (Database of Essential Genes, 
www.tubic.tju.edu.cn/deg, Zhang et al., 2004) databases was compared to the results 
from the TraDIS data for essentiality cross-validation. On one hand, DEG showed there 
are genes characterised as essential for at least one bacterial organism. On the other 
hand, the AEROPATH database reported some of the potential targets were not 
essential for P. aeruginosa. Information about drug-like compounds was further studied 
in the ChEMBL database (Bento et al., 2014), which contains a summary of the 
medicinal chemistry literature, and seeks to link chemical structures with specific 
targets. Previous work at Dstl and Prof. William N. Hunter labs was also used to inform 
target selection. The consistency in prediction of essentiality among different 
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organisms, presence of an available enzymatic assay, accurate structure data, and the 
existence of human homologues with high sequence identity were considered followed 
by the analysis of characterised inhibitors and QED values. Some enzymes involved in 
DNA/RNA biosynthesis, ribosome constituents, the ATP synthase system, scaffold or 
non-catalytic and uncharacterised proteins were not considered. Additionally, proteins 
with a high sequence homology (more than 50%) with human homologues were 
discarded. Four potential targets had a HTP assay described (marked as green in the 
traffic light score, see Appendix A). These are acetyl-CoA 
carboxylase:carboxyltransferase subunit α (AccA), 2-C-methyl-D-erythritol 4-
phosphate cytidylyltransferase (IspD), 4-diphosphocytidyl-2-C-methyl-D-erythritol 
kinase (IspE) and UDP-N-acetylglucosamine acyltransferase (LpxA) (Appendix A). 
However, there is no evidence of lead compound follow up so this could indicate 
difficulties and they were not included for the final target selection. 
 
2.1.2.1 Traffic light score 
The collected information was classified using the traffic light score defined in Frearson 
et al., (2007). For this project, variations in the definitions were implemented and are 
shown in Table 2.1. For evaluation of essentiality, data from TraDIS together with the 
information in AEROPATH and DEG databases were considered. Druggability was 
evaluated with the QED score and the presence of drug-like data separately. The first 
one was marked with a colour scale; red lowest QED score and green as the highest 
score, and the second as indicated in Table 2.1. For “human homologs”, due to the large 
number of targets, a first check was pursued using the sequence identity level and a 
further analysis was carried out for the potential targets looking for evidence of 
selectivity or essentiality in humans (see section 2.2 for details). The analysis of the 
tractability as a target of the candidates was done checking the size and subcellular 
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location (not coloured), the availability of assays and structures, and XtalPred 
prediction. The last was marked with a colour scale; red showing the highest scores and  
green the lowest. 
 
 
2.2 Selected targets 
 
From 3886 genes analysed in the TraDIS data, 130 were selected as encoding for 
probable essential targets. This were filtered as indicated in section 2.2 and resulted in 
75 candidates for further analysis (Appendix A).  Prioritisation of the targets was 
Criterion Red Amber Green 
Essentiality 
AEROPATH1 Non-essential. No 
evidence for gene 
essentiality  
Probably 
essential. There is 
weak evidence of 
gene essentiality 
Essential. Strong 
genetic evidence of 
gene essentiality 
for cell growth DEG
2 
Close human homologues1 
Human 
homologues 
present, showing 
30% sequence 
identity 
Human 
homologues 
present, sequence 
identity lower 
than 30%  
No human 
homologues 
Druggability 
Drug-like 
CPDs1,4,5 
No drug-like 
inhibitors 
Known drug-like 
inhibitors in other 
bacteria 
Known drug-like 
inhibitors in any of 
the targeted-
bacteria1,3,4 and 
ChEMBL 
homologues1,2 
ChEMBL 
homologues1,3 
No ChEMBL 
homologues 
ChEMBL 
homologues 
The target has 
active compounds 
in ChEMBL (so-
called ChEMBL 
target) 
Tractability 
as a target 
Assay 
feasibility4,5 
An assay has not 
been developed or 
involves 
radioactivity. 
An assay has been 
described  (non-
HTP assay) 
HTP assay 
available 
Structural 
information1,6 
No structures 
(including other 
bacteria) 
Structures 
available but not 
for the targeted 
organisms 
Structures available 
for the targeted 
organisms 
Table 2.1: Traffic light score definitions for criteria classification. CPDs: compounds 
abbreviation. Information collected from (1) AEROPATH, (2) DEG, (3) ChEMBL, (4), 
BRENDA database, (5) Literature, and (6) PDB database. 
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carried out accordingly to the experimental results and the progress towards target 
validation. 
 
2.2.1 First selected targets 
The first targets selected were kynurenine formamidase (KynB, Zummo et al., 2012), 
dihydrofolate synthase:folyl-poly-glutamate synthase (bifunctional protein FolC, Sheng 
et al., 2002), 3-hydroxyacyl-[acyl-carrier-protein] dehydratase (FabZ, White et al, 
2005), a lipid A export ATP-binding permease (MsbA, Ghanei et al., 2007) and 
AdoMet-dependent 5-methyluridine methyltransferase (RsmH or MraW, Wei et al., 
2012). KynB is the second enzyme involved in the tryptophan degradation pathway, the 
bifunctional protein FolC belongs to the folyl-poly-glutamate biosynthesis pathway, 
FabZ and MsbA are required for maintaining the integrity of the cell membrane, and 
RsmH is implicated in the post-translational modifications of ribosome RNA. FolC and 
MsbA have human homologues. In the first case it is referred to as the mitochondrial 
FolC, which presents only one of the activities (folyl-poly-glutamate synthase), and 
selectivity towards the bacterial FolC might be feasible (Wang et al., 2010). MsbA 
homologs involve proteins from the ABC transporter family and, as expected, the 
ATPase domain is conserved in this family. However, selectivity might be possible 
targeting other sites on the protein. Structures, inhibitors and enzymatic assays have 
been described for FabZ, FolC and MsbA. Less information is available for KynB and 
RsmH for which no inhibitors have been described. Additionally, no structural 
information was available for KynB, however assays have been described in both cases 
and XtalPred scores suggested crystallisation is feasible. Selection of KynB and RsmH 
was based on previous results; Dr. V. Srikannathasan, in Prof. Hunter lab, showed 
KynB has a different fold to the eukaryote homologue and it was predicted as essential 
in P. aeruginosa from genome-scale transposon experiments (Jacobs et al., 2003; 
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Liberati et al., 2006), and the Dstl labs had essentiality data for RsmH. These two 
targets were not identified from the TraDIS results. Experimental work towards the 
chemical validation of these first candidates was initiated and resulted in the 
prioritisation of KynB. In parallel, genetic validation, involving conditional knock-out 
generation for the different bacteria as well as random mutations, was being carried out 
at Dstl. Before moving to high-throughput screening to search for KynB inhibitors, Dstl 
reported KynB as non-essential for B. anthracis or B. pseudomallei growth, but 
indicated it might be involved in B. pseudomallei virulence (Prof. Richard W. Titball, 
personal communication). New information available (see Part Three and Appendix C) 
suggested FabZ, KynB and RsmH might not be suitable targets, so a further selection 
was carried out.  
 
2.2.2 Second selection 
The second selection included D-alanine—D-alanine ligase (Ddl, Prosser and de 
Carvalho, 2013), the cell division protein FtsZ (Errington et al., 2003), CTP synthase 
(PyrG, Yoshida et al., 2012), the proteolytic component of the caseinolytic protease 
(ClpP, Brötz-Oesterhelt and Sass, 2014), and the efflux pump NorM (Su et al., 2008), 
for further assessment. Ddl is involved in peptidoglycan layer biosynthesis, a reference 
pathway (Bermingham and Derrick, 2002; Bugg et al., 2011), together with folate 
metabolism, in drug discovery. Structures were available (Table 2.2), inhibitors 
identified and an enzymatic assay described suggesting this protein was a good 
candidate. In the case of FtsZ, structure and inhibitors were described however an 
enzymatic assay needs to be developed. PyrG is present in humans but is not essential 
and is not the preferred route for CTP synthesis in humans (Huang and Graves, 2002), 
so selectivity might be viable. There are examples of inhibitors, structures and assays 
available for this target. Also, in this second selection, there were two proteins that 
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could be used alternative approaches. ClpP produces toxicity to the cell when it is 
overexpressed or overactivated due to unspecific proteolysis and thus cell death. In this 
context, ClpP was considered. There is a human homologue (mitochondrial ClpP) but it 
might be possible to get selectivity towards bacterial proteins (Compton et al., 2013). 
Drug efflux pumps, such as NorM, produce intrinsic drug resistance. B. pseudomallei 
has a big drug extrusion network that confers multidrug resistance (Schweizer, 2003; 
Biot et al., 2011). Therefore, efflux pumps are essential for the growth of this bacterium 
under antibacterial drug stress, and inhibitors of efflux transport could be used to 
intensify the effect, or reverse resistance, of already known antibiotics in combinatorial 
therapies (Lomovskaya and Watkins, 2001). 
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2.3 Target prioritisation 
 
Selected target criteria analysis and results of the Dstl genetic validation are collected in 
Table 2.2 and the target prioritisation decisions shown in Figure 2.2. Preliminary data 
from Dr V. Srikannathasan served to prioritise KynB studies. Results from the Dstl on 
KynB and FolC essentiality, and problems with expression and purification of FabZ and 
RsmH, set FolC as the new priority. Later, failure on the optimisation of the previously 
described FolC enzymatic assay and the successful structure characterisation of Ddl, 
promoted the second to highest priority. Reprioritisation of FolC resulted from the 
failure of screening campaigns against Ddl and the identification of a new FolC assay. 
The following chapters (Part Three, Four, Five, Six and Appendix C) will include the 
experimental data obtained during the assessment of these potential antibacterial drug 
targets. 
 
Figure 2.2: Prioritisation of the targets during the course of the project. A summary of 
the events defining target priority is included. KynB was first prioritised regarding 
preliminary structural data. Essentiality data from the Dstl labs (and collaborators) 
involved the prioritisation of FolC and work on KynB was not followed. Then, 
problems on the FolC assay optimisation and Ddl essentiality data from the Dstl, 
suggested the prioritisation of Ddl. Finally, due to the lack of Ddl inhibitory hits from 
the compound screening campaigns and the identification of a new assay for FolC, the 
latter was incorporated as a priority. 
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PART THREE 
KYNURENINE FORMAMIDASE 
 
3.1 Introduction 
 
Tryptophan degradation is important both in prokaryotes and eukaryotes for the 
production of anthranilate and the precursor for NAD biosynthesis, quinolinate 
(Kurnasov et al., 2003). Anthranilate is a metabolite that supports the synthesis of 
aromatic amino acids (Voet and Voet, 2004), and is the main constituent of chorismate, 
which is used in the formation of the folate precursor para-aminobenzoate (Satoh et al., 
2014). In bacteria, tryptophan is also used in antibiotic production and provides a source 
of carbon and nitrogen (Kurnasov et al., 2003). 
 
Eukaryotic tryptophan catabolism products L-kynurenine and quinolinate are involved 
in neurogenic disorders (Stone and Darlington, 2002). The enzyme kynurenine 
transaminase (Enzyme Commission number (EC) 2.6.1.7, Stone and Darlington, 2002) 
produces kynurenic acid, an antagonist of acetylcholine receptors (AChRs), from L-
kynurenine. Kynurenic acid can inhibit N-methyl-D-aspartate (NMDA) glutamate 
receptors (NMDARs) but it has been shown it presents a greater affinity for AChRs. On 
the other hand, quinolinate is an agonist of NMDARs. Either over-activation or 
inhibition of these receptors causes neuronal cell damage. In Alzheimer’s disease, a 
high concentration of kynurenic acid in the brain hinders memory and learning 
processes due to the inhibition of AChRs. Quinolinate activates NMDARs producing 
cell damage by reactive oxygen species formation. It also promotes the secretion of 
cytokines and chemokines by astrocytes enhancing or activating inflammatory 
responses. Quinolinate has been related to the inhibition of phosphate removal from tau 
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triggering the increase in poly-phosphorylated tau concentration forming amyloid 
plaques (Rahman et al., 2009), a characteristic feature of Alzheimer’s disease. In 
Huntington’s, this pathway is also altered and shows a low concentration of L-
kynurenine and high levels of quinolinate in the brain which activates the 
overexpression of huntingtin contributing to the formation of toxic aggregates 
(Maddison and Giogini, 2015). Kynurenic acid seems to be involved in schizophrenia, 
and other psychiatric disorders, by inhibiting AChRs. Agonists of these receptors can be 
used to reduce the symptoms of these illnesses (Stone et al., 2013; Stone and 
Darlington, 2002). 
 
The aerobic degradation pathway via anthranilate is the preferred route in tryptophan 
catabolism and involves three enzymes; tryptophan 2,3-dioxygenase (TDO, EC 
1.13.11.11), kynurenine formamidase (EC 3.5.1.9) and kynureninase (EC 3.7.1.3) 
(Figure 3.1). The first enzyme performs the oxidation of L-tryptophan to N-formyl-L-
kynurenine (NFK), then kynurenine formamidase hydrolyses the amide group of NFK 
Figure 3.1: Tryptophan degradation pathway via L-kynurenine. In bold, the protein of 
interest. Three enzymes are needed for the conversion of L-kynurenine to quinolinate. 
In the box, 2-aminoacetophenone, which shares structural features with L-kynurenine. 
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to form L-kynurenine and formate. The third enzyme, kynureninase, is then responsible 
for anthranilate formation (Kurnasov et al., 2003). L-kynurenine can also progress into 
the quinolinate pathway to support NAD biosynthesis. The constituent enzymes of the 
degradation pathway are highly conserved with the exception of kynurenine 
formamidase (Zummo et al., 2012). The eukaryotic formamidase, called KFase, has 
been intensively studied because it is implicated in neurogenic disorders, however, less 
work has been carried out in the prokaryote homologue, called KynB (Han et al., 2012; 
Stone et al., 2013). This enzyme has been annotated in the AEROPATH database 
(www.aeropath.lifesci.dundee.ac.uk, Moynie et al., 2013) as essential for Pseudomonas 
aeruginosa growth and consequently it was included in the program for further 
characterisation. Comparing the amino acid sequences, KFase and KynB appear to be 
unrelated proteins as will be explained later.  
 
The amidase reaction can occur with either acidic or 
basic hydrolysis (Fyfe et al., 2008). In the latter case, a 
reactive cysteine or serine is responsible for catalysis. 
The known KFase active site presents a catalytic triad 
comprising a serine, an aspartate and a histidine. The 
reactive serine is located in a highly conserved amino 
acid sequence characteristic of the serine hydrolase 
family (Gly-X-Ser-X-Gly). Other known amidases such as trypanothione synthetase 
amidase (Fyfe et al., 2008), nicotinamidase (Fyfe et al., 2009) and the nitrilases (Pace 
and Brenner, 2001) use a reactive cysteine to perform the reaction. The structures of 
Drosophila melanogaster (DmKFase, Figure 3.2) and Saccharomyces cerevisiae KFase 
(ScKFase) revealed a similar α/β hydrolase fold (Han et al., 2012; Wogulis et al., 2008) 
even though their sequences share only 12% identity. This fold is characterised by eight 
Figure 3.2: Cartoon 
representation of DmKFase 
(PDB code 4E11). 
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parallel β-strands surrounded by 13 α-helices. There exist structural similarities between 
KFase, carboxylesterases (Wogulis et al., 2008) and 5’-pyridoxyl phosphate-dependent 
kynurenine aminotransferase (Rossi et al., 2004). 
 
KynB and KFase have a low amino acid sequence identity (10%) with a lack of a 
conserved motif. Comparing the KynB secondary structure prediction with the KFase 
structure, KynB seemed to present a distinct fold. Additionally, the size is considerably 
different with 300 amino acids in the case of KFase and 213 for KynB. All these factors 
suggest KynB is structurally and mechanistically unrelated to KFase. These 
observations also apply to other known amidases or amidohydrolases indicating KynB 
might also be different from these enzymes. Based on this, and that KynB has been 
described as an essential protein (AEROPATH; Farrow and Pesci, 2007), this enzyme 
was considered a potential antibacterial drug target. KynB from B. anthracis (BaKynB), 
B. cenocepacia (BcKynB) and P. aeruginosa (PaKynB) were investigated. The work 
was focused on the structure and biochemical characterisation of these proteins. To get 
information about the reaction mechanism and binding of the substrates, co-
crystallisation with L-kynurenine and the compound 2-aminoacetophenone was 
investigated. Additionally, confirmation of the kynurenine formamidase activity in 
these proteins was required. Once structures were obtained and the enzymatic assay 
optimised, the initial chemical validation of BaKynB as a new antibacterial drug would 
follow. However, results from the Dstl showed this protein is not essential for B. 
anthracis hence no further validation work was pursued. In this chapter, structures of 
apo-KynB and BaKynB complexed with 2-aminoacetophonone are reported. The 
structures reveal a distinct fold from other amidases and give information about 
important features for molecular recognition. Moreover, the BaKynB structure 
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complexed with 2-aminoacetophoneone gave information about the reaction 
mechanism.  
 
3.2 Experimental procedures 
 
Most of the genes reported in this thesis have been cloned and the encoded proteins 
purified using similar protocols. General protocols are described here and variations 
will be noted as appropriate. 
 
3.2.1 Recombinant protein production 
Synthetic genes encoding KynB in P. aeruginosa (PaKynB, UniProt: Q9I234), B. 
cenocepacia (BcKynB, B4E9I9) and B. anthracis (BaKynB, Q81PP9) were purchased 
(Genscript) having been codon optimised for expression in Escherichia coli K12. They 
were cloned into a modified pET15b vector (Novagen, called pET15bTEV) to create 
plasmids that produce an N-terminal hexahistidine-tagged (His6-tag) protein and a 
tobacco etch virus (TEV) protease cleavage site. The restriction enzymes used were 
NdeI (at the 3’ end of the DNA strand) and BamHI (at the 5’ end). All constructs were 
sequenced to check their integrity by the sequencing facility at the University of 
Dundee. Cloning of PaKynB was performed by Dr. V. Srikannathasan and BcKynB by 
Dr. M. Zoltner (see Table 3.1 for variations in the protocol). No mutations were 
observed in any of the genes. 
 
Gene expression and purification of the proteins started with freshly transformed E. coli 
strains, generally BL21(DE3). Bacteria were cultured at 37ºC in 10 ml of LB broth 
containing 50 µg ml-1 carbenicillin. In the case of pLysS strains, 20 µg ml-1 
chloramphenicol was also present in combination with carbenicillin. These cultures 
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were used as inoculum for 1 litre of LB/antibiotic mixtures. The bacteria were cultured 
at 37ºC until an O.D. of 0.6 at λ = 600 nm was achieved. The temperature was lowered 
to 20ºC, gene expression was induced with 1 mM IPTG and cultures were incubated 
overnight. Cells were then harvested by centrifugation (4,000 g at 4ºC for 10 minutes). 
Cultures were resuspended in a lysis buffer (buffer A, see Table 3.1) with the addition 
of complete EDTA-free protease inhibitor cocktail tablets from Roche. The cells were 
disrupted using a French press/cell disruptor, and homogenates were centrifuged at 
40,000 g for 30 minutes at 4ºC. The resulting supernatants were passed through a 0.45 
µm filter. Proteins were loaded on a 5-ml HisTrap HP column (GE Healthcare) to 
perform affinity chromatography (Ni-NTA). After a 10-column volume (CV) washing 
step using 90% buffers A and 10% of buffer B (buffer A and 0.8 M imidazole), the 
recombinant proteins were eluted applying a linear imidazole gradient. The eluted 
proteins were dialysed into buffer A and incubated overnight with 1 mg of His-tagged 
TEV protease per 20 mg of protein at 4ºC, then applied to a HisTrap HP column 
equilibrated with buffer A to remove the TEV protease, cleaved peptide and non-
cleaved material. Fractions containing the proteins were collected, concentrated and 
applied to a size-exclusion chromatography (SEC) column (HR 16/60, Superdex 75 
prep grade, GE Healthcare) equilibrated with buffer A. The SEC columns had been 
calibrated with molecular mass standards (thyroglobulin, 670 kDa; γ -globulin, 158 
kDa; serum albumin, 67 kDa; ovalbumin, 44 kDa; myoglobin, 17 kDa; vitamin B12, 1 
kDa). Protein purity and molecular weight were assessed by SDS-PAGE (Sodium 
Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis, Biorad stain-free precast gels) 
and MALDI-TOF-MS (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight 
Mass Spectrometry) analysis performed at the University of Dundee ‘Fingerprints’ 
Proteomics Facility using an Applied Biosystems Voyager DE-STR spectrometer. The 
stain-free SDS-PAGE gels do not require Coomassie Blue stain for protein 
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visualization. Instead, a trihalo compound covalently binds to tryptophan residues under 
UV irradiation resulting in UV-induced fluorescence (Short and Posch, 2011). Protein 
quaternary structure was investigated by native-PAGE (Invitrogen precast gels) and 
SEC. Specific details for the protein production of the three proteins are shown in Table 
3.1. 
Protein 
(MW, 
kDa) 
Restriction 
enzymes (Insert 
size, bp) 
Expression 
Lysis buffer, 
Ni-NTA 
(buffer A) 
Ni-NTA 
(buffer B) 
SEC 
(buffer C) 
PaKynB 
(23.2) 
NdeI/XhoI 
(645) 
BL21(DE3) 
pLysS, 1mM 
IPTG, 16ºC 
O/N 
25 mM Tris-
HCl, pH 7.5, 
and 100 mM 
NaCl  
Buffer A 
and 0.5 M 
imidazole 
10 mM NaH2PO4/Na2 
HPO4 pH 7.8, 20 mM 
NaCl and 0.5 mM 
Tris-HCl 
BcKynB 
(23.2) 
NdeI/XhoI 
(645) 
BL21(DE3) 
pLysS, 1 mM 
IPTG, 16ºC 
O/N 
25 mM Tris-
HCl, pH 7.5, 
and 100 mM 
NaCl 
Buffer A 
and 0.5 M 
imidazole 
10 mM NaH2PO4/Na2 
HPO4 pH 7.8, 20 mM 
NaCl and 0.5 mM 
Tris-HCl 
BaKynB 
(22.7) 
NdeI/BamHI 
(633) 
BL21(DE3), 1 
mM IPTG, 
20ºC O/N 
20 mM Tris-
HCl, pH 7.4, 
and 200 mM 
NaCl 
Buffer A 
and 0.8 M 
imidazole 
Buffer A 
 
Protein concentrations were measured by absorbance at 280 nm using the Lambert-Beer 
law and the predicted molar extinction coefficients estimated using the ExPASy 
bioinformatics resource portal PROTPARAM (Gasteiger et al., 2003): 
ε(PaKynB)=28210  M-1 cm-1, ε(BcKynB)=28210 M-1 cm-1 and ε(BaKynB)=20970 M-1 
cm-1. 
 
3.2.2 Crystallographic analysis  
3.2.2.1 Crystallisation and diffraction measurements 
Pure PaKynB and BcKynB were concentrated to 7.5 mg ml-1 and BaKynB to 4 mg ml-1 
in buffer A to provide a stock solution for crystallisation experiments. Commercial 
Table 3.1: Protein production details for KynB including: the restriction enzymes used 
for the cloning, the protein expression conditions (E. coli strain, IPTG concentration 
and overnight (O/N) culture temperature), and buffers used during purification (buffers 
A, B and C). Protein molecular weight and corresponding gene size are annotated in 
brackets in the first two columns.  
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screens from Molecular Dimensions and Qiagen were used as the first crystallisation 
trials. These were performed in 96-well sitting drop plates with a Phoenix liquid 
handling system (Rigaku-MSC) using a ratio of 1:1 for protein solution:reservoir and 
final volumes of 0.2 and 0.4 µl for every condition. Then, plates were incubated at room 
temperature in a Gallery DT plate hotel (Rigaku-MSC). 
 
In the case of PaKynB, a number of promising conditions were identified from the 
crystallisation screens Morpheus (Molecular Dimensions), The Classics Suite (Qiagen), 
JSCG Plus (Molecular Dimensions) and MIDAS (Molecular Dimensions). Crystals 
were obtained after 2 to 30 days of incubation at 21ºC. Optimisation in hanging drop 
plates gave some improvement, however most of the crystals obtained were small 
(maximum dimension less than 15 µm) and the biggest PaKynB crystal was around 40 
x 20 x 20 µm in a condition containing 0.1 M HEPES pH 7.5, 0.1 M NaCl and 1.6 M 
(NH4)2SO4. Crystals were tested in-house and at the Diamond synchrotron using from 
20 to 80% (v/v) glycerol for cryo-protection and then flash frozen in liquid nitrogen. 
These crystals showed no diffraction. Parallel experiments carried out by Dr. V. 
Srikannathasan, gave improved PaKynB crystals and the structure was determined. The 
reservoir condition contained 0.1 M Hepes, pH 7.5, 20% (w/v) PEG 4000 and 10% 
(v/v) propan-2-ol. The BcKynB crystal was obtained by Dr. V. Srikannathasan using a 
reservoir comprising 13% (w/v) PEG 3350, 5 mM CoCl2, 5 mM CdCl2, 5 mM MgCl2 
and 5 mM NiCl2. 
 
Before data collection, crystals were incubated for a few seconds in a solution 
containing the reservoir condition and 25% (v/v) glycerol. Diffraction data for PaKynB 
and BcKynB were collected on the Diamond Light Source beamline I03 using a Pilatus 
6M-F detector, indexed and integrated using XDS (Kabsch, 2010), scaled and analysed 
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with SCALA and POINTLESS (Evans, 2005) from the CCP4i suite (Winn et al., 2011). 
The first BaKynB crystals were obtained using The PEGs Suite (Qiagen) and The 
Classics Suite. Optimisation was carried out and small diffracting crystals obtained 
using a reservoir containing 0.1 M Tris-HCl pH 8.5, 0.15 M MgCl2, and 30% PEG 
4000. They were flash frozen in liquid nitrogen and tested on the in-house X-ray 
generator and Diamond Light Source I03. These samples were mechanically twinned 
and further optimisation was required. The experiment consisted of 24-well hanging 
drop plates, including different dioxane concentrations (from 1% (v/v) to 5% (v/v)), and 
a ratio of 1:1 in final volumes of 2 and 4 µl at 20◦C. The presence of 1.5-2% (v/v) 
dioxane improved the quality of the sample and BaKynB crystals were flash frozen 
directly from the drops in which they grew. Diffraction data were obtained using the in-
house X-ray facility (Rigaku M007HF X-ray generator with a Saturn 944HG+ CCD 
detector). Data were indexed and integrated using iMOSFLM (Leslie and Powell, 2007) 
and scaled and analysed by AIMLESS (Evans, 2011) from the CCP4i suite. To obtain 
information about the binding of the product, co-crystallisation in the presence of L-
kynurenine was carried out. If the substrate NFK were added, the reaction would have 
progressed whereas KynB requires the presence of both products, L-kynurenine and 
formate, for the reverse catalysis. Prior to crystallisation, the BaKynB protein stock 
solution was incubated with 8 mM L-kynurenine for 10 minutes at room temperature. A 
compound that mimics the substrate and product structures, 2-aminoacetophenone 
(Figure 3.1), was also used for co-crystallisation. To obtain crystals of the BaKynB:2-
aminoacetophenone complex, the protein was incubated with 5% (v/v) of the compound 
before crystallisation. Preparation of the ligand stock at 20% (v/v) concentration was 
performed in a solution containing buffer A and 20% (w/v) PEG 4000. Diffraction data 
for the BaKynB:2-aminoacetophene complex were obtained at the Diamond Light 
Source using beamline I03. The data showed the BaKynB:2-aminoacetophenone crystal 
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is isomorphous with the previous BaKynB crystals. 
 
3.2.2.2 Structure determination 
The first KynB structure, PaKynB, was determined by Dr. V. Srikannathasan using 
molecular replacement (MOLREP, Vagin and Teplyakov, 2009) with one subunit of a 
putative metal-dependent hydrolase from Geobacillus stearothermophilus 
(GsHydrolase, PDB code 1R61). All water molecules and ions were removed from the 
search model. The GsHydrolase structure shares 25% sequence identity with PaKynB. 
The resolution of the search model is 2.5 Å and one Zn2+ was included in the active site. 
However, the ion was assigned an occupancy of 0.5 and had a B-factor of about 90 Å2. 
No publication is available so there are no details about the Zn2+ assignment. PaKynB 
and BcKynB share a sequence identity of 64% so the BcKynB structure was solved 
using a partially refined PaKynB as the search model (by Dr. V. Srikannathasan) and 
then the BaKynB structure was solved using BcKynB (40% sequence identity) as the 
search model. Refinement protocols for the different models were similar. These 
involved first rigid body refinement as part of the molecular replacement calculations, 
then iterative cycles of restrained refinement combining REFMAC (Murshudov et al., 
2011) with electron and difference density map inspections, and model manipulations in 
COOT (Emsley et al., 2010). The starting B-factors for each model were derived from 
the Wilson B-factor. The number of peptide chains in the asymmetric unit was 
estimated using the Matthews coefficient (Vm), which refers to the crystal volume per 
unit of molecular weight. It is calculated from the volume of the unit cell, protein 
molecular weight, the number of asymmetric units within the unit cell and the number 
of molecules in the asymmetric unit (N). Vm values are calculated for different N and 
compared with the experimental data from the PDB. The probability of presenting a 
particular N is determined by the proximity of Vm to an experimental range 
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(Kantardjieff and Rupp, 2003). Determination of Vm and the percentage of bulk solvent 
(disorder solvent between protein molecules in the crystals, Weichenberger et al., 2015) 
values were carried out with CCP4i. Two polypeptide chains constitute the asymmetric 
unit of PaKynB (showing a Vm of 3.6 Å3 Da-1 and bulk solvent 66%) and four in the 
case of BcKynB (Vm 2.8 Å3 Da-1, bulk solvent 56%) and BaKynB (Vm 2.2 Å3 Da-1, bulk 
solvent 44%). Tight non-crystallographic symmetry (NCS) restraints were imposed at 
the beginning of all refinements, which were gradually released during the process. 
Additionally, the weighting of the external restrains was modified from the default 
parameters. The weighting values were obtained from PDB_REDO (Joosten et al., 
2014). Although L-kynurenine was present in the crystallisation mixture, no evidence of 
its presence was found in electron density maps. Even with a higher concentration of 2-
aminoacetophenone present, this ligand was only observed in one active site. Once the 
protein structures were complete, alternative side-chain rotamers, water molecules, 
metal ions and ligands were incorporated into the models. A correction for a twinning 
component of 0.15, calculated in REFMAC, was applied in refinement of the 
BaKynB:2-aminoacetophenone complex. Refinements were terminated when geometry 
of the model did not improve, there were no significant changes in Rwork and Rfree values 
and inspection of the difference density maps suggested that no further corrections or 
additions were justified.  The assignment of the two cations present in the active sites is 
described below. 
 
3.2.2.3 Cation identification  
The difference Fourier maps suggested the presence of metals in the active site. The 
presence of Zn2+ was first confirmed in PaKynB and BaKynB crystals using X-ray 
absorption near-edge structure (XANES) spectroscopy measured at Diamond Light 
Source on beamline I03 using a Vortex Silicon Drift detector and an excitation energy 
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range from 9626.7 to 9690.14 eV. Since no Zn2+ was added during protein production, 
purification or crystallisation, then the most likely source is the media used to culture 
the E. coli. In the case of BcKynB, crystals grew in the presence of different metal ions 
(5 mM CoCl2, 5 mM CdCl2, 5 mM MgCl2 and 5 mM NiCl2 ) so XANES spectroscopy 
was not suitable for the determination of the presence of non-added metal ions in the 
loop. 
 
The electron density and anomalous scattering were used to identify the two cations 
present in the BcKynB active site. Firstly, 12 sulfur atoms in the asymmetric unit, with 
an average B-factor of 16.4 ± 4.1 Å2, were removed from the model to calculate their 
positive density in a difference Fourier map. The average peak height was 17.6 ± 3.2 σ 
what gives 1.1 σ per electron. In the case of the BcKynB metal ion sites, the map 
showed positive density peaks with heights of 46.5 ± 4.6 σ (peak-1, corresponding with 
42 e-) and 68.4 ± 4.6 σ (peak-2, 62 e-) in the four active sites. These height values 
indicate the presence of two different metal atoms per active site. The coordinating 
atoms surrounding the metal ions sites are more ordered than the 12 sulfur atoms 
removed for this calculation. The average B-factor of these atoms is 10.6 ± 1.1 Å2 for 
the peak-1 site and 11.9 ± 2.4 Å2 for peak-2 (1.5 and 1.3 times lower than sulfur, 
respectively). Taking this into account, a B-factor-adjusted calculation suggests that the 
ions sites are occupied by ions of approximately 28 e- (peak-1) and 48 e- (peak-2). 
Comparing these values with the atomic numbers of the metals present in the 
crystallisation condition suggested peak-1 corresponds with a Zn2+ ion and peak-2 with 
a Cd2+ since the expected values for these ions are 28 and 46 e-, respectively. The 
average refined B-factors for Zn2+ and Cd2+ are 10.1 ± 1.1 and 11.4 ± 1.1 Å2. Additional 
confirmation was obtained by an anomalous dispersion difference Fourier calculation. 
Data collection was performed at λ = 0.9795 Å. At this wavelength the theoretical f ′′ 
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values for Zn2+ and Cd2+ are 2.480 and 2.132 e- (Sasaki, 1989). Therefore, an 
anomalous difference Fourier would show a slightly larger signal at the Zn2+ position. 
The program FFT (Fast Fourier Transform) from the CCP4i suite was used to determine 
the anomalous difference Fourier map. The average heights of the peaks are 24.2 ± 1.6 
σ at the Zn2+ site and 22.5 ± 1.8 σ at Cd2+ over the four subunits, and the difference 
between the heights was consistent in the four active sites of the asymmetric unit (1.7 ± 
0.2 σ). This matches with the expected result confirming the presence of one Zn2+ and 
one Cd2+ at each active site. 
 
3.2.2.4. Purification and structure determination of BaKynB in the presence of EDTA 
Crystallographic data indicated two Zn2+ ions were present in the active site of 
BaKynB. To check the involvement of the Zn2+ in the reaction, enzymatic assays were 
carried out in the presence of EDTA. This compound is a standard high affinity cation-
chelating agent. No decrease in enzyme activity was observed when the assay buffer 
contained 100 mM EDTA (See Results and discussion, section 3.3.4). To check whether 
the Zn2+ ions can be removed or not by the EDTA, BaKynB was incubated with 10 mM 
EDTA (BaKynB-EDTA) at 4ºC overnight. As a control, BaKynB in the absence of 
EDTA was also incubated under the same conditions. Excess EDTA was removed by 
SEC. These samples were assayed at 1 mM NFK concentration, in the presence and 
absence of 50 mM EDTA or 0.2 mM ZnCl2.  
 
BaKynB-EDTA was crystallised, in the same conditions as BaKynB, in the absence and 
presence of 5 mM CdCl2 (BaKynB-EDTA-Cd2+) to test Cd2+ binding. Diffraction data 
were collected at Diamond Light Source beamline I03. Data reduction and analysis was 
performed using iMOSFLM and AIMLESS. The cell content analysis using the 
Matthew’s coefficient suggested the presence of two peptide chains in the asymmetric 
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unit (Vm value of 2.1 Å3 Da-1 and bulk solvent of 41% for both samples), indicating the 
crystals were not isomorphous with the previous BaKynB (space groups and cell 
dimensions are detailed in section 3.3.2). The structures were solved using MOLREP 
and the BaKynB dimer as the search model. A round of rigid body refinement using 
REFMAC was carried out and the difference Fourier map obtained. Peaks of positive 
density were observed in the Zn2+ binding sites (Table 3.2). Only two sulfur atoms were 
available in the structures (Met47) and used for the number of e- determination for each 
peak. The results are similar to the other KynB. In the case of BaKynB-EDTA structure, 
two Zn2+ are present in the active site. For BaKynB-EDTA-Cd2+ the calculated e- values 
are bigger than expected but the difference in the peak height indicates two different 
metal ions are present, as shown for BcKynB. The crystallisation condition contained 
only two metals ions; Zn2+ and Cd2+, so the cations were included in the model. For 
both structures, a round of refinement was performed to generate difference Fourier 
maps and B-factors of the metal sites. No difference map peaks at the cation positions, 
were observed. Reasonable B-factors were obtained in BaKynB-EDTA-Cd2+. In the 
case of BaKynB-EDTA, higher B-factors were noticed (Table 3.2). This could be 
explained if not all the metal sites in the crystal were fully occupied. Full refinement of 
these structures was not continued. The presence of Cd2+ is consistent with BcKynB 
results. 
 
 
 
 
Protein Peak height average, and calculated e
- number B-factors average (Å2) 
Site 1  Site 2  Sulfur  Site 1  Site 2  Sulfur  
BaKynB-
EDTA 
12.5 ± 0.3 σ 
(25 e-) 
13.6 ± 1.1 σ 
(27 e-) 7.8 ± 0.7 σ 
46.3 
± 4.0 
47.6 
± 1.3 
37.9 
± 5.8 
BaKynB-
EDTA-Cd2+ 
15.0 ± 0.8 σ 
(38 e-) 
20.5 ± 2.1 σ 
(52 e-) 6.3 ± 1.0 σ 
19.0 
± 4.0 
27.4 
± 5.7  
28.4 
± 5.6 
Table 3.2: Analysis of the metal ion sites in BaKynB-EDTA and BaKynB-EDTA-Cd2+ 
structures. Average of the difference Fourier map peaks, calculated e- numbers and B-
factors for metal sites and sulfurs. 
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3.2.2.5 Analysis of models and structure comparisons 
MolProbity (Chen et al., 2010) was used to assess geometry of all models. The B-factor 
average was calculated using the software BAVERAGE from the CCP4i suite. 
Secondary structure determination used both DSSP (Touw et al., 2015) and visual 
inspection, and subunit interface surface area calculations were carried out with PISA 
(Krissinel and Henrick, 2007). Figures were prepared using ALINE (Bond and 
Schüttelkopf, 2009) and PyMOL (www.pymol.org). The DALI server (Holm and 
Rosenstrom, 2010) was used to search the PDB for structural homologues, whereas 
superpositions were calculated using DALILITE (Hasegawa and Holm, 2009).  
 
3.2.3 Enzymatic assay 
Kynurenine formamidase activity was measured using a spectrophotometric assay. The 
assay was optimised to obtain Km, Vmax and kcat values for KynB. The assay is based on 
the increase in absorbance due to L-kynurenine formation (Katz et al., 1987; Bougie, 
2011), which is detected by measuring the absorbance at 365 nm with a UV-2450 
Shimadzu spectrophotometer over a period of 160 seconds. Reactions were performed 
in triplicate using 1 ml final volume, at 25 ºC, using 0.025, 0.15, 0.25, 0.5, 0.7, 1, 1.5, 2 
and 3 mM NFK substrate (Dalton Pharma Services), and 500 ng of enzyme (20 nM). 
The buffer used contained 0.1 M NaH2PO4/Na2HPO4 pH 7.4, and 20 µM ZnCl2. His6-
tagged and non-His6-tagged proteins were tested to compare activities. Also, two 
additional pH values were used. In these cases, the assay buffers consisted of 
NaH2PO4/Na2HPO4 pH 8.4 and pH 6.4. The initial velocity for each substrate 
concentration were calculated by fitting a linear equation to the data of the increase in 
L-kynurenine concentration during 1 min, and data were analysed using the Michaelis-
Menten equation (SigmaPlot, Systat Software). The L-kynurenine concentration was 
calculated using the Lambert-Beer law and ε365 of 4220 M
-1 cm-1 (Bougie, 2011). 
Part Three: Kynurenine formamidase  	
	
39 
3.2.4 Tryptophan fluorescence: fluorescence spectroscopy 
Tryptophan fluorescence was used to investigate ligand binding. If the association of a 
ligand causes a conformational or environmental change in tryptophan residues, a 
difference in fluorescence may be observed. Fluorescence measurements for BaKynB 
were performed using a LS-55 PerkinElmer spectrometer. To determine the maximum 
fluorescence due to tryptophan the excitation used was 280 nm and the emission 
wavelength detection ranged from 300 to 400 nm. The sensitivity of the detector was 
fixed to 800 V, and the peak of maximum emission was experimentally determined to 
be 337 nm. The sample (2 ml) contained 20 µg of BaKynB (400 nM), 0.02 M Tris/HCl, 
pH 7.4 and 0.2 M NaCl. The two products of the KynB catalysed reaction, L-
kynurenine and formate, and 2-aminoacetophenone were investigated separately. 
Concentrations ranged from 0 to 800 µM, with increments of 5 µM (for low 
concentrations), 10 µM (from 200 µM to 500 µM of ligand) and 100 µM (high 
concentrations) in the case of L- kynurenine and 2-aminoacetophenone. For formate, 
concentrations from 0 to 500 µM (same increments) were tested. A control experiment 
was carried out to check if there was fluorescence emission from L-kynurnine or 2-
aminoacetophenone. The buffer in the presence of the maximum concentration of ligand 
and no protein present showed no fluorescence emission from either L-kynurenine or 2-
aminoacetophenone under the experimental conditions. Results were represented as 
percentage of protein saturation within different ligand concentrations to determine Kd 
values using the one-site saturation binding curve using GraphPad Prism 
(www.graphpad.com). 
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3.3 Results and discussion 
 
3.3.1 Recombinant protein production 
Recombinant protein expression optimisation provided a yield of 10 mg L-1 in the case 
of PaKynB and BcKynB, and 53 mg L-1 for BaKynB. SDS-PAGE indicated a high level 
of purity for the three samples. A native-PAGE and SEC were performed to investigate 
the BaKynB quaternary structure. Results showed a band of approximately 43 kDa and 
a peak of about 46 kDa (SEC) indicating dimer formation. The MALDI-TOF trace also 
indicated highly pure samples had been obtained, and confirmed the monomer 
molecular weight (23.38 kDa). A peak corresponding with the dimer molecular weight 
(46.78 kDa) was observed (data not shown). Similarly, the MALDI-TOF trace of 
PaKynB showed two peaks of 23.36 and 46.76 kDa. 
 
In the case of PaKynB, His6-tag cleavage by TEV protease was not efficient and severe 
protein aggregation/precipitation was observed. To improve His6-tag cleavage, different 
incubation temperatures and times were tested. Severe protein aggregation was 
observed when using temperatures lower than 30ºC, and incubation times longer than 2 
hours at 30ºC. The enzyme assay (see later) indicated that the His6-tag PaKynB 
possessed a level of activity comparable with that of other samples, and the non-His6-
tag protein was inactive. Consequently, the His6-tag of PaKynB was left on for further 
experiments. Non-His6-tagged BakynB and BcKynB samples were always used unless 
otherwise indicated. 
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3.3.2 Crystallisation and structure determination 
PaKynB crystals were obtained for a range of crystallographic conditions, however they 
did not diffract (Figure 3.3). Eventually, diffracting crystals for PaKynB and BcKynB 
were obtained by Dr.V. Srikannathasan.  
 
BaKynB aggregated at relatively low concentrations (7 mg ml-1). The protein stock was 
finally set up to 4 mg ml-1 in buffer A. Optimisation was carried out and resulted in 
crystals large enough to test on the in-house X-ray generator and at the Diamond Light 
Source beamline I03. Good diffraction was obtained from the crystal in Figure 3.4A but 
it showed twinning and the space 
group could not be assigned reliably. 
The crystal appearance and the 
splitting of the diffraction intensities 
(Figure 3.4B) suggest a mechanical 
twin. Further crystallisation 
optimisation was performed in the 
presence of various dioxane 
concentrations. Well-ordered 
diffracting crystals were obtained 
and structure determination pursued. 
Additionally, well-diffracting 
crystals grew in the presence of 2-
aminoacetophenone and provided a dataset for determining a ligand:protein complex 
Figure 3.3: PaKynB crystals. (A) Hanging 
drop: 0.05 M HEPES pH 7.5, 1% (v/v) 
PEG 400, 1 M (NH4)2SO4 and 4 mg ml-1 
protein in buffer A. (B) Sitting drop:  
0.05 M HEPES pH 7.5, 0.05 M NaCl, 0.8 
M (NH4)2SO4, and 4 mg ml-1 protein in 
buffer A. 
B	
50	µm	
A	
50	µm	
Figure 3.4: BaKynB diffracting crystals. (A) 
Hanging drop: 0.05 M Tris-HCl pH 8.0, 0.15 M 
MgCl2 and 15% (w/v) PEG 4000, and 2 mg ml-1 
protein in buffer A. (B) Diffraction pattern from 
crystal A and an image expansion to show a 
mechanical defect.  
A 
B 
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structure. The crystallographic statistics for KynB are shown in Table 3.3. Statistics are 
shown in Table 3.4 for the crystals obtained after BaKynB incubation with EDTA. 
 
 
  
Structure PaKynB BcKynB BaKynB BaKynB:ligand 
PDB code 4COB 4COG 4CO9 4CZ1 
Space group P3121 P21 P21 P21 
Wavelength (Å) 0.9795 0.9795 1.5418 0.9791 
Unit cell dimensions    
a, b, c (Å) 
112.7, 112.7 
90.76 
76.9, 50.1, 35.2, 
β=94.14º 
73.2, 66.0, 83.8, 
β=90.32º 
73.7, 66.6, 84.0, 
β=90.24º 
Resolution rangea (Å) 28.90 - 2.37 28.37 - 1.60 42.48 - 1.95 42.64 - 2.25 
No. reflections 133546 479924 202165 104599 
Unique reflections 27365 134904 58336 38046 
Completeness (%) 99.2 (94.5) 99.3 (99.8) 99.4 (94.1) 98.1 (97.7) 
Rmergeb 0.057 (0.571) 0.068 (0.477) 0.063 (0.166) 0.164 (0.551) 
Redundancy 4.9 3.6 3.5 2.7 
< I/σ(I)> 16.8 (2.4) 12.8 (3.0) 11.1 (4.3) 4.8 (2.2) 
Wilson B (Å2) 43.87 14.97 11.84 15.33 
Rworkc/Rfreed 0.1519 / 0.1945 0.1489 / 0.1842 0.1715 / 0.2066 0.1837 / 0.2241 
DPIe (Å) 0.198 0.068 0.137 0.086 
Bond lengths r.m.s.d. 
(Å) / anglesf (º) 0.018 / 1.890 0.025 / 2.429 0.008 / 1.322 0.017 / 1.684 
Average B-factors (Å2) 51.4 16.4 15.3 20.9 
Protein residues 412 831 829 825 
Water molecules 181 1068 906 793 
Metal ions 4 Zn2+ 4 Zn
2+, 4 Cd2+, 8 
Mg2+ 8 Zn
2+, 5 Mg2+ 8 Zn2+, 3 Mg2+ 
Ligands - 
12 glycerol, 10 
1,2-ethanediol, 1 
polyethylene 
glycol 
2 dioxane, 3 1,2-
ethanediol 
2-amino 
acetophenone 
Ramachandran 
analyses     
Favoured regions (%) 96.1 96.1 97.2 96.5 
Allowed regions (%) 100 100 100 100 
Table 3.3: Crystallographic statistics. a. Values in parentheses refer to the highest 
resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i Ii(hkl); where Ii(hkl) is the 
intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean value of 
Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed 
structure factor and Fc is the calculated structure factor. d. Rfree is the same as Rwork 
except calculated with a subset, 5 %, of data that are excluded from the refinement 
calculations. e. Diffraction Precision Index (Cruickshank, 1999). f.(Engh and Huber, 
1991). 
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Structure BaKynB-EDTA BaKynB-EDTA-Cd2+ 
Space group P21 P21 
Wavelength (Å) 0.9791 0.9791 
Unit cell dimensions    
a, b, c (Å) 
65.8, 44.8, 67.8 
β=107.6 
65.9, 44.9, 68.2  
β=108.0 
Resolution rangea (Å) 53.92 - 2.30 64.88 - 2.7 
No. reflections 60829 60831 
Unique reflections 16737 10690 
Completeness (%) 98.6 (98.2) 100 (100) 
Rmergeb 0.115 (0.651) 0.171 (0.638) 
Redundancy 3.6 (3.5) 5.7 (6.0) 
< I/σ(I)> 6.8 (2.4) 11.8 (7.2) 
Wilson B (Å2) 24.49 21.67 
Rworkc/Rfreed 0.1919 / 0.2725 * 0.2103 / 0.2779 * 
Table 3.4: Crystallographic statistics. a. Values in parentheses refer to the highest 
resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i Ii(hkl); where Ii(hkl) is the 
intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean value of 
Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed 
structure factor and Fc is the calculated structure factor. d. Rfree is the same as Rwork 
except calculated with a subset, 5 %, of data that are excluded from the refinement 
calculations. (*) Refinement not completed. 
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3.3.3 KynB structure 
The high structural homology between the KynB structures means that only one 
representative needs to be described in detail, concentrating on BaKynB since there are 
high resolution apo and ligand-bound structures. Four subunits (A, B, C and D) are 
found in the asymmetric unit of BaKynB and BcKynB, and two (A and B) in PaKynB. 
 
3.3.3.1 Overall structure and dimer formation 
KynB structure shows a new amidase fold 
unrelated to KFase. Each monomer contains 
12 β-strands, four α-helices and three short 
segments of 310-helix between β4 and β5 
(Figure 3.5). Eight of the β-strands form a 
β-barrel-like domain if considering β1 and 
β4 as a single strand. One side of the β-
barrel-like domain is surrounded by three α-
helices. This fold is highly conserved within 
the KynB structures, consistent with the 
high degree of their amino acid sequence 
identity. KynB homologues for Gram-
negative (BcKynB and PaKynB) share 
about 64% identity while Gram-positive 
(BaKynB) and Gram-negative have 40% 
(Figure 3.6). 
Figure 3.5: Cartoon representation of 
BaKynB dimer. The front (top image) 
and lateral (bottom) views are shown. 
Subunit A: blue (β-strands), red (α-
helices) and green (loops). Subunit B: 
yellow. α-helices are numbered using 
α followed by numbers. β-strands are 
named with numbers. Zn2+ ions are 
represented as grey spheres.  
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The KynB crystal structures showed dimer formation (A-B and C-D subunits, Figure 
3.5). This is consistent with the results from native-PAGE and SEC analysis. The dimer 
interface is formed by interaction of about 25% of the accessible surface area of each 
subunit. It involves the interaction of β1, β11, β12, and short helical segments between 
residues 68 and 74 from both subunits. The dimer arrangement results in the formation 
of a characteristic feature of this fold, an antiparallel four-stranded β-sheet involving 
β2-β3 from each subunit. The arrangement of the subunits is also highly conserved. The 
overlay of the KynB monomers and dimers (Appendix B) shows a high structural 
homology between the different homologues. In BaKynB and BcKynB, subunits A and 
C have higher structural similarity than A and B (or D and C), and the same feature 
applies to B and D subunits. Dimer overlay (Figure 3.7) gives r.m.s.d. (root-mean-
square deviation) values between the Gram-negative representatives of 0.7 Å, and 
between Gram-positive and Gram-negative about 1.25 Å (Appendix B). More 
Figure 3.6: Alignment of BaKynB, PaKynB and BcKynB amino acid sequences. 
Highly conserved residues are annotated in black, and conserved in two of the proteins 
in grey. BaKynB secondary structure is represented as red cylinders (α-helices) and 
blue arrows (β-strands). Amino acids present in the active site pocket are indicated with 
green triangles. Red triangles and red star mark residues implicated in enzyme 
catalysis. The green star indicates a conserved tryptophan in the active site pocket.  
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specifically, residues that are conserved in all KynB subunits are positioned in the 
active site pocket and the β-barrel like domain. 
 
3.3.3.2 The KynB active site  
The active site pocket is mainly formed by residues from loops between β1-β2, β3-β4 
and β4-β5, from α4 and β10 from one subunit and β3 from the other (Figure 3.5). 
Structural comparisons indicate that the details in the active sites are conserved (Figure 
3.8). In the active site two cations interact with His50, His54, Asp56, His161 and 
Glu173 in BaKynB and BcKynB, and His48, His52, Asp54, His160 and Glu172 for 
PaKynB. There is also a residue that might be important for substrate recognition (see 
later), Trp20 (Trp18 in PaKynB) that confers a hydrophobic environment. An 
investigation of available KynB amino acid sequences was conducted. First, a search of 
the bacterial kynurenine formamidase proteins annotated in UniProt (www.uniprot.org) 
was performed. This gave 380 unique sequences. The search was then filtered to 336 
entries that share 30% sequence identity or more with BaKynB using the NCBI BLAST 
server (National Center for Biotechnology Information Basic Local Alignment Search 
Tool, Johnson et al., 2008). Sequences were aligned using Clustal Omega (Sievers et 
al., 2011). The result showed His54, Asp56 and His60 are strictly conserved in all 
A B 
Figure 3.7: (A) Overlay of the Cα atoms from BaKynB, PaKynB and BcKynB. 
Colours indicate the sequence identity; red (residues conserved in every protein), 
yellow (residues conserved in two of the proteins), grey (non-conserved residues). (B) 
Surface representation of the BaKynB dimer and coloured with sequence identity 
conservation from A. The arrow indicates the active site pocket. 
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sequences, while His50, His161 and Glu173 are present in 99.7% of the entries. Trp20 
is conserved in 81% of the entries and in 17.8% phenylalanine and tyrosine occupy the 
same position. These results confirm the importance of cation-interacting residues and 
the presence of an aromatic group in the active site pocket. 
 
Two Zn2+ ions were first found in the PaKynB and BaKynB active sites. In the case of 
BcKynB one Zn2+ and one Cd2+ were present in each active site. The presence of the 
Zn2+ ions in PaKynB and BaKynB was confirmed by XANES measurements (Figure 
3.9) and difference Fourier maps. BcKynB cation characterisation was assessed by 
difference Fourier and anomalous difference Fourier maps (Figure 3.10). Three ordered 
waters were observed binding the cations in BaKynB and generate a Zn2+ coordination 
number of six. For PaKynB, only two waters are visible, probably due to lower 
resolution, and in BcKynB waters have been replaced by glycerol (Figure 3.8). 
Figure 3.8: KynB active site. (A) Superposition of BaKynB (violet), BcKynB (blue) 
and PaKynB (yellow) active sites. (B) The BaKynB active site with difference density 
for the water molecules (red spheres) showed as green chicken wire and contoured at 
5σ. (C) The BcKynB active site with glycerol bound to the metal ions. (D) The PaKynB 
active site. Coordination contacts are shown as continuous lines and Zn2+ ions as grey 
spheres. 
A 
C D 
B 
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The structure of the BaKynB:2-aminoacetophenone complex provides information 
about substrate recognition (Figure 3.11). Compound binding was first confirmed using 
tryptophan fluorescence (see section 3.3.5). In the structure, 2-aminoacetophenone is 
aligned parallel to Trp20. This model also provides information about the reaction 
mechanism. The amino group and the oxygen from the keto group form an 
intramolecular hydrogen bond that will stabilise the conformation of the intermediate at 
the active site. The occurrence of the hydrogen bond was confirmed by a search of 
structurally related compounds at the Cambridge Structural Database (CSD, Allen, 
2002). A search of the two 2-aminoacetophonone conformations (with and without the 
intramolecular hydrogen bond) was carried out and identified 28 compounds containing 
the ligand scaffold. Inspection of these compounds showed the intramolecular hydrogen 
bond was present in all cases.  
Figure 3.9: XANES spectra. K-edge XANES spectra showing the anomalous scattering 
factor f’ and f’’ values within a range of X-ray energy from 9626.7 to 9690.14 eV. (A) 
BaKynB (B) PaKynB. 
Figure 3.10: Anomalous 
difference Fourier map for 
BcKynB. The map is shown 
as blue chicken wire (5.0 σ). 
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A comparaison with available structures was performed using the DALI web server. 
Results revealed similarity between KynB and three proteins. These are a putative 
metal-dependent hydrolase/cyclase (PDB codes 3KRV and 1R61, sequence identity 
25%) carrying one Zn2+, an isatin hydrolase containing a single Mn2+ (Bjerregaard-
Andersen et al., 2014, sequence identity 23%) and a hypothetical protein with no metal 
ion present (2B0A, sequence identity 23%). Proteins with PDB codes 3KRV, 1R61 and 
2B0A were solved by the Protein Structure Initiative (Gabanyi et al., 2011) and there 
are no accompanying publications. The isatin hydrolase, an α/β hydrolase, shows 
similarities with KynB in the overall structure, the active site residues and aspects of the 
metal ion binding (Figure 3.12). It has one Mn2+ ion bound to an Asp, and two His that 
are positioned in a similar manner to His50, Asp56 and His60 in BaKynB. Instead of a 
second metal, a water molecule is present contacting with the same Asp as Mg2+ and the 
other His (His161 in BaKynB). The residues at the equivalent positions of Trp20 and 
Glu173 are not conserved. Indeed, the Glu173 is replaced by an alanine. This might 
prevent the incorporation of a second metal ion in the active site. A leucine residue is 
placed in the Trp20 position maintaining the hydrophobic properties of this site. 
Figure 3.11: 2-aminoacetophenone 
(black) in the BaKynB active site. The 
ligand intramolecular hydrogen bond is 
represented as a dashed line, and water 
molecules as red spheres. 
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3.3.3.3 Reaction mechanism 
The presence of the two metal ions in KynB indicate a different mechanism to KFase 
and will likely follow acidic hydrolysis. The mechanism may be similar to that 
proposed for metalloenzymes from the amidohydrolase superfamily such as type B β-
lactamases (Schenk et al., 2012; Bebrone, 2007), phosphotriesterases (Bigley and 
Raushel, 2013), leucine aminopeptidases (Sträter et al., 1999) and dihydro-orotases 
(Lee et al., 2007). This family presents flexible loops at the active site important for 
substrate recognition (Seibert and Raushell, 2005). In KynB, the catalytic site is 
relatively rigid. More specifically, BaKynB Zn2+-binding residues have an average B-
factor of 9.6 Å2 while the overall average is 15.1 Å2. KynB functions with a binuclear 
Zn2+ active center which shares similarity with other metalloenzymes, for example 
phosphodiesterases and dihydro-orotases. In these proteins, the two Zn2+ are 3.5-4.0 Å 
apart and a low coordination number (four) allows the formation of an intermediate 
state by increasing coordination to five or six (Holm and Sander, 1997; Seibert and 
Raushel, 2005). In KynB, the cations are 3.1 Å apart in a more crowded environment 
and already have a coordination number of six. This suggests the coordinating water 
might be important for catalysis. 
W20	/	L35	
H161	/	H212	
H60	/	H83	
H50	/	H73	H54	/	H77	
D56	/	D79	
E173	/	A224	
Figure 3.12: (A) Cartoon representation of the Cα overlay of BaKynB  (yellow) and 
isatin hydrolase  (4J0N, green). Loops have been smoothed to facilitate the 
interpretation. (B) Sticks representation of the active sites pockets. Grey spheres: Zn2+ 
ions from BaKynB. Purple sphere: isatin hydrolase Mn2+ ion. 
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Following these considerations, a mechanism of catalysis can be proposed (Figure 
3.13). The binding of the substrate is driven by the presence of Trp20. The acidic 
environment provided by the binuclear Zn2+ decreases the water pKa. Then His60 
acquires a proton from the water and generates a hydroxide. This nucleophile attacks 
the carbonyl component of NFK. The intermediate formation will probably involve 
interaction with Ser149. The products are formed by proton donation from His60 to the 
amine and subsequently C-N bond breakage (Figure 3.13). 
 
 
 
3.3.4 Enzyme kinetics 
Enzyme assays confirmed the KynB proteins presented kynurenine formamidase 
activity and allowed the determination of kinetic parameters for different protein 
samples and pH values (Table 3.5). The assay was performed with His6-tagged and non-
His6-tagged proteins. In the case of PaKynB, only the protein containing the His6 tag 
was active but the other enzymes showed similar activities for both samples. Two 
additional pH values were tested for BaKynB. At pH 6.4 the activity remained similar 
to pH 7.4 and pH 8.5 showed a slightly higher activity.  
 
Figure 3.13: Proposed reaction mechanism. 
Formate 
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The kinetic parameters for PaKynB-His6, BaKynB and BcKynB are similar to each 
other. Streptomyces parvulus and Ralstonia metallidurans (Katz et al., 1987) KynB 
showed lower activities than the tested proteins. However, the reactions were carried 
out at 30◦C and 37◦C respectively, so the variation in activity might be due to the assay 
conditions. In the case of Bacillus cereus KynB (Bougie, 2011), the assays were 
performed at room temperature and the values are comparable to the data shown in 
Table 3.5. 
 
During the assay, at tested conditions and NFK concentrations, no substrate inhibition 
was observed and protein saturation was obtained at around 2 mM of NFK. Activity for 
Protein Vmax (nmol min-1) 
Km 
(mM) 
kcat 
(s-1) 
kcat / Km 
(M-1 s-1) x104 
SA 
(U mg-1) 
EDTA 
effect 
BaKynB 
pH 7.4* 65.41 ± 2.64 0.40 ± 0.05 50.56 12.64 130.82 No 
BaKynB-His6 
pH 7.4 48.45 0.44 37.45 8.51 96.90 No 
BaKynB 
pH 6.4 81.27 0.67 62.82 9.38 162.54 No 
BaKynB 
pH 8.5 142.83 0.82 110.40 13.46 285.66 No 
BcKynB 
pH 7.4* 58.15 ± 0.98 0.57 ± 0.02 43.94 7.71 116.30 No 
BcKynB-His6 
pH 7.4 57.39 0.78 43.37 5.56 114.78 No 
PaKynB-His6 
pH 7.4* 147.99 ± 8.42 0.98 ± 0.13 114.21 11.65 295.98 No 
BceKynB - 0.17 31.1 18.3 68.5 No 
SpKynB - 0.31 - - 26.8 No 
RmKynB - 0.075 0.77 1.03 3.5 Yes 
Table 3.5: Kinetic parameters of KynB samples. Vmax: maximum catalytic velocity. Km: 
Michaelis-Menten constant. Specific activity (SA): amount of active enzyme from the 
total protein quantity. kcat: number of substrate molecules that are transformed per 
active site and per time unit. kcat/ Km: defines the catalytic efficiency. EDTA effect: if 
there was an effect in enzyme activity when EDTA was present in the reaction solution. 
Bacillus cereus (BceKynB), Streptomyces parvulus (SpKynB) and Ralstonia 
metallidurans (RmKynB). (*) Samples used for crystallisation. Samples in blue indicate 
the assay was performed in triplicates and single assays are indicated in black. 
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BaKynB-His6 and BcKynB-His6 is similar to the non-tagged proteins, which were used 
for further assays. Higher activity is shown at pH 8.5 (Figure 3.14). 
BaKynB and PaKynB structures showed the presence of two Zn2+ ions at the active site. 
Assays were performed in the presence of different concentrations of EDTA. If the 
cations are required for catalysis, then the enzyme should have a lower enzyme activity 
in the presence of EDTA compared to the normal assay. Initial assays showed no 
activity decrease when EDTA was added up to 100 mM. Subsequently, the following 
experiment was performed.  
 
BaKynB was incubated with and without 10 mM EDTA (BaKynB-EDTA) at 4ºC 
overnight before SEC. These samples were then assayed in the presence and absence of 
EDTA or ZnCl2. Results showed a very small decrease in activity for BaKynB-EDTA 
in comparison with the control sample (Table 3.6). Comparing the samples in the 
presence and absence of 50 mM EDTA, BaKynB-EDTA samples showed 1.8 times less 
initial velocity. When 0.2 mM ZnCl2 was added, BaKynB-EDTA sample increased its 
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Figure 3.14: (A) Initial velocity plotted against substrate concentration for the different 
protein samples;  (green) PaKynB-His6, (dark blue) BaKynB, (red) BcKynB, (light 
blue) BaKynB-His6, (orange) BcKynB-His6. (B) Initial velocity against substrate 
concentration at three different pH values; (green) BaKynB pH 8.5, (purple) BaKynB 
pH 6.4, (blue) BaKynB pH 7.5. 
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activity 2.5 times and BaKynB sample 1.5 times. Assuming, Zn2+ is important for 
catalysis, incomplete removal of the Zn2+ ions by the EDTA could explain this result. 
The presence of a small amount of Zn2+-free protein may explain the decrease in 
activity. The increase in protein activity by the addition of ZnCl2 could be an indication 
for an activating role of Zn2+. In addition, crystallography was performed with 
BaKynB-EDTA to confirm if the Zn2+ was completely removed after the EDTA 
incubation. Diffracting crystals were obtained for BaKynB-EDTA and BaKynB-EDTA 
incubated with 5 mM CdCl2 (BaKynB-EDTA-Cd2+). BaKynB-EDTA revealed two Zn2+ 
ions were present at the active site. Data from BaKynB-EDTA-Cd2+ showed one Zn2+ 
and one Cd2+ at the active site of every subunit (Figure 3.15). 
 
 
 
 
 
These results suggest that either Zn2+ has not been removed after protein incubation 
with EDTA or, taking into account the enzymatic data, a small amount of the cation was 
removed. One explanation might be that the active site is not accessible for EDTA to 
chelate and extract the cations. That Cd2+ can replace one of the Zn2+ ions is probably 
due to a higher affinity for one of metal sites, together with the high concentration used. 
Protein EDTA 50 mM 
0.2 mM 
ZnCl2 
Vo 
(nmol min-1) 
BaKynB-EDTA - - 15.6 
BaKynB-EDTA + - 17.1 
BaKynB-EDTA - + 38.4 
BaKynB - - 27.0 
BaKynB + - 29.9 
BaKynB - + 41.2 
Table 3.6: Summary of the EDTA experiment results. BaKynB-EDTA: sample 
incubated with 10 mM EDTA over night. BaKynB: sample incubated without EDTA 
overnight. In column two it is indicated if 50 mM EDTA was added (+) or not (-) to the 
assay mixture. In column three it is indicated if 0.2 mM ZnCl2 was added (+) or not (-) 
to the assay mixture. Vo: initial velocity in nmol of L-kynurenine per minute. 
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3.3.5 Fluorescence spectroscopy of BaKynB 
The presence of a tryptophan at the active site pocket allowed the study of binding of 
various compounds using fluorescence spectroscopy. Binding of L-kynurenine, formate 
and 2-aminoacetophenone with BaKynB was investigated. When L-kynurenine and 2-
aminoacetophenone were added there was a decrease of the fluorescence emission and 
shift of the maximum from 337 nm to 310 nm (Figure 3.16). 
Figure 3.15: Difference Fourier peaks for metal sites. Blue maps are the electron 
density maps at contoured level 2.0 σ, and the difference maps are shown in green (A) 
BaKynB-EDTA, difference map at 5.0 σ. (B) BaKynB-EDTA-Cd2+, difference map at 
11.0 σ. 
A B 
Zn2+ 
Zn2+ 
Zn2+ 
Cd2+ 
Figure 3.16: Emission spectra from BaKynB using an excitation wavelength of 290 
nm. (A) In the presence of L-kynurenine. Titration with 2-aminoacetophenone gave 
similar results. Red line: Without L-kynurenine. (Maximum InF peak at 337 nm). Top 
green line: Lowest L-kynurenine concentration tested. Dark blue bottom line: Highest 
concentration of L-kynurenine tested. (Shift of the maximum InF to 310 nm). (B) In the 
presence of formate. Maximum InF peak at 337 nm.  
  
  
A B 
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This confirmed the binding of 2-aminoacetopenone and L-kynurenine with Kd values of 
60 µM and 50 µM, respectively (Figure 3.17). In the case of L-formate, no differences 
in fluorescence were detected with the increasing concentrations of the compound. 
These results are consistent with the proposed reaction mechanism. As inferred from 
BaKynB:2-aminoacetophenone structure, L-kynurenine and 2-aminoacetophenone bind 
parallel to the tryptophan. This creates quenching of the fluorescence emission and the 
binding can be detected. However, the location of formate in the active site would be far 
from the tryptophan and no interference with the fluorescence will be observed. 
 
3.4 Conclusions 
 
Three KynB enzymes from different bacteria, including Gram-negative and Gram-
positive representatives, were cloned, expressed, purified, crystallised and the 
kynurenine formamidase activity confirmed. The structures showed a new amidase fold 
highly conserved across these species. The active site contains two Zn2+ ions in a rigid 
and crowded environment. The presence of Zn2+ indicates the amidase reaction takes 
place in an acidic environment and the mechanism diverges from KFase. The structure 
of a BaKynB:2-aminoacetophenone complex gave information about substrate binding 
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Figure 3.17: Plot of the percentage of enzyme saturation against L-kynurenine (green) 
and 2-aminoacetophenone (blue) concentration. 
Kd	≈	60	μM	 Kd	≈	50	μM	
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suggesting Trp20 is a key feature in KynB. Moreover, it provides information to 
propose a distinct amidase reaction mechanism.  
 
The differences found in protein structure and enzyme mechanism between the 
prokaryote kynurenine formamidase and the eukaryote KFase suggest KynB is a 
potential drug target. Moreover, optimisation of protein crystallography and enzyme 
assays made this target suitable for compound screenings and hit validation. However, 
results on essentiality from the Dstl revealed it is not an essential target in either B. 
anthracis or B. pseudomallei. For this reason, no further work was carried out. 
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PART FOUR 
D-ALANINE—D-ALANINE LIGASE 
 
4.1 Introduction 
 
D-alanine (D-Ala) is a key amino acid in bacteria. It contributes to structural roles in 
peptidoglycan (PG) layer formation and in lantibiotics (Cava et al., 2010). This D-
amino acid is particularly important in Gram-positive bacteria where is linked to 
lipoteichoic acid (LA) by an ester bond (D-Ala:LA) (Childs and Neuhaus, 1980). The 
amount of D-Ala:LA in the PG layer regulates ion homeostasis, cell wall permeability, 
biofilm formation, cell adhesion and mediates drug resistance (Neuhaus and Baddiley, 
2003). An increase in temperature, pH and NaCl/KCl concentration results in a decrease 
in D-Ala:LA formation. This leads to a change in the electromechanical properties of 
the cell wall, producing a more electronegative net charge of the layer. In terms of 
cation binding (e.g. Mg2+, Ca2+), a lower D-Ala ester level increases wall permeability 
to these components and serves to maintain cation homeostasis in the cell. The 
existence of D-Ala esters also prevents the binding of endolysins to LA influencing 
their effects. Regarding drug sensitivity, the decrease in D-Ala:LA enhances the 
antibacterial potency of cationic compounds (e.g. vancomycin, teicoplanin and 
balhimycin) and bactericidal enzymes. Human phospholipase A2 acts as an anti-
Staphylococcus agent. It is a Ca2+-dependent enzyme, and a higher level of Ca2+ in the 
peptidoglycan layer results in a greater enzyme activity. In similar fashion, a higher 
amount of D-Ala:LA leads to a more positively charged layer and has been shown to be 
involved in antibacterial resistance to cationic compounds. LA has an important role in 
biofilm formation and cell adhesion. These processes are also Ca2+-dependent and the 
lack of D-Ala:LA results in the lost of cell adhesion. In this case, the function of LA is 
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the presentation of Ca2+ to adhesins necessary for cell aggregation. This extends to 
virulence, where adhesion to the host tissue is also limited by D-Ala:LA levels 
(Neuhaus and Baddiley, 2003). 
 
The alanine enantiomers can be 
transported into the cell by an 
Ala/Gly/Ser transporter, a H+ 
symporter (Robbins and Oxender, 
1973) or synthesised by bacteria. The 
route for the biosynthesis of D-Ala is 
through the enzyme alanine racemase 
(AlaR, EC 5.1.1.1, Zajdowicz et al., 
2011) and an important role of this 
D-amino acid is the formation of the 
PG layer precursor D-alanyl—D-
alanine (Bugg et al., 2011). The 
enzyme involved in the synthesis of the dipeptide is D-alanine—D-alanine ligase (Ddl, 
EC 6.3.2.4), the second enzyme of the PG biosynthesis pathway. D-Ala—D-Ala will 
link to UDP-N-acetyl-muramyl-L-Ala-D-Glu-meso-diaminopimelate (UDP-NAcMur-
A-E-mDAP) to form a pentapeptide (UDP-NAcMur-A-E-mDAP-D-Ala—D-Ala). Then 
MraY (phospho-NAcMur-pentapeptide translocase, EC 2.7.8.13) removes UMP 
generating phospho-NAcMur-A-E-mDAP-D-Ala—D-Ala that binds to a membrane 
acceptor (undecaprenyl phosphate). Then, MurG (peptidoglycan glycosyltransferase, 
EC 2.4.1.227) incorporates N-acetyl-glucosamine (NAcGlc) in the phosphate position. 
It is transferred to the periplasmic space by flippases (still to be identified) where PBPs 
(penicillin-binding proteins, EC 3.4.16.4) crosslink and polymerise NAcGlc-NAcMur-
Figure 4.1: Schematic of the PG layer. Two 
tetrapeptide chains are shown. Peptide 
components are marked with boxes; filled box 
for peptide 1 and empty box for peptide 2. 
	
Part Four: D-alanine—D-alanine ligase  	
	
60 
A-E-mDAP-D-Ala—D-Ala. Finally, DacA (D-Ala—D-Ala carboxypeptidase, EC 
3.4.17.14) removes the last D-Ala from the peptide chain (Bouhss et al., 2008; Bugg et 
al., 2011). Figure 4.1 shows a schematic representation of the PG arrangement. 
 
The PG biosynthesis pathway presents a number of potential drug targets and we 
directed our attention to Ddl. In some bacteria such as E. coli, there exist two Ddl 
proteins (called DdlA and DdlB, Zawadzke et al., 1991) with a sequence identity of 
about 30% that might result in a lower sensitivity for Ddl inhibitors. There are 587 
reviewed Ddl sequences in UniProt (www.uniprot.org), and 18 bacteria presenting two 
Ddl proteins with sequence identities from 26 to 58%. We are interested in Ddl as new 
target against B. pseudomallei and F. tularensis so a search for orthogonal DdlA and 
DdlB sequences was performed using NCBI BLAST (Johnson et al., 2008). Only one 
sequence corresponding to DdlB was found in both cases, and as indicated in Part Two, 
the Dstl labs reported Ddl is essential for B. pseudomallei. 
 
The first DdlB structure described was from E. coli (EcDdl, Fan et al., 1997) and 
another 28, reporting apo and ligand-bound complexes, from various species have been 
determined. These include the enzymes from Burkholderia ambifaria (PDB code 4EG0, 
Baugh et al., 2013), B. anthracis (3R5X), B. pseudomallei (4EGQ) and Y. pestis 
(3V4Z). Some of these structures have informed on aspects of mechanism and 
supported biochemical studies. Two structures of DdlA from Salmonella typhimurium 
have also been determined (3Q1K and QIT2). Ddl presents a fold conserved among 
different proteins, called the ATP-grasp family in which 21 ligases and kinases are 
included (Fawaz et al., 2011). See Results and discussion for further details.  
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The Ddl catalysed reaction follows a sequential ordered mechanism (Prosser and de 
Carvalho, 2013). ATP binds and the protein conformation changes. The first substrate, 
N-terminal D-Ala, is phosphorylated and then the C-terminal D-Ala ligated as the 
phosphate dissociates. Later D-Ala—D-Ala is released followed by ADP (Figure 4.2). 
The binding order of each D-Ala has not yet been clarified. The mechanism was first 
proposed by Fan et al. (1994) after obtaining the EcDdl structure in the presence of an 
intermediate homologue (phosphinate). The reaction mechanism is shared with other 
ligases from the ATP-grasp family and characterised by the formation of an 
acylphosphate intermediate. The residues implicated in catalysis are highly conserved 
between ligases from the ATP-grasp superfamily (Fawaz et al., 2011). 
Figure 4.2: A proposed mechanism for Ddl (Fan et al., 1994). (A) Schematic reaction. 
(B) Mechanism details and amino acids involved. 
A 
B 
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D-cycloserine (DCS) is a Ddl and AlaR inhibitor (Prosser and de Carvalho, 2013). It is 
an antibacterial used as a second-line treatment for tuberculosis (Li et al., 2010). 
However, it is also an agonist of the NMDA (9-N-methyl-D-aspartate) receptor 
(Ollivaux et al., 2014), reduces kynurenic acid synthesis in neurons (Baran and 
Kepplinger, 2014), and is used to treat some psychiatric disorders (Hofmann et al., 
2006). DCS promiscuity, in terms of protein binding, also produces numerous side 
effects (Li et al., 2010). The DCS Ki values for Ddl range from 2 to 920 µM depending 
on the targeted organism (BRENDA database, www.brenda-enzymes.org) and MIC 
(minimum inhibitory concentration) values from 8 to 32 µg ml-1 (Putty et al., 2011). 
There is an EcDdl structure with a DCS analogue ([(4R)-4-azanyl-4,5-dihydro-1,2-
oxazol-3-yl]dihydrogen phosphate, PDB code 4C5A) in the active site pocket. 
However, the phosphate is located in the ATP γ-phosphate position which suggests the 
binding might be driven by the anionic component. Therefore, it is not clear how 
relevant this structure is for the study of DCS binding. The lack of potency of DCS, plus 
the adverse side effects, indicates this compound might not be an ideal candidate for 
using as an antibacterial drug targeting Ddl. However it can be a good starting point for 
the development of new drugs. 
 
Several types of Ddl inhibitors have been developed (Figure 4.3). Parsons et al. (1988) 
developed a series of phosphinates, the first Ddl inhibitors distinct from DCS. The best 
compounds inhibited Streptococcus faecalis Ddl with IC50 of 4-50 µM but MIC values 
for nine different bacteria (4-256 µg ml-1) showed DCS still has more potency (MICs of 
4-16 µg ml-1) than phosphinates. Optimisation of these compounds has been carried out 
(Ellsworth et al., 1996; Fan et al., 1997) but no MIC reported. The most potent 
phosphinate (in Figure 4.3) binds to the D-Ala pocket and behaves like an irreversible 
inhibitor. Ddl transfers the γ-phosphate to generate a phosphinophosphate, which has a 
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dissociation constant of days (Fan et al., 1997). More recently, diazenocarboxamides 
with Ddl inhibitory activity (IC50 15-50 µM) have been described (Kovač et al., 2007). 
Determination of MIC values (64-256 µg ml-1) indicates that further improvement is 
required before these compounds could progress. Sova et al. (2009) characterised a 
hydroxyethylamine as a Ddl inhibitor with an IC50 of 110 µM. Recently, D-boroAla and 
derivatives were described as Ddl inhibitors (Putty et al., 2011). MIC values were 
reported against various bacteria and show an improvement, compared to DCS, in 
Salmonella typhi (from 64 with DCS to 8 µg ml-1) and Enterococcus faecium (from 32 
to 16 µg ml-1). They also report a MIC value against B. pseudomallei (64 µg ml-1) but 
no information about DCS inhibition is available. However, the inhibitory constants of 
D-boroAla compounds have not been performed so Ddl inhibition has not been directly 
confirmed. Instead of measuring the enzyme activity, the D-Ala and D-Ala—D-Ala 
concentrations in the presence of various compounds are reported suggesting they are 
Ddl inhibitors (Putty et al., 2011). An allosteric inhibitor (with Ki values of 20-144 µM 
for the different protein:substrate complexes) for Staphylococcus aureus Ddl has been 
described and suggests the inhibitory mechanism involves the destabilisation of the 
- - 
Hydroxyethylamine 
Figure 4.3: Examples of Ddl inhibitors.  
D-cycloserine 
Phosphinate 
D-Ala-(PO2--CH2)-D-Phe 
Diazenocarboxamides D-boroAla 
Allosteric inhibitor 
3-chloro-2,2-dimethyl-N-
[4(trifluoromethyl)phenyl] 
propanamide 
- - 
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reaction intermediate (Liu et al., 2006). Further details on the MIC effect have not been 
described. A complicating factor in the development of Ddl inhibitors is the fact that 
these compounds are polar and, consequently, they require active transport for 
translocation into the cytoplasm.  
 
Despite the early success in finding ligands there has been little progress in developing 
highly potent inhibitors of Ddl. The lack of clear follow up of the characterised 
compounds might indicate issues hindering inhibitor validation. The objective here was 
to assess Ddl as a target for B. pseudomallei (BpDdl) and F. tularensis (FtDdl), and 
initiate a search for new inhibitor scaffolds. In order to achieve this, it is necessary to 
produce recombinant protein, obtain crystals in the presence of ligands (including DCS) 
and establish an assay for validating enzyme inhibition. To search for new inhibitors, an 
HTP assay was developed and compound library screens conducted. 
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4.2 Experimental procedures 
 
A flow chart of the experiments carried out is shown in Figure 4.4. 
 
  
Figure 4.4: Experimental flow chart. Dashed arrow correlates experiments. Km: 
Michaelis-Menten constant. Ki: inhibition constant. HTP: high-throughput. ELF: 
European Lead Factory. DDU: Drug Discovery Unit.  
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4.2.1 Recombinant protein production 
Genes encoding for FtDdl (UniProt: Q14JP9, protein mass 32 kDa) and BpDdl 
(Q63QJ9, protein mass 33 kDa) were purchased from GeneWiz and had 814 bp and 942 
bp respectively. The genes were cloned into a pET15bTEV vector using the restriction 
enzymes NdeI (at the 3’ DNA end) and BamHI (5’ end) in similar fashion for KynB 
(section 3.2.1). Cloned vectors were sequenced and gene integrity confirmed. 
 
Recombinant expression was achieved with BL21(DE3) cells, 1 mM IPTG for 
induction and incubating overnight (O/N) at 20ºC. Purification involved a Ni-NTA 
column using buffer A (20 mM Tris-HCl pH 7.4, 200 mM NaCl, 5 mM MgCl2) and 
buffer B (20 mM Tris-HCl pH 7.4, 200 mM NaCl, 5 mM MgCl2, 800 mM imidazole). 
The His6-tag was cleaved, during dialysis into buffer A, using 1 mg of TEV per 10 mg 
of Ddl at 4ºC and incubated O/N. A second Ni-NTA column was performed using the 
same buffers A and B. To analyse the quaternary structure, SEC, using the HiLoad 
16/60 superdex 200 prep grade column (GE Healthcare), was carried out with buffer A 
and a native-PAGE (Novex). In the case of FtDdl various quaternary structures were 
found in SEC. The peak corresponding with a dimer was pooled and prepared for 
native-PAGE analysis. For crystallisation, two different samples, corresponding to the 
monomer and dimer peaks, were used. Protein purity and molecular weight were 
assessed by SDS-PAGE. Protein concentration was determined using the molar 
extinction coefficients ε(FtDdl)=29005 M-1 cm-1 and ε(BpDdl)=27515 M-1 cm-1 as 
calculated in PROTPARAM (Gasteiger et al., 2003). 
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4.2.2 Crystallographic analysis 
4.2.2.1 Protein crystallisation 
Protein samples were concentrated to 25 mg ml-1, incubated with 5 mM ATP for 30 
minutes on ice, and used for crystallisation trials. Three commercial crystallisation 
screens were tested using 1:1 and 1:2 protein solution:reservoir ratios. These were The 
Classics Suite from Qiagen, the JCSG plus screening from Molecular Dimensions, and 
the PEGs screen also from Molecular Dimensions. Optimisation was performed in 
hanging drop plates, 1:1 protein solution:reservoir ratio and a final drop volume of 2 µl 
or 4 µl. Optimisation plates for FtDdl were set up for conditions H9 JCSG plus and G1 
from The Classics Suite, and conditions H12 from The Classics Suite and A2 and H9 
from JCSG plus for BpDdl. Microseeding was used as an additional optimisation step 
for BpDdl (Figure 4.5). The seeds were diluted in a solution with the same reservoir 
components. Three serial 1/5 seed dilutions were performed. The new H9 JCSG plus 
optimisation plate contained 1:1, 4µl drops and 0.5 µl of the different seed dilutions 
were added to each drop. For each condition, 4 drops were prepared. The optimisation 
conditions contained 0.05 to 0.3 M Li2SO4, 0.1 M Bis-Tris pH 5.5 and 15-30% (w/v) 
PEG 3350. Crystals were obtained after co-crystallisation with different ligand 
combinations using 10 mM for ATP, DCS, D-Ala+ADP, D-Ala—D-Ala+AMP, 
Figure 4.5: Microseeding procedure scheme (A-D). A first step for crystal breakage is 
done using a glass probe (A, microseeding tool). Then the drop is transferred into an 
eppendorf tube containing a bead (helps further for fragmentation) and the seeds are 
vortexed for 30 seconds (B-C). Then, serial 1/5 seed dilutions are prepared (D). 
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DCS+AMP, DCS+AMPPNP (an non-hydrolysable ATP homologue) and 1 mM of 
compound #3 which had been identified from a fragment screen. The protein was 
incubated for 30 minutes in the presence of the different compounds prior to setting up 
crystallisation. 
 
4.2.2.2 Diffraction and structure determination 
Optimised BpDdl crystals, grown in the presence of ATP, were tested using the in-
house X-ray generator (Rigaku M007HF with a Saturn 944HG+ CCD detector). They 
diffracted to a resolution of 2 to 2.5 Å. A 2.0 Å resolution data set was collected on 
ESRF beamline BM30-A (BpDdl:AMP-1). The data were indexed and integrated using 
XDS (Kabsch, 2010), and scaled and analysed using AIMLESS (Evans, 2011). The 
structure was solved with PhaserMR (McCoy et al., 2007) using the 2.2 Å resolution 
apo-BpDdl structure (PDB code 4EGQ). The model had two subunits in the asymmetric 
unit. The Matthews coefficient suggested two subunits were present in the BpDdl:AMP-
1 asymmetric unit (Vm of 2.27 Å3 Da-1 and bulk solvent of 46%). The apo-BpDdl dimer 
was first used for the molecular replacement but no solutions were found. This, together 
with the different space group (P1) that apo-BpDdl presented, suggested there were 
structural differences. Finally, the structure was solved using the apo-BpDdl subunit A. 
All waters and ligands were removed prior to molecular replacement. A 2.0 Å AMP-
bound BpDdl structure was then obtained. BpDdl:AMP-1 refinement involved a first 
round of rigid body refinement followed by cycles of restrained refinement using 
REFMAC (Murshudov et al., 2011), electron and difference density map checks, and 
model manipulations made with COOT (Emsley et al., 2010). Other crystals grown in 
the presence of AMP+D-Ala—D-Ala, AMPPNP+DCS, AMP+DCS, DCS, #3 and 
without ligands were obtained and tested on the in-house X-ray generator and Diamond 
Light Source beamline I04-1. A total number of 13 data sets were collected at Diamond. 
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Data sets were indexed and integrated using XDSgui and iMOLSFLM (Leslie and 
Powell, 2007), and scaled and merged with AIMLESS. All crystals were isomorphous 
with BpDdl:AMP-1. The resolution, Rmerge, signal-to-noise ratio (<I/σ(I)>), 
completeness and redundancy ranges for these 13 data sets are summarized in Table 4.1. 
 
 
 
 
 
 
 
The structure was determined for a crystal grown in the presence of ADP and D-Ala 
(1.3 Å resolution). Molecular replacement was performed with the refined subunit A 
from BpDdl:AMP-1. The results showed the presence of AMP and this structure was 
named BpDdl:AMP-2. Molecular replacement using the refined BpDdl:AMP-2 dimer 
was carried out to solve the structure at 1.5 Å from a crystal containing AMP and D-
Ala—D-Ala. In this case, both AMP and D-Ala—D-Ala were present and named 
BpDdl:D-Ala—D-Ala. Refinement for both structures involved tight non-
crystallographic symmetry (NCS) restraints at the beginning, which were released after 
the first refinement cycles. For the three structures, side-chain rotamers, water 
molecules and ligands were added when the protein models were completed. Given that 
high resolution diffraction data were available, anisotropic thermal factors were 
included in the refinement. Refinement was finished when no improvements were 
observed in model geometry and the Rfree and Rwork values, and density maps indicated 
no further changes were justified. For the other 11 structures, omit maps were inspected 
after one cycle of refinement using the BpDdl:AMP-2 dimer model. AMP was present 
in all samples, even when no ligands were added. This indicated AMP might be present 
 Overall High resolution shell 
High resolution limit (Å) 1.30 - 1.85 
Rmerge 0.035 - 0.071 0.266 - 0.665 
<I/σ(I)> 7.9 - 17.4 1.9 - 4.5 
Completeness (%) 94 - 98.6 93.3 - 99.11 
Redundancy 2.8 - 4.8 2.8 - 5.0 
Table 4.1: Crystallographic statistics summary of data sets from the Diamond Light 
Source beamline I04-1. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i Ii(hkl); where Ii(hkl) is 
the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean value of 
Ii(hkl) for all i measurements. 
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in the protein solution. To investigate this, determination of the AMP in the samples 
was carried out (see section 4.3.4.2). There was no reliable electron density for some 
residues in the models and they were not included. The absent amino acids are: 1) 
residues 1-3, 153-155 (subunit A) and 1-8, 153-155 (subunit B) in BpDdl:AMP-1 
model, 2) residues 1-2 (subunit A) and 1-3 (subunit B) in BpDdl:AMP-2, and 3) 
residues 1 (subunit A) and 1-3 (subunit B) in BpDdl:D-Ala—D-Ala. 
 
4.2.2.3 Ligand identification 
All crystals were harvested form drops containing Li2SO4, MgCl2, NaCl, Tris-HCl, Bis-
Tris, PEG 3350 and the ligand combinations described above. This was taken into 
account when making decisions about the presence of ligands in the models. 
 
Difference Fourier maps at the AMP site clearly indicated this compound was present in 
all structures. Substitutions of AMP by ADP were tried in BpDdl:AMP-1 and 
BpDdl:AMP-2. This showed strong negative electron density (about 14 σ level) at the β-
phosphate of ADP inferring AMP is the molecule present. In the case of BpDdl:D-
Ala—D-Ala, a difference Fourier map suggested the presence of D-Ala—D-Ala. If full 
occupancy was assigned for all the ligand atoms, then negative electron density was 
noted at the N-terminus. However, if only one D-Ala was placed, a positive feature was 
observed indicating a bigger molecule was present. According to this, D-Ala—D-Ala 
was added and zero occupancy was assigned for the N-terminal amino and methyl 
groups. 
 
Additionally, the difference Fourier maps suggested the presence of other entities in 
both BpDdl:AMP-2 and BpDdl:D-Ala—D-Ala. To investigate this, eight sulfur atoms in 
the asymmetric unit were removed to calculate their positive density from the difference 
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Fourier map. The average B-factors of these sulfurs were 17.3 Å2 in BpDdl:AMP-2, and 
16.7 Å2 in BpDdl:D-Ala—D-Ala. From the difference Fourier map, average values of 
1.9 σ per electron (BpDdl:AMP-2) and 1.8 σ per electron (BpDdl:D-Ala—D-Ala) were 
calculated. These values were used to estimate the number of electrons at the sites of 
interest. 
 
The ion sites close to His70 (subunit A) presented values of 28.1 σ (14 electrons, 
BpDdl:AMP-2) and 22.7 σ (12.6 electrons, BpDdl:D-Ala—D-Ala). When Mg2+ ions 
were added, they refined with B-factors of 18 Å2 and 22 Å2. The average coordinate 
bond length with waters is 2.09 Å in BpDdl:AMP-2 and 2.11 Å in BpDdl:D-Ala—D-
Ala. The coordination bond distances to the N from His70 are 2.14 Å and 2.10 Å 
respectively. These values are close to the expected coordinate bond lengths of 2.07 Å 
for waters and 2.05 Å for N from histidines (Harding, 2001). They presented a 
coordination geometry of 6 that is characteristic of Mg2+ ions. All this confirmed the 
presence of Mg2+. 
 
Two other difference peaks were observed in BpDdl:AMP-2 (near residues 293 from 
subunit A, 221 from subunit B) and three in BpDdl:D-Ala—D-Ala (near residues 293 
from subunit A, 221 and 290 from subunit B). Firstly, the positive density sites in 
BpDdl:D-Ala—D-Ala were characterised. They presented values of 18.9, 11.3 and 16.5 
σ (11, 6 and 9 electrons respectively), and the same tetrahedral-like shape. These sites 
did not show evidence (e.g. additional positive density peaks corresponding to 
coordinating-water molecules) of a coordination number of 6 so Mg2+ was discarded as 
the probable ligand. When Cl- was placed, positive electron density around the Cl- and 
average B-factor value of 45 Å were observed. Replacement of Cl- by SO42- molecules 
made the B-factor decrease (average of 26.7 Å) and no positive density was present. 
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Negative electron density was observed at one of the sites and an occupancy of 0.5 was 
assigned. The positions of the two difference peaks in BpDdl:AMP-2 were conserved 
with the BpDdl:D-Ala—D-Ala structure and SO42- ions were also placed with 0.5 
occupancy (B-factors average of 30 Å). The SO42- molecules interact with N (from, Arg, 
Asn, Gly and Lys), and O (Tyr, water) atoms, that can behave as hydrogen bond donors. 
The SO42- ions located near residues 221 are in the D-Ala binding pocket. Comparing 
the models with the phosphinate-bound E. coli Ddl structure (PDB code 1IOV), the 
SO42- ions are located in a different position than the phosphate of the possible reaction 
intermediate. 
 
4.2.2.4 Further structural analysis 
To assess the geometry of the models MolProbity (Chen et al., 2010) was used. 
Secondary-structure was determined with DSSP (Touw et al., 2015), dimer formation 
analysed using PISA (Krissinel and Henrick, 2007), and B-factors analysed using 
Baverage from the CCP4i suite. Figures were prepared using ALINE (Bond and 
Schüttelkopf, 2009), PyMOL (www.pymol.org) and Molsoft ICM (www.molsoft.com). 
The DALI server (Holm and Rosenstrom, 2010) was used to search for structural 
homologues. Electrostatic surfaces were determined using Molsoft ICM. 
 
A comparison of the protein sequences of all Ddl orthologues was carried out. First, a 
search for relevant sequences in UniProt (www.uniprot.org) was conducted. The 
identified sequences were grouped by 50% identity and aligned using Clustal Omega 
(Sievers et al., 2011) with group representatives (588 sequences). 
 
Analysis of the protein dimer interface was carried out using Molsoft ICM. First, a Cα 
overlay of the available Ddl structures with BpDdl:AMP-2 was performed. Then, using 
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the “contact areas” tool, residues at the dimer interface were identified. This was used to 
analyse the conservation of these amino acids in different organisms. 
 
The druggability score, described previously, predicts the likelihood of a pocket to bind 
drug-like compounds. The pocket finder tool from the Molsoft ICM defines pockets 
from a three-dimensional structure and provides a druggability score for each. This was 
used to calculate the theoretical druggability of BpDdl pockets in the presence and 
absence of the co-factor. When the score is greater than 0.5 the pocket is considered 
druggable. Two proteins were used as controls, dihydrofolate reductase (DHFR, Keedy 
et al., 2014, PDB code 4PSS) and neuraminidase (Vavricka et al., 2013, PDB code 
4H53). DHFR presents a well-defined druggable pocket while neuraminidase has highly 
polar pockets difficult to target and is considered as non-druggable-like by Molsoft 
ICM. 
 
4.2.3 AMP detection 
The crystallographic analysis revealed that AMP was bound to the protein even when 
no nucleotide was added. Therefore, the AMP-Glo kit from Promega was used to 
quantify the presence of AMP in the purified BpDdl sample. This assay measures the 
presence of AMP using a system of coupled enzymes. The first one, adenylate kinase 
(AK), transforms AMP to ADP by transferring the γ-phosphate from dCTP. A second 
enzyme, nucleoside-diphosphate kinase (NDK), transfers the γ-phosphate from dCTP to 
ADP and forms ATP. The enzyme luciferase oxidises the substrate luciferin 
hydrolysing the ATP releasing AMP, pyrophosphate, CO2 and light (Figure 4.6). 
 
 
 
Figure 4.6: AMP-Glo kit reactions.  
AMP ADP AMP + PPi ATP 
dCTP dCDP 
	
dCTP dCDP 
	
Luciferin 
+ O2 
Oxyluciferin 
+ CO2 + Light 
		AK 	NDK 	Luciferase 
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The reaction was performed in a 96-well white plate, using 25 µl of sample, in triplicate 
and with the layout described in Figure 4.7. The addition of the different reagents and 
the standard curve preparation were carried out as indicated in the kit manual. The 
signal was measured with the FLUOstar OPTIMA microplate reader from BMG 
Labtech. 
 
The control protein, selected because it does not bind AMP/ADP/ATP, was BaKynB. 
Samples were pre-treated for denaturation before performing the AMP determination 
assay. Samples treatments included variations in the temperature and pH, and digesting 
the proteins with chymotrypsin. On one hand, BpDdl and BaKynB samples were 
incubated for 20 minutes at 100ºC prior to the assay performance. In parallel, the pH of 
the samples was first decreased to 2 by the addition of HCl. After incubating the 
samples for 2 minutes, NaOH was added and a pH of 10 was obtained. Again, 
incubation was for 2 minutes and HCl used to reach a pH value of 7. The samples used 
for chymotrypsin digestion were BpDdl, BaKynB and BaKynB in the presence of 2 µM 
AMP (BaKynB-AMP). First the samples were incubated for 20 minutes at 100ºC. 
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Ch 
KynB 
Ch+ 
Ddl 
Ch   
E 10 5 2.5 1.25 0.63 0.31 0.16 0.08 0.04 0.02 0.01 0 
F WO KynB WT 
Ddl 
WT 
KynB 
ΔpH 
Ddl 
ΔpH 
KynB 
ΔT 
Ddl 
ΔT 
KynB 
Ch 
KynB 
Ch+ 
Ddl 
Ch   
G             
H             
Figure 4.7: Plate layout for the AMP detection experiment. WO wells contain only 
buffer (without protein or AMP). In blue are the standard curve samples and the 
numbers indicate the AMP contractions (µM). KynB is the sample BaKynB, and Ddl 
is BpDdl. WT indicates the samples where not treated. ΔT, ΔpH, Ch and Ch+ are used 
when samples were under temperature and pH stress or digested with chymotrypsin. + 
indicates 2 µM AMP was added to the sample. 
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Chymotrypsin was added to a final ratio chymotrypsin:sample of 1:20 and the mixture 
was incubated O/N at 25ºC. Then, the samples were filtered using an Amicon ULTRA 
3K concentrator. The protein concentration in each well was 4 mg ml-1 for BaKynB and 
25 mg ml-1 for BpDdl. 
 
4.2.4 Enzyme kinetics: coupled enzymatic assay 
The activity of BpDdl was measured using a 
spectrophotometric assay (Prosser and de 
Carvalho, 2013). The formation of ADP was 
measured by a pyruvate kinase/ lactate 
dehydrogenase (PK/LDH) coupling system 
(Figure 4.8). PK carries out the first coupled 
reaction, a transfer of the phosphate from 
the phospho-enol-pyruvate (PEP) to the 
ADP produced by Ddl to form pyruvate and 
ATP. Next, LDH reduces pyruvate to lactate 
by NADH oxidation. The decrease in the 
absorbance at 340 nm due to NADH oxidation is recorded. Measurements were made 
using a UV-2450 Shimadzu spectrophotometer. The decrease in NADH concentration 
can be quantified using the ε340nm(NADH) = 6220 M-1cm-1 and the Lambert-Beer law. 
 
The Ddl catalysed reaction presents a sequential ordered mechanism and the equations 
used are described in Prosser and de Carvalho, 2013 (Equation 4.1).  
D-Ala—D-Ala 
	
	
2 D-Ala 
ADP + P
i
 ATP 
PEP Pyruvate 
Lactate 
NADH 
NAD
+
 
	
		 PK 
	
Ddl 
LDH 
Abs
340nm
 
Figure 4.8: Enzymatic assay scheme. 
Ddl (B. pseudomallei Ddl), PK 
(pyruvate kinase), LDH (lactate 
dehydrogenase), PEP (phospho-enol 
pyruvate), Abs (absorbance). 
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4.2.4.1 D-alanine Km determination 
The assay buffer contained 100 mM Tris-HCl pH 8, 100 mM KCl, 10 mM MgCl2, 2.5 
mM PEP, 0.4 mM NADH, 5 µl ml-1 PK/LDH mixture from SIGMA, 30 µM BpDdl, 500 
µM ATP and variable concentrations of D-Ala (0.1, 0.3, 0.5, 0.7, 1, 1.5, 2, 2.5, 3, 5, 10, 
20 and 100 mM). Ten times (10x) concentrated D-Ala stocks were prepared for every 
D-Ala assay concentration so the volume added was always kept constant (10 µl). The 
final reaction volume was 100 µl. A master mix was prepared containing all assay 
buffer components except the D-Ala and the enzyme. All components were incubated 
for 30 minutes at 30ºC and then the assay performed in triplicate. Negative controls 
included master mix with BpDdl and without substrate, and master mix without BpDdl 
and with D-Ala. No decrease in the absorbance was detected in the negative controls 
during the assay period. The positive control was the PK/LDH system and instead of 
ATP, 0.4 mM ADP was added.  
 
 
 
Initial velocities were obtained by measuring the steady-state rate for 60 seconds. The 
absorbance data were plotted against time (seconds) and adjusted using a linear 
Equation 4.2: (A) Michaelis-Menten equation. (B) Double reciprocal equation for Km1 
calculation. V = reaction velocity (nmol/min), Km1 = Michaelis-Menten constant for the 
first D-Ala (M), Km2 = Michaelis-Menten constant for the second D-Ala (M), Vmax = 
maximum velocity of the reaction (nmol/min), [S] = variable substrate concentration 
(M). 
V =  
kcat [S] 
Km2 + [S] 
(A) (B) =  
1 
V kcat 
1 1 +  [S]	Km2 Km1 Km2	 [S]2 + 
V = kcat 
 
[ATP] [D-Ala] 
Ki,ATP Km2 + Km2[ATP] + Km,ATP[D-Ala] + [ATP] [D-Ala] 
Equation 4.1: General equation for Ddl mechanism (Prosser and de Carvalho, 2013). 
Ki,ATP and Km,ATP are the inhibition and Michaelis-Menten constants for ATP, Km2 the 
Michaelis-Menten constant for the second D-Ala (considering Km1 from the first D-Ala 
much smaller than Km2), and kcat the catalytic constant. 
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regression analysis. The initial velocities were obtained from the slope of the regression 
lines and plotted against the concentration of D-Ala. At a constant and saturating 
concentration of ATP, there exist two Km; one for the first D-Ala to bind (Km1) and 
another for the second (Km2). For their determination different equations were used. 
Firstly, the kcat and Km2 values were obtained under the assumption that Km1 is much 
smaller than Km2. According to this, the general velocity equation will be the Michaelis-
Menten equation (Equation 4.2A, Jonson and Goody, 2011). The maximum velocity of 
the reaction (Vmax) can then be calculated from: 
kcat = Vmax / [E]T, where [E]T is the total enzyme concentration. 
 
The Km2 and kcat values can be included in the reciprocal plot Equation 4.2B to calculate 
the Km1 at low D-Ala concentration (0.1 to 1 mM).  
 
Determination of Km1 and Km2 values was also carried out at pH 7.5 using D-Ala 
concentrations of 0.1, 0.5, 1 1.5, 2, 2.5, 3, 5 and 20 mM. Data analysis was performed 
as described above. 
 
4.2.4.2 ATP Km determination 
The assay buffer contained 100 mM Tris-HCl pH 8, 10 mM KCl, 10 mM MgCl2, 2.5 
mM PEP, 0.4 mM NADH, 5 µl ml-1 PK/LDH mix from SIGMA, 10 mM D-Ala, 20 µM 
BpDdl and various ATP concentrations (0.1, 0.2, 0.5, 1.2 and 3 mM). ATP stocks were 
prepared at 10x the final assay concentration. A master mix was prepared containing all 
assay buffer components except for ATP and enzyme. The same controls and 
experimental procedures as in Km(D-Ala) determination experiments were carried out.  
Initial velocities were analysed using the substrate inhibition equation (Equation 4.3), 
included in GraphPad Prism (www.graphpad.com). 
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4.2.4.3 D-cycloserine and fosmidomycin inhibition assays 
Experiments were performed in the presence of different inhibitor concentrations to 
determine Km(D-Ala). In the case of DCS the concentrations used were 100, 200, 250, 
300, 500 and 1000 µM. For fosmidomycin, concentrations of 1, 10, 100, 500, 1000 µM 
were tested. Stocks (10x) for every inhibitor final concentration were prepared (see 
section 4.2.8.2 for compound structures and source-stock concentration). Each Ki 
determination experiment was conducted for about 12 hours. To check for loss of 
BpDdl activity during the assay, an experiment without inhibitors was performed before 
and after the inhibition assay.  
 
Ki calculations were performed using double reciprocal plots (Equation 4.4A). This will 
inform about the mechanism of inhibition. The linearised data were fitted into linear 
regression lines. The slopes of these lines were then plotted against the concentration of 
DCS (Equation 4.4B) and data were again fitted into a linear regression curve. The 
intercept with the y-axis gives the value of Km/Vmax and the slope the Km/(VmaxKi). 
V =  
Vmax [S] 
Km,ATP + [S] ( 1 + [S]/Ki )  
Equation 4.3: Substrate inhibition. V = reaction 
velocity (nmol/min), Km,ATP = Michaelis-Menten 
constant (M) for ATP, Vmax = maximum velocity 
of the reaction (nmol/min), [S] = ATP 
concentration (M). 	
Equation 4.4: (A) Double reciprocal 
equation for competitive inhibition. (B) 
Secondary representation for inhibitory 
data. V = reaction velocity (nmol/min), 
Km = Michaelis-Menten constant (M), 
Vmax = maximum velocity of the 
reaction (nmol/min), [S] = substrate 
concentration (M), [I] = inhibitor 
concentration, Ki = inhibitory constant. 
 
(A) 1 
V 
= 
Vmax  
1 
+ 
Km 
Vmax 
1 + Ki  
[I] 
[S]  
1 
(B) Slope = + [I] 
Km 
Vmax 
Km 
Vmax Ki 
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Rearrangement of these equations allows calculation of the Ki (Prosser and de Carvalho, 
2013). 
 
To check for inhibition of any of the coupled enzymes, a cross-validation assay was 
performed. The assay buffer in this case contained 100 mM Tris-HCl pH 8, 100 mM 
KCl, 10 mM MgCl2, 2.5 mM PEP, 0.4 mM NADH, 5 µl ml-1 PK/LDH mixture from 
SIGMA and 0.5 mM ADP. Concentrations of 0.5 and 10 mM DCS (from stock 1M) and 
a positive control (without inhibitor) were tested. Calculation of velocity rates were 
performed as in section 4.2.4.1. 
 
4.2.4.4 Ddl activity at different pH values 
BpDdl activity at different pH values was tested. In this case, the reaction mixture 
contained 100 mM of the buffer (Table 4.2), 10 mM KCl, 10 mM MgCl2, 2.5 mM PEP, 
0.4 mM NADH, 5 µl ml-1 PK/LDH mix from SIGMA, 0.5 mM ATP, 10 mM D-Ala, 
and 20 µM BpDdl (added for starting the reaction). The buffers used for the different 
pH values are annotated in Table 4.2. The maximum reaction rate was assigned as 
100% activity. 
 
 
 
 
 
 
 
 
 
 
 
Buffer pH Buffer pH 
Bis-Tris 5.5 Tris-HCl 8.0 
Tricine 5.1 Tris-HCl 8.5 
MES 6.0 HEPES 8.5 
HEPES 7.5 BICINE 9.0 
Tris-HCl 7.5 CHES 9.5 
Table 4.2: Buffers used for the determination of the pH effect curve. 
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4.2.5 Enzyme kinetics: malachite green assay and high-throughput assay 
development 
Another detection method used for characterising BpDdl was the malachite green assay. 
The reagents were purchased from Enzo Life Sciences as a ready-to-use mixture, called 
BIOMOL Green. The mixture contains molybdate (MoO42−) and malachite green 
(organic dye). MoO42− binds to the released phosphate generating the MoO42−:Pi 
complex. Then malachite (yellow) binds to MoO42−:Pi and produces a green 
malachite:MoO42−:Pi  complex that absorbs at 620 nm (Pegan et al., 2010). The acidic 
nature of this mixture (pH about 1) necessitates an end-point assay. 
 
A HTP assay was developed for screening compound libraries (sections from 4.2.5.1 to 
4.2.5.5). The BIOMOL Green assay was used to determine the optimum enzyme 
concentration, Km and a time course experiment to check for linearity. Two compound 
libraries were screened. The first one was obtained from the European Lead Factory 
(ELF, www.europeanleadfactory.eu), a partnership between public and private 
organisations. The HTP assay development and the ELF library screen, which contains 
a selection of compounds from three different commercially available sources, were 
conducted at the ELF in NewHouse, Scotland. These are the NCC (NIH Clinical 
Collection, www.nihclinicalcollection.com) library that contains known drugs in 
clinical trials, the Selleck Bioactive screen (www.selleckchem.com) containing known 
drugs, natural products and known protein inhibitors, and the BioAscent library 
comprising a lead-like small molecule collection. The second library screen was with 
the DDU (Drug Discovery Unit, www.drugdiscovery.dundee.ac.uk) small diversity set. 
It consists of a collection of compounds that covers a wide range of the chemical space. 
The plates for the HTP assay were clear bottom black/white 384 well plates from 
Greiner (code 781091 for black and 781101 for clear plates). For the ELF screen, black 
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plates were used and clear plates for the diversity set screening. The reactions were 
performed at room temperature and in a final volume of 30 µl. 
 
4.2.5.1 Optimisation of enzyme concentration 
The assay buffer contained 100 mM Tris-HCl pH 8, 10 mM KCl and MgCl2 and final 
substrate and co-factor concentrations of 10 mM D-Ala and 0.25 mM ATP. The assay 
solutions were prepared as follows: - Assay buffer (B) - Protein solution 2x (P2x): 60 nM BpDdl in B - Substrate solution 2x (S2x): 20 mM D-alanine, 0.5 mM ATP in B 
The plate was prepared adding 18 µl P2x in row A and assay buffer in the rest of the 
rows. Serial dilutions were performed (3 µl from rowA/n to rown+1) from row A to P in a 
final volume of 15 µl. Row P was the “without enzyme” control. 
To start the reaction, 15 µl of S2x were added to every well at different time points per 
column (0, 5, 10, 15, 17, 19, 19.5 and 20 min) in triplicate as indicated in Table 4.3. For 
the last 3 columns, the reaction was stopped before adding the S2x. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Column tadd (min) 
tincubation 
(min) Column tadd (min) 
tincubation 
(min) 
1 0 20 13 17 3 
2 0 20 14 17 3 
3 0 20 15 17 3 
4 5 15 16 19 1 
5 5 15 17 19 1 
6 5 15 18 19 1 
7 10 10 19 19.5 1.5 
8 10 10 20 19.5 1.5 
9 10 10 21 19.5 1.5 
10 15 5 22 20 0 
11 15 5 23 20 0 
12 15 5 24 20 0 
Table 4.3: Assay plate time points. tadd = time when the reaction was started. tincubation = 
length of incubation before stopping the reaction.   
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Next, 30 µl of BIOMOL Green were added to each well simultaneously. Due to the low 
pH of the final mixture, non-enzymatic hydrolysis of ATP can occur and the released 
phosphate interacts with MoO42- to increase the background signal. To avoid this, after 
incubating the mixture for 5 minutes, 5 µl of 20% (w/v) tri-sodium citrate were added to 
every well. Citrate forms a complex with free MoO42-:Pi preventing further binding of 
malachite (Aherne et al., 2003). Prior to the absorbance measurement, the reaction was 
incubated for 20 minutes. The final plate layout is given in Figure 4.9. 
 
 
 
 
 
 
Absorbance was recorded at 620 nm using on EnVision plate reader from PerkinElmer. 
Data were analysed using Microsoft EXCEL. Absorbance was plotted against time for 
each protein concentration to calculate the initial velocities. 
 
4.2.5.2 D-alanine Km determination 
The different buffers prepared for the D-Ala Km determination are: - Buffer B: 100 mM Tris-HCl pH 8, 10 mM KCl, 10 mM MgCl2  - Protein solution 2x (P2x): 0.4 nM BpDdl in B - Substrate solution 2x (S2x): 20 mM D-alanine and 1 mM ATP in B - Assay buffer (B2x): B and 1 mM ATP 
Variations in the D-Ala concentration were set up by rows, and different time points in 
columns (10 sec, 30 sec, 1, 1.5, 2, 3, 5, 7, 10, 15, and 20 min). First 20 µl of S2x were 
  1 2 3 4 5 6 7 8 9 21 22 23 24 
 
[ENZ] nM 
// min 20 20 20 15 15 15 10 10 10 0.5 0 0 0 
A 30              
B 5              
C 8.3E-01              
D 1.4E-01              
O 3.8E-10              
P 0.0E+00              
Figure 4.9: Layout of the plate for the enzyme titration experiment. Every row contains 
a different protein concentration and every column was used for a specific time point. 
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added in rows A and B, and 15µl of B2x from rows C to O. Serial dilutions were made 
by adding 5 µl from rowA/odd number to rowodd number+1, and from rowB/even number to roweven 
number+1. Columns 1 and 2 were filled with 15 µl of B instead of P2x (negative control, 
without enzyme). Row P did not contain the substrate D-Ala. The layout of the plate is 
shown in Figure 4.10. 
 
 
 
 
 
 
 
 
The reaction was started by adding 15 µl of P2x to columns 3 to 24 at different time 
points (Table 4.4). 
 
The addition of BIOMOL Green and tri-sodium citrate was performed as in section 
4.2.5.1. 
 
Data analysis was carried out using Microsoft EXCEL for initial velocity calculations. 
In this case, only calculation of Km2 was performed. GraphPad Prism was used for Km2 
determination using the Michaelis-Menten equation. 
 
  1 2 3 4 5 6 
 [D-Ala] //sec WO 0 10 
A 10       
B 10       
C 2.5       
D 2.5       
E 0.625       
Column tadd (min) treaction (sec) Column tadd (min) treaction (sec) 
1 WO 0 13 17 180 
2 WO 0 14 17 180 
3 20 0 15 15 300 
4 20 0 16 15 300 
5 19.2 10 17 13 420 
6 19.2 10 18 13 420 
7 19.5 30 19 10 600 
8 19.5 30 20 10 600 
9 19 60 21 5 900 
10 19 60 22 5 900 
11 18 120 23 0 1200 
12 18 120 24 0 1200 
Table 4.4: Assay 
plate time points. 
tadd = time when 
the reaction was 
started. tincubation = 
how long the 
reaction was 
incubated before 
stopping it. WO 
indicates BpDdl 
was not present in 
the well. 
   
Figure 4.10: Plate layout for the Km 
determination experiments. There are 
four replicates for every time point 
(the double line square shows the 
replicates for the first time point). 
WO indicates BpDdl was not present 
in the well. 
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Km2 in the presence of a lower ATP concentration was calculated following the protocol 
described in this section but using a fixed ATP concentration of 0.2 mM instead of 0.5 
mM. 
 
4.2.5.3 ATP Km determination 
A similar buffer preparation was set up as used for D-Ala Km determination: - Buffer B: 100 mM Tris-HCl pH 8, 10 mM KCl, 10 mM MgCl2  - Protein solution 2x (P2x): 0.4 nM BpDdl in B - Substrate solution 2x (S2x): 1 mM ATP and 20 mM D-Ala in B - Assay buffer (B2x): B and 20 mM D-Ala 
Variations in ATP concentrations were set up by rows and different time points in 
columns (10 sec, 30 sec, 1, 1.5, 2, 3, 5, 7, 10, 15, and 20 min). First 20 µl of S2x were 
added in rows A and B, and 15 µl of B2x from rows C to P. Serial 1/4 dilutions were 
made by adding 5 µl from rowA/odd number to rowodd number+1, and from rowB/even number to 
roweven number+1. Columns 1 and 2 were filled with 15 µl of B instead of P2x (negative 
control, without enzyme). Row P did not contain the substrate D-Ala. The layout of part 
of the plate is represented in Figure 4.11. 
 
The reaction was started by adding 15 µl of P2x to columns 3 to 24 at different time 
points (Table 4.5, section 4.2.5.2). 
 
 
  1 2 3 4 5 6 
 [ATP] //sec WO 0 10 
A 0.75       
B 0.75       
C 0.187       
D 0.187       
E 0.047       
Figure 4.11: Plate layout for the Km 
determination experiments. There 
are four replicates for every time 
point (the double line square shows 
the replicates for the first time 
point). WO indicates BpDdl was 
not present in the well. 
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The addition of BIOMOL Green and tri-sodium citrate was performed as explained in 
section 4.2.5.1, and data analysis as in section 4.2.5.2. 
 
4.2.5.4 Time course experiment  
To determine whether the assay was linear under the chosen assay conditions, a time 
course experiment was carried out. Assay solutions included: - Buffer B: 100 mM Tris-HCl pH 8, 10 mM KCl, 10 mM MgCl2  - Protein solution 2x (P2x): 0.4 nM BpDdl in B - Substrate solution 2x (S2x): 400 µM ATP and 10 mM D-Ala in B 
The reaction was started at time points 2.5 minutes apart during 90 minutes (see plate 
layout in Figure 4.12). In this case, there are 8 replicates for each time point. 
 
 
  
  
 
Calculations of the Z’ score (Equation 4.5) and the signal-to-noise ratio were performed 
using Microsoft EXCEL. 
 
4.2.5.5 Determination of DMSO tolerance and D-cycloserine IC50 
The assay solutions used in this experiment were: - Buffer B: 100 mM Tris-HCl pH 8, 10 mM KCl, 10 mM MgCl2  - Protein solution 3x (P3x): 0.6 nM BpDdl in B - Substrate solution 3x (S3x): 600 µM ATP and 15 mM D-Ala in B - Compounds (CPD) solutions 3x: 
 0 4 8 12 80 84 88 92 
A         
H         
I         
P         
Equation 4.5: Z’ score equation. s.d = 
standard deviation, max = maximum signal, 
min = minimum signal.   
Z’ =  1 - 
3 (s.d.max + s.d.min) 
mean(max) – mean(min) 
Figure 4.12: Time course 
experiment plate layout. Numbers 
indicate the reaction time (min) for 
each column. 
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o DCS solution A (DCS3x_A): 1 mM DCS in B 
o DCS solution B (DCS3x_B): 0.1 mM DCS in B 
o DMSO solution (DMSO3x): 80% DMSO in B 
 
Three different plates were set up. Plate 1 (CPD plate, Figure 4.13) was divided into 
four different sections. The first addressed the assay in the absence of any inhibitor. The 
second and third were prepared using 40 µl of DCS3x_A in column 11 and 40 µl 
DCS3x_B in column 1. The rest of the wells were filled with 20µl of B. Then 1/2 serial 
dilutions were performed. The same procedure was used in the fourth area preparation  
adding first 40 µl of DMSO3x in column 11. Plate 2 (Protein plate) contained 20 µl of 
P3x in rows from A to D and I to L, and 20 µl of B in rows E to H and M to P. The third 
plate was used for the enzyme assay and contained 10 µl of S3x in every well. 
 
Using a Beckman Biomek FX, 10 µl from the CPD plate were transferred into the assay 
plate. To start the reaction, 10 µl from the Protein plate were added to the assay plate 
(see final plate layout in Figure 4.13). The mixture was incubated for 60 minutes at 
room temperature. Then, the standard BIOMOL Green procedure (section 4.2.5.1) was 
applied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 No inhibitors added DCS dose-response (high concentration) 
A           300 150 75 37.5 18.8 9.4 4.7 2.3 1.2 0.6 
B           300 150 75 37.5 18.8 9.4 4.7 2.3 1.2 0.6 
G           300 150 75 37.5 18.8 9.4 4.7 2.3 1.2 0.6 
H           300 150 75 37.5 18.8 9.4 4.7 2.3 1.2 0.6 
I 30 15 7.5 3.8 1.9 0.9 0.5 0.2 0.1 0.1 27 13.5 6.8 3.4 1.7 0.8 0.4 0.2 0.1 0.1 
J 30 15 7.5 3.8 1.9 0.9 0.5 0.2 0.1 0.1 27 13.5 6.8 3.4 1.7 0.8 0.4 0.2 0.1 0.1 
O 30 15 7.5 3.8 1.9 0.9 0.5 0.2 0.1 0.1 27 13.5 6.8 3.4 1.7 0.8 0.4 0.2 0.1 0.1 
P 30 15 7.5 3.8 1.9 0.9 0.5 0.2 0.1 0.1 27 13.5 6.8 3.4 1.7 0.8 0.4 0.2 0.1 0.1 
 DCS dose-response (low concentration) DMSO dose-response 
Figure 4.13: The dose-response experiment plate layout. Concentrations of the compounds are 
annotated in each well. Thick black lines divide the four different plate areas corresponding to a 
positive control (no inhibitors added), dose-response for DCS at high and low concentrations, 
and the DMSO tolerance experiment. 
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4.2.6 ELF library screen 
All compounds were tested at a concentration of 10 µM. Columns 1 to 4 included 
positive (normal reaction without compounds added) and negative controls (without 
enzyme). Compounds were dispensed using an Echo acoustic dispenser from Labcyte. 
The reaction solutions contained the same components as buffer B2x and P2x in section 
4.2.5.4. The assay was allow to proceed for 1h and then 30 µl of BIOMOL Green and 5 
µl of 20% (w/v) tri-sodium citrate were added as described above. 
 
Data were first analysed using ActivityBase XE (www.idbs.com). This program tracks 
each well with the compound it contains and calculates the signal-to-noise ratio, the Z’ 
score and the percentage effect (Equation 4.6) seen at every plate/well. This data can be 
processed using Microsoft EXCEL to select hits. A compound was considered a hit 
when the normalized percentage of effect was higher than the median plus three times 
the standard deviation. 
 
4.2.6.1 Validation of hits 
A two step assessment of compound activity was carried out to validate the quality or 
usefulness of the hits.  
 
Step 1: Replica plate and BIOMOL Green assay interference   
From the ELF screening, 74 compounds were considered hits. These compounds were 
dispensed to a final compound concentration of 20 µM and randomly located (in 
duplicate) in the plate. Three compound plates were set up to perform different assays. 
The replica plate contained 15 µl of B2x (10 mM D-Ala, 0.4 mM ATP, 100 mM Tris-
Equation 4.6: Percentage of effect 
equation. signal is the signal in wells, 
max the maximum signal control, and 
min minimum signal control. 
% effect = 100 - 
100 signal – mean(max) 
mean(max) – mean(min) 
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HCl pH 8, 10 mM KCl and 10 mM MgCl2) and 15 µl of P2x (0.4 nM BpDdl) except in 
the area A1 to L4 where 15 µl of B was placed instead of P2x. It was also necessary to 
check if there is any interference of the compounds with the assay. To assess this, plates 
containing the BIOMOL Green mixture but in the absence of the BpDdl assay 
components were set up. The BIOMOL–Pi plate contained the same compounds in the 
same order as the replica plate but only 30 µl of buffer containing 100 mM Tris-HCl pH 
8, 10 mM KCl and 10 mM MgCl2 was dispensed in each well. In the case of the 
BIOMOL+Pi plate, 30 µl of 100 mM Tris-HCl pH 8, 10 mM KCl and 10 mM MgCl2 in 
the presence of 70 µM phosphate were added to the wells. The amount of phosphate 
needed in this assay had to be similar to the concentration that is released by BpDdl by 
the time the assay is stopped. To calculate this, a standard curve was determined from 
experiments at different phosphate concentrations (40, 20, 10, 5, 2.5, 1.3, 0.6 and 0 µM) 
in a final volume of 30 µl, and in triplicate. From the regression line equation (obtained 
using Microsoft EXCEL), 70 µM phosphate was determined as the approximate 
phosphate concentration and used on the BIOMOL+Pi plate. This validation step would 
indicate false positives. Data were analysed using ActivityBase XE and Microsoft 
EXCEL. Compounds inhibiting more than 30% of BpDdl activity were selected for the 
IC50 determination experiment.  
 
Step 2: IC50 determination 
The IC50 or potency experiment included control wells in columns 1 to 3, and was 
carried out in duplicate. The same assay solutions as in Step 1, in the presence and 
absence of 0.01% (w/v) Tween-20 and 1 mM TCEP were used. The compounds were 
tested at concentrations: 20, 6.7, 2.2, 0.7,0.2, 0.08 and 0.03 µM. Data were analysed 
using ActivityBase XE and Microsoft EXCEL. 
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4.2.7 Small diversity set screen 
4.2.7.1 Assay development and screening 
Prior to screening, a peer review of the HTP assay with DDU staff was carried out. 
They suggested lowering the pH to more physiological values (7.5). The activity of the 
enzyme at this pH was lower than at pH 8 so further HTP assay optimisation was 
required to improve the signal-to-noise ratio. Km(D-Ala) and Km(ATP) at pH 7.5 were 
determined as described in sections 4.2.5.2-4 but including 0.01% (w/v) Tween-20 and 
1 mM TCEP in the assay buffer, and in the presence of 1 nM BpDdl. The time course 
experiment was performed using 3, 2 and 1 mM D-Ala and 500 µM of ATP (following 
the same procedure as in section 4.2.5.1). 
 
The small DDU diversity set was used at a final concentration of 30 µM for each 
compound. The reaction was carried out with 1 mM D-Ala and 0.5 mM ATP, and 
incubated for 12 minutes. In each plate, column 23 was used for the negative control 
(without enzyme) and column 24 the positive control (with enzyme and in the absence 
of compounds). Solutions were dispensed using a Matrix Wellmate microplate 
dispenser (Thermo Scientific) and the absorbance measured using a PHERAstar (BMG 
Labtech). 
 
Data were first analysed using ActivityBase XE, as indicated in section 4.2.6, and 
Microsoft EXCEL to select hits. In this case, 30% inhibition was considered a hit. 
 
4.2.7.2 Validation of hits 
Hits were validated using a potency assay. The compounds were tested at different 
concentrations (1/10 dilutions starting at 100 µM) in duplicate. Duplicates were set up 
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in independent plates with separately prepared buffer, substrates and protein stocks. The 
plate layout is described in Figure 4.14.  The reaction and data analysis were carried out  
 as for section 4.2.6.1.  
 
Data were first analysed using ActivityBase and processed using Microsoft EXCEL to 
select hits and calculate IC50 values. 
 
4.2.8 Biolayer interferometry and a fragment library screen 
 Biolayer interferometry (BLI) is a real-time method for measuring ligand binding. An 
incident white light is guided through a glass fiber sensor where the target protein is 
attached. The reflected light is registered by the instrument as the interface between the 
optical layer and the glass fiber, and the interface between the surface and the solution. 
The reflected light is divided by colour channel filters into different wavelengths. The 
interference pattern of the reflected light is then analysed and an interferometric profile 
obtained (relative intensity against wavelength plot). When a compound binds to the 
protein, the thickness of the biolayer surface increases and the interferometric profile 
shifts. This difference in the wavelength, is plotted against time (Figure 4.15, BLI 
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Figure 4.14: Dose-response 
experiment plate layout.  
Figure 4.15: A scheme of BLI signal detection. (A) The reflected light is perceived by 
the instrument. (B) Interferometric profiles in the absence of compounds (blue) and in 
the presence of a compound that binds to the protein (orange). (C) Octet output plot. 
Wavelength shift (Δλ) in nm against time (seconds) plot. 
Δ
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applications notes at www.fortebio.com). Measurements were made with an 
OctetRED384 (ForteBio). 
 
To immobilize BpDdl His6-tag high affinity sensors were used. The surface of these 
sensors, like Ni-NTA columns, contains immobilised tris-nitriloacetic acid (tris-NTA) 
that has been charged with Ni2+ to assist the His6 tail binding. The ligands were placed 
in 96 or 384-well plates together with reference wells (containing the assay buffer 
without ligands). The following protocols were used during the experiment: 
1) Protein binding to the sensors: the protein is prepared in the assay buffer in a 96-
well plate. - Column 1: 200 µl of buffer. - Column 2: 200 µl of protein dilution in buffer. - Sensor position protocol: 
1. Baseline for 60 seconds at column 1. 
2. Charge sensors at column 2 for 900 seconds. 
3. Wash at column A for 600 seconds. 
2) Ligand screening 384-well plates. The sensor location program is the following: - Baseline: columnn+1, odd rows, for 60 seconds. - Association: columnn+1, even rows, for 120 seconds. - Dissociation: columnn+1, odd rows, for 120 seconds. - Baseline, association and dissociation steps for every plate column. 
3) Stripping protein from the sensors: - Column 1: 200 µl of buffer. - Column 2: 200 µl of 10 mM glycine pH 1.7. - Column 3: 200 µl of 10 mM NiCl2. - Sensor location protocol: 
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1. Baseline for 60 seconds at column 1. 
2. Strip: 5 seconds at column 2. 
3. Neutralize: 5 seconds at column 1. 
4. Repeat 2-3 for 5 times. 
5. Recharge: 60 seconds at column 3. 
6. Wash: 600 seconds at column 1. 
 
4.2.8.1 Experimental set up 
Ni-NTA sensors were purchased from ForteBio, and black plates from Greiner (code 
781209). Sensors used were incubated at room temperature with binding buffer (100 
mM Tris-HCl pH 8, 10 mM KCl and 10 mM MgCl2). A control protein (TEV protease) 
was used. This would inform about promiscuous binders. 
 
Four different concentrations (0.5, 5, 10 and 20 µM) of BpDdl and TEV protease were 
prepared in binding buffer, and tested following protocol 1 described above. The 
minimum protein concentration that allows a saturation of the binding of the sensor in 
the experiment time was chosen for carrying out the screening. 
 
ATP was used as a control compound. The plates used were 96-well plates, with 200 µl 
of buffer and ATP concentrations of 500, 166.7, 55.6, 18.5, 6.2 and 2 µM (serial 1/3 
dilutions). The baseline and dissociation measurements were performed using column 1. 
Columns 2 to 12 contained increasing concentrations of ATP (column 12 contains the 
highest ATP concentration). Protocol 2 was used for this experiment.  
 
The screen was performed using a protein concentration of 10 µM, compound 
concentration of 100 µM, ATP concentration of 500 µM, in a final volume of 100 µl. 
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Protocol 2, as described earlier, was used and protein was stripped from sensors and 
recharged before starting a new assay plate. 
 
4.2.8.2 Validation of hits  
From the fragment screen, 11 hits were selected (Table 4.5). As an initial validation, 
these hits were assayed at a concentration of 500 µM. Stock preparation of each 
compound is described in Table 4.5. 2 mM D-Ala was included in the assay buffer. 
Only one compound with an inhibition effect greater than 20% was followed up for Ki 
determination.  
 
The Ki of compound #3 was determined as for DCS using final #3 concentrations of 
200, 500, 2000 and 5000 µM. Stocks (10x) for every inhibitor final concentration were 
prepared. Ki calculation was performed in the same manner as Ki,DCS. 
  
Part Four: D-alanine—D-alanine ligase  	
	
94 
  
# Name Structure Source Alternative Stock preparation 
- D-cycloserine 
 
Sigma, C6880 - 1 M in water 
- Fosmidomycin 
 
Molecular Probes, 
FR-31564 - 
100 mM in 
water 
1 
[2-(Morpholin-4-
ylmethyl)phenyl]methan
ol hydrochloride 
 
Sigma, CBR00740 - 100 mM in water 
2 
4-[(2,5-dimethyl-1H-
pyrrol-1-yl) 
methyl]piperidine 
 
Sigma, CDS018123 - 
40 mM in 
10% 
DMSO 
3 N-(2-chlorobenzyl) acetamide 
 
Enamine, BBV-
46868559 - 
50 mM in 
50% 
DMSO 
4 
2-(1-methanesulfonyl 
pyrrolidin-3-yl)acetic 
acid*  
Enamine, 
alternative, BBV-
33919693,  (1-
methanesulfonylpyrr
olidin-3-yl)methanol  
100 mM in 
water 
5 2-methanesulfonamido-N,N-dimethylacetamide 
 
Enamine, BBV-
46887175 - 
100 mM in 
water 
6 (2-hydroxy-2-phenylethyl)urea* 
 
Enamine, 
alternative, BBV-
24876420,  (2-
hydroxy-2-
phenylethyl)urea 
 
100 mM in 
water 
7 c-(2-ethyl-2H-pyrazol-3-yl)-methylamine 
 
Sigma, CDS006901 - 100 mM in water 
8 3-amino-5-methylisoxazole 
 
Sigma, 232270 - 1 M in water 
9 oxolane-3-sulfonamide 
 
Enamine, EN300-
75960 - 
100 mM in 
water 
10 N-phenethylacetaminde 
 
Sigma, S581887 - 100 mM in water 
11 5-amino-3,4-dimethylisoxazole 
 
Sigma, 280240 - 100 mM in water 
Table 4.5: Information on compounds tested as potential inhibitors. # is the number 
given to the fragment screening hits. The full name, structure, and suppliers are detailed 
in columns 2 to 4. Some compounds were not commercially available (*) so an 
alternative compound was purchased (structure in column 5). The last column indicates 
the compound stock preparation. 
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4.3 Results and discussion 
 
4.3.1 Recombinant protein production  
Efficient recombinant protein production systems were prepared. Yields for both 
proteins, BpDdl (mass 33.3 kDa) and FtDdl (mass 32.8 kDa), were about 20 mg per 
litre. SEC was carried out to investigate the quaternary structure of Ddl. From previous 
studies it is expected to observe Ddl dimerisation (Meziane-Cherif et al., 2010). The 
results showed that the recombinant FtDdl is heterogeneous with at least three species 
with estimated masses 27, 75 and 137 kDa. In the case of BpDdl, single species of 
apparent mass of 42 kDa, has been identified (Figure 4.16). The observed values are 
different from the expected masses and in the case of BpDdl the difference differs by 
about 10 kDa. The inconsistency in the molecular masses was checked in native-PAGE 
Figure 4.16: (A) SEC chromatogram for FtDdl (red) and BpDdl (blue). Ddl peaks are 
numbered. (B) Equilibration curves with FtDdl (top) and BpDdl (bottom) peaks plotted. 
Each peak is coloured differently. The expected value for monomers is marked with an 
arrow and dimer with a double arrow. 
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gels (Figure 4.17). For FtDdl, the peak corresponding with the monomer was kept and 
used in native-PAGE and crystallisation. Several species were found in the native-
PAGE indicating there might be a dynamic mixture of quaternary structures. A very 
light band corresponding to the monomer can be seen for a more concentrated sample. 
Well defined bands can be identified as dimer (66 kDa) and hexamer (194 kDa), 
octamer (260 kDa) and tetradecamer (420 kDa). This is consistent with the result from 
the SEC. In the case of BpDdl, two bands corresponding with about 43 kDa (monomer) 
and 106 kDa can be seen. The second band could be an aggregation product as the 
samples for native-PAGE were more concentrated than the used for SEC. 
 
 
In native-PAGE, using a lower BpDdl concentration, two bands of about 43 kDa and 
106 kDa were observed. The apparent Ddl molecular weight using SEC and native-
PAGE differs from the expected values determined from the amino acid sequence. 
However, in SDS-PAGE, both proteins migrate with a molecular weight of about 30 
kDa. The difference between the BpDdl apparent mass and the expected value could be 
due to presence of a cysteine on the surface of BpDdl (Cys232, not present in FtDdl) as 
it might cause disulfide bond formation. The quaternary structure could also be analysed 
using SAXS (small-angle X-ray scattering). The protein concentration used for the 
crystallisation trails is 20-50 times greater than the samples used for SEC and native-
Figure 4.17: Native-PAGE 3-12%. 
Molecular weight standards are in 
lane 1. (A) FtDdl Native-PAGE with 
3 ng (lane 2) and 5 ng (lane 3) of 
sample. The arrow indicates the 
dimer.  (B) BpDdl Native-PAGE with 
10 ng (lane 2) of sample. The arrow 
indicates the monomer and * the 
expected value for BpDdl dimer. 
A B
B 
1       2      3 1       2   
* 
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PAGE. If the dimer or oligomer formation is dependent on protein concentration, this 
implies the samples used for crystallisation could have a different assembly/species 
components to those used for quaternary structure investigation. This could be further 
investigated with DLS (dynamic light scattering) using different sample concentrations 
and would indicate if the samples used for crystallisation were monodisperse or 
contained several species. 
 
4.3.2 Crystallisation and structure determination 
Two different FtDdl samples were screened; one corresponding with the SEC dimer 
peak and the other with the monomer. Small crystals were obtained with both samples 
(Figure 4.18) in conditions H9 from JCSG plus and G1-G2 from The Classics Suite. 
Optimisation plates for FtDdl were set up but did not lead to improvements in crystal 
size. This might be due to the presence of a non-homogeneous sample (see Figure 4.17). 
 
For BpDdl, six hits from various JCSG plus and The Classics Suite conditions were 
obtained. All BpDdl crystals grew in clusters. BpDdl crystal optimisation was 
performed for the conditions H12 from The Classics Suite, and A2 and H9 from JCSG 
plus. Only needle-shaped clustered crystals grew (Figure 4.18). These needles were 
used for microseeding, which led to an improvement. The biggest crystals were 
obtained with a 1/125 diluted seed stock (Figure 4.18C) and diffracted to 2.5-2.0 Å 
using the in-house X-ray generator. At the Diamond Light Source beamline I04 data to 
beyond 2 Å were obtained. Co-crystallisation was carried out with various ligand 
combinations and three structures of BpDdl were completed. The crystallographic 
statistics are given in Table 4.6. Two contained AMP (at 2.0 Å and 1.3 Å resolution) 
and the third had AMP and D-alanyl-D-alanine bound (1.5 Å). Another 11 data sets 
were collected from crystals grown in conditions containing different ligand 
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combinations. Even when no co-factor was added, the structures had AMP bound. To 
check whether the samples contained AMP or it was a contaminant from the 
crystallisation components, an assay for the determination of AMP was performed 
(section 4.3.4.2). 
 
 
 
 
 
  
Figure 4.18: (A) BpDdl crystals. 
Commercial screening The Classics 
Suite from Qiagen, condition E9. Ratio 
protein: precipitant 1:1. (B) FtDdl 
crystals. Commercial screening JCSG 
Plus from Molecular Dimensions, 
condition H9. Ratio protein: precipitant 
1:1. (C) Optimised BpDdl crystals. 
Condition in the drop: 0.1 M Li2SO4, 
0.05 M Bis-Tris pH 5.5, 12.5% (w/v) 
PEG 3350 and 12.5 mg ml-1 protein. 
C	
100	μm	
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Structure BpDdl:AMP-1 BpDdl:AMP-2 BpDdl:D-Ala—D-Ala 
Space group P21 P21 P21 
Wavelength (Å) 0.979895 0.917410 0.917410 
Unit cell dimensions    
a, b, c (Å), β (º) 
69.58, 61.23, 70.4 
90.18 
69.65, 61.15, 70.08 
90.17 
69.64, 61.13, 69.67 
90.31 
Resolution rangea (Å) 45.97 - 2.0 49.33 – 1.3 49.23 – 1.5 
No. Reflections 131259 672251 283077 
Unique reflections 39982 141049 90609 
Completeness (%) 99.4 (99.7) 97.7 (95.7) 96.6 (98.3) 
Rmergeb 0.108 (0.608) 0.04 (0.665) 0.049 (0.448) 
Redundancy 3.3 4.8 3.1 
< I/σ(I)> 8.7 (2.1) 15.0 (2.1) 10.5 (2.1) 
Wilson B (Å2) 19.20 14.58 15.40 
Rworkc/Rfreed 0.1802 / 0.2415 0.1486 / 0.1917 0.1321 / 0.2071 
DPIe (Å) 0.20 0.05 0.08 
Bond lengths (Å) / 
anglesf (º) 
0.0160 / 1.8103 0.0172 / 2.0453 0.0269 / 2.5848 
Average B-factors (Å2) 18.48 23.94 25.23 
Protein residues 913 1412 1345 
Water molecules 292 785 709 
Metal ions 0 1 (Mg2+) 1 (Mg2+) 
Ligands 8 (2 AMP, 3 SO4
2-, 3 
ethylene glycol) 
7 (2 AMP, 2 SO42-, 3 
ethylene glycol) 
15 (2 AMP, 1 D-Ala—D-Ala, 
3 SO42-, 8 ethylene glycol, 1 
poly-ethylene glycol) 
Ramachandran 
analyses    
Favoured regions (%) 97.2 98 98 
Allowed regions (%) 99.8 99.8 99.8 
Outliers D5, A55, G75 and D257 (subunit B) 
G153, S155 (subunit 
A) and D257 (subunit 
B) 
G153 (subunit A) and D257 
(subunit B) 
Table 4.6: Crystallographic statistics. a. Values in parentheses refer to the highest 
resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i Ii(hkl); where Ii(hkl) is the 
intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean value of 
Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed 
structure factor and Fc is the calculated structure factor. d. Rfree is the same as Rwork 
except calculated with a subset, 5 %, of data that are excluded from the refinement 
calculations. e. Diffraction Precision Index (Cruickshank, 1999). f.(Engh and 
Huber,1991). 
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4.3.3 Ddl structure  
4.3.3.1 Overall structure 
Previous work showed Ddl is a member of the ATP-grasp superfamily. This family 
presents a characteristic and highly conserved fold despite the low sequence identity 
(about 10-20%) that the different proteins share. ATP-grasp proteins contain three well-
defined domains and the ATP binding pocket is the region with the highest structure 
conservation (Fawaz et al., 2011). In the case of Ddl, the domains are called N-terminal, 
central and C-terminal (Figure 4.19). BpDdl secondary structure comprises 10 α-
helixes, one 310-helix, one π-helix and 12 β-strands (Figure 4.20). As in other Ddl 
proteins (Fan et al., 1997; Lee et al., 2006; Wu et al., 2008; Bruning et al., 2011; Doan 
et al., 2014), the N-terminal domain presents an α/β-domain and the central and C-
terminal domains show the ATP-grasp fold; two α/β-domains that generate a narrow 
pocket for the ATP binding. The active site is located in the C-terminal domain whereas 
residues from the central and the C-terminal domains form the ATP binding pocket. 
Two loops are implicated in the binding of the co-factor and the substrates. The P-loop 
(residues 149 to 159) is located in the central domain, between β-strands 5 and 6, and 
Figure 4.19: Cartoon 
representation of the 
BpDdl:AMP-2 
structure. Subunit A is 
coloured in blue, green 
and orange, and 
subunit B in yellow. 
AMP is represented in 
sticks. α-helixes and β-
strands have named as 
in Figure 4.20. 310 and 
π helixes are marked. 
The N and C-termini 
are labelled as CT and 
NT.  
310 
AMP 
pocket 
D-Ala 
pocket 
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interacts with the γ-β phosphates of ATP. The ω-loop is located in the C-terminal 
domain and presents a π-helix configuration involving residues 198 to 222. 
 
BpDdl has a dimer in the asymmetric unit where each subunit is aligned perpendicularly 
to each other. Conformational differences are noted between monomers (Figure 4.21), 
which might correspond to structural changes that Ddl undergoes during catalysis. One 
dimer is present in the asymmetric unit of BpDdl:AMP-2 and BpDdl:D-Ala—D-Ala, 
and subunits were named A and B. 
Figure 4.20: Alignment of BpDdl, FtDdl, BaDdl (B. ambifaria Ddl), EcDdl (E. coli 
Ddl) and MtDdl (M. tuberculosis Ddl). BpDdl secondary structure is included. β-strands 
are represented as blue arrows, α-helixes as red cylinders, 310-helix as a red spiral, π-
helix as a green spiral. Amino acids that interact with ATP are marked with red triangles 
and the residue with stacking interactions with a red circle. Active site pocket residues 
are indicated with blue triangles/star and the metal binding residues as stars. 
Part Four: D-alanine—D-alanine ligase  	
	
102 
 
Structural overlays indicate that the conformational differences between subunits are 
conserved in BpDdl:AMP-2 and BpDdl:D-Ala—D-Ala structures. The r.m.s.d. (root-
mean-square deviation) values from the overlays are shown in Figure 4.22. This 
difference in conformation is not observed in other previously characterised dimeric Ddl 
structures (shown in Table 4.7). The BpDdl dimer is 
formed by about 12-13% of the monomer accessible 
surface area (ASA) and involves residues from α3, 
α4, α5 and the C-terminal region of α8. Looking at 
the available structures from different organisms 
(Table 4.7), the dimer arrangement is shared in all 
organisms, and the percentage of ASA involved in 
the dimerisation, also called buried surface area 
(BSA), is similar in different Ddl structures (Table 
4.7). These BSA values are lower than expected for a surface with a high probability of 
forming assemblies (at least 5000 Å2). The specificity of the interaction is determined 
by the P-value, which measures the probability of having similar observed solvation 
A 
 
B 
 
A 
 
B 
 
0.88 
0.88 
0.
09
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12
 
0.8
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0.91 
Figure 4.22: Structural 
comparisons. Values for 
r.m.s.d. (Å) for Cα overlay of 
BpDdl subunits. BpDdl:AMP-
2 subunits are coloured in 
blue and BpDdl:D-Ala—D-
Ala in orange. 
Figure 4.21: Stereo view of the Cα overlay of subunit A (in green) and B (grey) from 
BpDdl:D-Ala—D-Ala. The green sphere is Mg2+. 
AMP AMP 
D-Ala—D-Ala D-Ala—D-Ala 
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free energy gain (ΔiG) in other surface areas. Thus, when the P-value is greater than 0.5 
it means the surface has a lower hydrophobicity than expected and indicates the 
interaction is likely due to crystal packing or unspecific molecules arrangement. In 
contrast, a P-value lower than 0.5 indicates the hydrophobicity is higher than expected 
and the interaction is probably specific (Krissinel and Henrick, 2005; Krissinel and 
Henrick, 2007). Despite the low BSA values, the P-values indicate the dimer assembly 
is specific in all the structures (Table 4.7). Mycobacterium tuberculosis Ddl (MtDdl, 
Bruning et al., 2011) binds in the same manner than the rest Ddl but has a lower contact 
area, showing that around half of analysed residues are not involved in dimer formation, 
and no contacts are noticed in α3 and α8. Also, the P-value is higher for MtDdl than the 
other structures, consistent with these observations. Ddl structures can be grouped 
according to the additional number of amino acids, compared to BpDdl, at the C-
terminal end of α10. When extra residues are present, α10 is elongated towards the 
partner subunit and more contacts assist dimer formation. This is the case for Bacillus 
anthracis (BaDdl), Streptococcus mutants (SmDdl, Lu et al., 2010), S. aureus (SaDdl, 
Liu et al., 2006), Coxiella burneii (CbDdl, Franklin et al., 2015) and Xantomonas 
oryzae (XoDdl, Doan et al., 2014), where an elongated α10, carrying from 8 to 20 
additional residues, is observed. The conservation, among the different orthologues, of 
the residues contributing to the dimer formation in BpDdl is shown in Table 4.7. The 
highest conserved residues, Gly77, Gly81, Val95, Ala99 and Asp103 are present in 12-
13 structures of the 14 analysed and three of them are located near the binding pockets 
(Gly77, Val95 and Asp103). Despite differences in the rest of the residues, the dimer 
arrangement seems to be a recurrent feature in these Ddl crystals.  
  
Part Four: D-alanine—D-alanine ligase  	
	
104 
 
 
 
 
 
  
Organism Bp Bam Bx Yp Ec Tt Tc 
PDB BpDdl-AMP 4EG0 4EGJ 3V4Z 4C5C 2YZG 2FB9 
ID (%) - 92 89 49 48 31 31 
r.m.s.d. (Å) 0.12* 0.39 0.63 1.28 1.92 1.84 1.85 
ResDimer (%) - 100 100 45 (21) 45 (28) 41 (17) 41 (17) 
ASAA (Å2) 13896 12529 12231 13489 13186 14918 15331 
BSAA (Å2) 1793 1287 1089 1331 1666 1372 1368 
BSAA (%) 13 10 9 10 13 9 9 
P-valueA 0.007 0.060 0.090 0.022 0.008 0.018 0.044 
ASAB (Å2) 13163 12823 11431 13601 13109 13983 15331 
BSAB (Å2) 1540 1309 1089 1061 1496 1372 1368 
BSAB  (%) 12 10 10 8 11 10 9 
P-valueB 0.014 0.064 0.094 0.008 0.010 0.018 0.048 
        
Organism Xo Ba Sa Cb Sm Mt Hp 
PDB 4ME6 3R23 2I87 3TQT 3K3P 3LWB 2PVP 
ID (%) 30 34 25 24 28 30 23 
r.m.s.d. (Å) 1.54 1.60 1.73 1.95 2.33 1.63 3.76 
ResDimer (%) 38 (21) 24 (28) 24 (28) 24 (24) 24 (21) 17 (14) 17 (34) 
ASAA (Å2) 16009 14940 16632 16012 14731 14807 16997 
BSAA (Å2) 1800 1433 2329 2294 1557 954 1454 
BSAA (%) 11 10 14 14 11 6 9 
P-valueA 0.013 0.046 0.176 0.021 0.169 0.382 0.158 
ASAB (Å2) 16041 14842 16879 15532 14669 13426 16365 
BSAB (Å2) 1800 1281 2325 2294 1557 959 1454 
BSAB  (%) 11 9 14 15 11 7 9 
P-valueB 0.011 0.041 0.083 0.003 0.187 0.333 0.091 
Table 4.7: Comparison of BpDdl with orthologues. The first section of the table shows, 
the percentage of the protein sequence similarity (ID), r.m.s.d. values of the Cα overlay 
of BpDdl-AMP-2 subunit B and a selected Ddl monomer, and the percentage of resides 
in the dimer interface (ResDimer) that are conserved and semi-conserved (in brackets). 
The second part includes the ASA, BSA values for each subunit (indicated in the 
subscript), and P-values (probability of the specificity of the interface). BSA is noted as 
Å2 and %. (*) overlay performed between subunits B from BpDdl:AMP-2 and BpDdl-
D-Ala—D-Ala. B. anthracis (Ba), B. ambifaria (Bam), B. pseudomallei (Bp), B. 
xenovorans (Bx), C. burneii (Cb), E. coli (Ec), H. pylori (Hp), M. tuberculosis (Mt), S. 
aureus (Sa), S. mutants (Sm), Thermus thermophilus (Tt), T. caldophilus (Tc), X. oryzae 
(Xo) and Y. pestis (Yp). 
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Comparison of the BpDdl structures with other available structures showed the highest 
homology with the B. ambifaria Ddl (92% identity and 0.6 Å r.m.s.d. for the monomer 
Cα overlay). As expected, other proteins from the ATP-grasp superfamily, such as 
acetyl-CoA-carboxylase and biotin carboxylase (18-19% identity and 2.8-2.7 Å 
r.m.s.d.), were also noted as structural homologues. The major structural similarity in 
the ATP-grasp fold family is found in the central and C-terminal domains. A 
comparison of BpDdl:AMP-2 structure with a representative of the ATP-grasp 
superfamily (Figure 4.23) shows the high structural homology that this superfamily 
presents especially in the ATP-binding site. Major structural differences were found at 
the N-terminal domain and the position of the central domain (more open or closed 
conformations).  
 
4.3.3.2 Co-factor and substrate pockets 
Both co-factor and substrate binding sites are shown in Figure 4.24. They are highly 
conserved in Ddl sequences (Figure 4.20). Indeed, the ATP-binding site residues 
(Lys104, Gly153, Glu184, Asp262, Glu275 and Asn277) are also conserved within 
Figure 4.23: Stereo view of the overlay of BpDdl:AMP-2 and glycinamide 
ribonucleotide synthetase (PurD, Sampei et al., 2010, PDB code 2YW2), two members 
of the ATP-grasp superfamily. The r.m.s.d. value for the overlay is 4.56 Å. The N-
terminal domain is coloured in blue, the central domain in green and the ATP-grasp 
domain in purple. PurD is coloured in grey. 
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different functional proteins from the ATP-grasp superfamily (Fawaz et al., 2011). The 
recognition of ATP involves residues from the central and C-terminal domains. These 
include Lys104, Lys148 and Glu275 binding to the phosphate, and Glu184, Lys185, 
Ile187, Glu192, Phe214 and Tyr215 that are involved in adenosine recognition. In the 
case of D-Ala—D-Ala, the residues interacting are Tyr215, Tyr221, Asp277, Arg260, 
Gly281, Ser286, Leu287 and a Mg2+-bound water molecule. The D-Ala—D-Ala peptide 
is poorly defined at the N-terminus and was refined with zero occupancy. 
 
An alignment of the protein sequences available in UniProt showed high conservation 
in residues from both pockets. In the D-Ala pocket, residues Lys220, Arg260, Asp277 
and Gly281 are conserved in all sequences and Leu287 in 90%. These are key residues 
for the catalysis according to the proposed reaction mechanism as they polarise and 
keep the substrates and the intermediate in place (Figure 4.2). Less conservation is 
noticed for Phe214, Tyr215 and Tyr221 (40-50%) but other aromatic residues are in 
these positions. These amino acids could be involved in placing ATP and D-Ala in the 
correct position for catalysis. In the ATP pocket, Lys104, Lys148, Glu184, Glu192 and 
Figure 4.24: (A) ATP binding pocket. AMP is represented as dark grey sticks and the 
2Fo-Fc map (5.0 σ) is shown as a green mesh. (B) D-Ala binding pocket. The dark grey 
sticks represent D-Ala—D-Ala. Red circles indicate atoms with zero occupancy. The 
ω-loop is represented as a yellow cartoon. The Fo-Fc map is represented as a green 
mesh (2.3 σ). Hydrogen bond interactions are indicated with black lines. 
B A 
N277 
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Glu275 are conserved in 98% to 100% of the sequences. These residues are likely to be 
important for ATP binding. 
 
When BpDdl:D-Ala—D-Ala was compared with other product and substrate-bound 
structures (from EcDdl: 1IOV, 4C5B, 4C5C; from TtDdl: 2ZDH and 2ZDQ, including 
ADP+phosphinate, ADP+D-Ala, ATP+D-Ala—D-Ala, ADP+D-Ala, ATP+D-Ala 
respectively), differences in the substrate and product binding were found (Figure 4.25). 
The Cα overlay of BpDdl:D-Ala—D-Ala (subunit A) with these ligand-bound structures 
showed the position of D-Ala—D-Ala is different from previously characterised 
proteins. The product in BpDdl:D-Ala—D-Ala is located further from the co-factor. 
This is highlighted when overlaying the ATP and AMP molecules instead of the Cα 
(Figure 4.25B). Additionally, the position of the Mg2+ is different. In other Ddl 
structures (e.g. EcDdl, PDB code 4C5C) two Mg2+ ions interact with Asp262, Glu275 
and γ-β phosphates from ATP. However in BpDdl:D-Ala—D-Ala only one Mg2+ is 
observed, interacting with His70. The overall BpDdl:D-Ala—D-Ala conformation 
presents a more open form than in other structures, suggesting it is an intermediate 
Figure 4.25: Overlay of BpDdl:D-Ala—D-Ala (grey) and EcDdl (45C5, in yellow). 
Ligands are represented as sticks. Mg2+ are represented as spheres coloured in green 
(BpDdl:D-Ala—D-Ala) or yellow (EcDdl). (A) Cα overall overlay. (B) Overlay using 
the co-factors. 
A B 
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conformation. However, it cannot be distinguished if this corresponds to a substrate 
binding or product release phase. 
 
4.3.3.3 Conformational change 
In common with other Ddl examples, BpDdl undergoes a large conformational change, 
involved in configuring the active site, when the co-factor binds (Figure 4.26). Binding 
generates a more compressed conformation where the central domain moves towards 
the centre of the structure and the ω-loop rotates and generates the active site pocket. 
 
ATP binding stabilises the ω-loop conformation enforcing interactions with Tyr215 and 
helps to create the closed confirmation. Phe214 is able to interact with a hydrophobic 
area of the central domain and Glu213 with Lys160 to close the ATP binding pocket. 
The conformational change of the central domain involves a movement/shift of α7 of 
about 12.5 Å and 7.6 Å for α6 (average distances from both subunits) favoured by the 
AMP and ω-loop interactions. Additionally, the conformation of the P-loop is stabilised 
Figure 4.26: (A) Ribbon diagram of the superposition of the apo-BpDdl (4EGQ in dark 
red) and BpDdl:AMP-2 (yellow). AMP is represented with sticks. (B) Residues 
implicated in co-factor binding. Blue indicates the N-terminal domain, orange the 
central domain and green the C-terminal domain. 
B A 
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by AMP interactions, the ω-loop and the N-terminal domain residues (Figure 4.21). In 
apo-BpDdl, the P-loop is disordered and not included in the model but in the AMP-
bound structures this loop is ordered with an average B-factor of 36.7 Å2 (the overall 
average B-factor value is 24.6 Å2).  
 
There are apo and ligand-bound structures for SaDdl (2I8C, 2I80, apo: 2I87; Liu et al., 
2006) and TtDdl (2YZM, 2YZN, 2ZDH, 2ZDG, 2ZDQ, apo; 2YZG). In both cases, the 
conformational changes are not as large as in BpDdl. Movement of the TtDdl central 
domains involves an α7 translation of 4.7 Å, while no differences in SaDdl are 
observed. As indicated in section 4.2.3 and 4.3.4.2, purified BpDdl contained AMP and 
apo-BpDdl could not obtained. With this in mind, density maps of the apo SaDdl and 
TtDdl structures were inspected to check for missed co-factors. Both TtDdl and SaDdl 
showed no evidence of co-factors in the ATP pockets. This might suggest either these 
apo forms are crystallographic artefacts (the conformation is driven by the 
crystallisation conditions), or the conformational changes are distinct among different 
organisms. 
 
A comparison of the electrostatic surfaces of apo-BpDdl and BpDdl:AMP-2 indicated a 
difference when the co-factor is bound (Figure 4.27). The D-Ala pocket is more 
electropositive in the AMP-bound structure. Therefore, at pH 7.5, D-Ala (pI = 6.01) 
would preferably bind to the BpDdl:AMP-2 conformation over the apo form. This 
suggests that the D-Ala pocket is formed after the ω-loop conformational change. The 
residues involved in the electrostatic properties of the different conformations (Glu22, 
Asp262, Glu275 and Asn277 in apo-BpDdl, and His70, Arg260, and Asn277 in 
BpDdl:AMP-2) are highly conserved. Also, as described previously, His70, Arg260, 
and Asn277 are key amino acids for Ddl catalysis. This is consistent with the hypothesis 
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that the generation of a favourable environment for catalysis is dependent on ATP 
binding, and extends to the sequential ordered mechanism previously characterised (Fan 
et al., 1994) where ATP is the first component to bind Ddl.  
 
4.3.3.4 Druggability 
Analysis of the BpDdl:AMP-2 and the apo-BpDdl structures with the pocket finder tool 
from Molsoft ICM showed distinct pockets in the D-Ala and ATP binding sites (Figure 
4.28). This indicates that the conformational change generates differences in the 
pockets. The software reports a druggability score for each pocket. A pocket is 
considered druggable-like when the score is greater than 0.5. The control proteins 
DHFR and neuraminidase showed druggability scores of 0.8 and -0.18. The values 
obtained for the ATP and D-Ala pockets in apo-BpDdl are -1.45 and -1.56 respectively. 
In the case of BpDdl:AMP-2 subunit A, these values are 0.02 and -1.60 respectively. On 
the other hand, BpDdl:AMP-2 subunit B presents druggability scores of 0.79 (ATP 
pocket) and 0.77 (D-Ala pocket). This suggests druggable-like pockets are only found 
in the more closed conformation.  
Figure 4.27: Electrostatic surface representation of (A) apo-BpDdl (4EGQ) and (B) 
BpDdl:AMP-2 structures. Orange arrows indicate the D-Ala pocket location and black 
arrows the ATP pocket. Dashed arrows indicate ATP pocket is closed and D-Ala pocket 
is formed. On the right side of each surface an enlargement of the D-Ala pockets are 
shown and amino acids marked. 
A 
N277 
D262 E275 
E22 Apo-BpDdl 
B 
N277 
R260 H70 
BpDdl:AMP-2 
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Examples of human proteins from the ATP-grasp family are glutathione synthetase 
(Dinescu et al., 2004), inositol phosphate kinase (Josefsen et al., 2007), ATP-citrate 
lyase (Sun et al., 2011), pyruvate phosphate dikinase (Wu et al., 2013), and succinyl-
CoA ligase (Jaberi et al., 2013). Also, other human kinases, such as the Ser/Thr kinase 
c-Jun N-terminal (JNK1, PDB code 4QTD, Chaikuad et al., 2014), share similarities 
with the ATP-grasp domain. Due to the high similarity of the ATP binding pocket 
between different functional proteins, targeting this pocket might result in inhibition of 
human enzymes and trigger side effects. To avoid this, the inhibitor search was focused 
on obtaining new inhibitors targeting the D-Ala binding pocket. 
 
4.3.4 Biochemical characterisation 
4.3.4.1 Enzyme kinetics 
Enzyme activity was investigated using a coupled spectrophotometric assay and a 
BIOMOL Green assay at pH 7.5 and 8. The results are shown in Table 4.8. Calculation 
Apo-BpDdl BpDdl:AMP-2 /A BpDdl:AMP-2 /B A B C 
Figure 4.28: BpDdl pockets. Blue pocket is in the D-Ala binding site and red pocket in 
the ATP binding site. (A) Open conformation, Apo-BpDdl (4EGQ). (B) Closed 
conformation BpDdl:AMP-2 subunit A. (C) BpDdl:AMP-2 subunit B. 
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of Km values were carried out using different equations (see Experimental procedures). 
Ddl binds to two substrates and one co-factor, and, consequently, there will be three Km 
values; one corresponding to the first D-Ala (Km1), the second D-Ala (Km2) and the third 
ATP (KATP).   
 
Using the coupled assay, inhibition of the enzyme activity was observed at high 
concentrations of ATP and Ki,ATP was also determined. In the case of the BIOMOL 
Green assay, high ATP concentrations decrease the signal-to-noise ratio due to non-
enzymatic ATP hydrolysis. This compromises the robustness of the assay and 
consequently, concentrations no greater than 1 mM were tested initially. Using 1 mM of 
ATP led to a decrease in the signal-to-noise ratio. A test at high ATP concentrations 
was performed and showed the same enzyme inhibition seen at the coupled assay. 
 
For the calculations of D-Ala Km in the BIOMOL Green assay, only Km2 was taken into 
account and data were analysed with the Michaelis-Menten equation. As high ATP 
concentration cannot be used with BIOMOL Green, enzyme inhibition was not 
observed during the experiment and KATP was determined using the Michaelis-Menten 
equation.  
 
The values for Km2 were consistent between the coupled and the BIOMOL assays. 
Comparing the Km values with other previously described Ddl enzymes, there is more 
similarity between BpDdl and MtDdl or EcDdl than HpDdl. Indeed, HpDdl seems to be 
the least related Ddl, not only having a lower amino acid percentage identity but also 
being a non-saturable enzyme with different kinetic parameters. For many enzymes, the 
Km values are similar to the physiological concentration of the substrate (Copeland, 
2010). In D-Ala producing bacteria, the physiological concentration inside the cell is 
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not known but it is produced in mM concentrations (Lam et al., 2009) so this would 
match with the Km2 values observed.  
 
 
 
 
The BpDdl samples used for performing the assays had AMP-bound, so the KATP 
determination is compromised. No information about the presence of AMP or co-factor 
analogues in HpDdl, EcDdl and MtDdl has been previously reported. Purification of 
MtDdl (Prosser and de Caravalho, 2013) and HpDdl (Wu et al., 2008) was carried out 
using nickel-affinity columns while EcDdl used ion exchange (Zawdzake et al., 1991; 
Ellsworth et al., 1996). It might be expected that MtDdl and HpDdl also co-purified 
with the co-factor as the purification is similar to BpDdl, however direct confirmation 
should be carried out.  
 
A test at different pH values indicated the optimum for BpDdl is pH 8. Differences in 
the activity due to the change in the pH are visible in the Km2 and the Vmax. At a lower 
pH there is an increase of 1.2 times in the Km2 and 1.7 times decrease in the Vmax. To 
further explore this, activity was measured over a pH range of 5.1 to 9.5. Regarding 
this, a test at different pH values has been carried out (Figure 4.29). The ATP and D-Ala 
Detection 
method pH Km1
 (mM) Km2 (mM) KATP (mM) Ki,ATP (mM) 
Vmax (nmol 
NAD+ min-1) 
Coupled 8 0.37 ± 0.085 4.19 ± 0.71 0.07 ± 0.01 3.16 ± 0.59 21.85 ± 0.98 
Coupled 7.5 0.35 ± 0.03 5.12 ± 1.09 - - 12.92 ± 1.38 
Biomol 8 - 4.9 0.13 - - 
BiomolTCEP/Tween 8A - 3.2 0.2 - - 
Biomol200µM ATP 8B - 2.3 - - - 
BiomolTCEP/Tween 7.5A - 5.4 0.27 - - 
HpDdl1 8 1.89 627C 0.000087 - - 
EcDdl2 7.8 0.0012 1.13 0.049 - - 
MtDdl3 8 0.075 ± 0.01 3.6 ± 0.6 0.31 ± 0.05 - - 
Table 4.8: Ddl kinetic parameters. It shows Km values for two D-Ala and ATP, the Ki 
for ATP, and the Vmax of the reaction. (A) In the presence of 1mM TCEP and 0.01% 
(w/v) Tween-20. (B) Km2 in the presence of 200 µM ATP instead of 500 µM ATP. (C) 
Maximum D-Ala concentration tested. (-) Not determined. 1(Wu et al., 2008), 
2(Ellsworth et al., 1996), 3(Prosser and de Caravalho, 2013). 
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concentrations were kept constant at 10 mM D-Ala and 0.5 mM ATP. The peak of the 
maximum activity is observed at pH 8 (100% relative activity) and the activity 
decreases around 1.7 times at pH 7.5 (56% relative activity). This is consistent with the 
results from the Km experiments. 
To identify a control inhibitor to support 
the screening experiments, the already 
known Ddl inhibitor DCS and 
fosmidomycin, an intermediate-like 
compound, were tested and Ki,DCS 
calculated. In the case of fosmidomycin, 
no inhibition was observed. 
Determination of the Ki and the 
mechanism of inhibition for DCS were 
assessed. Information about the mode of action of the inhibitor can be deduced from 
Vmax and Km values. If it is a competitive inhibitor, at high concentrations of substrate, 
the effect of the inhibitor will be nullified so the Vmax will be the same as the non-
inhibited protein. However, the binding of the substrate will be altered and the Km will 
change. On the other hand, an uncompetitive/allosteric inhibitor generally inhibits by 
binding a distinct pocket from where substrates /co-factors bind. This will cause a 
decrease in the Vmax and Km (and increase in the specific activity Km/Vmax). This can be 
checked using a double reciprocal plot. From Equation 4.4, the intercept of the 
regression lines with the y axis gives the 1/Vmax value. In the case of DCS, all but one of 
the regression lines present the same intercept (Figure 4.30). This indicates the Vmax has 
not changed and suggests DCS is a D-Ala competitive inhibitor with a Ki,DCS value of 
100 µM. At the highest DCS concentration tested, a different Vmax was observed. This is 
a characteristic of uncompetitive inhibitors and may indicate that the dynamics of 
Figure 4.29: pH effect on the reaction 
velocity. The activity is shown as the 
relative activity referred to the maximum 
activity at pH 8.  
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binding changes. DCS could be binding both D-Ala pockets and so display different 
binding behaviour. For MtDdl (Ki,DSC of 25 µM) and EcDdl (Ki,CDS of 185 µM), it was 
reported that slow binding of DCS occurs (Prosser and de Carvalho, 2013). 
Additionally, they found the slow binding is not present at high DCS concentration 
(1000 µM). This indicates there is a difference in binding at this concentration. A 
similar observation might apply to BpDdl. 
 
4.3.4.2 AMP detection 
Characterisation of structures from a range of different conditions revealed all had AMP 
bound. To determine whether the AMP was present in the purified sample or not, an 
AMP detection assay was carried. Denatured and folded samples were compared. The 
AMP-Glo assay contains various enzymes, so denaturation of the samples should not 
interfere with assay performance.  
 
Firstly, BaKynB, BaKynB in the presence of 2 µM AMP and BpDdl were treated for 
denaturation by 1) pH variation, 2) temperature variation and 3) chymotrypsin 
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Figure 4.30: (A) Double reciprocal plot for the DCS inhibition. (B) Plot of the slopes 
from the reciprocal plot against the concentration of DCS. From the equation of the 
slope of this line the Ki,DCS can be determined (Equation 3).  
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digestion. The experimental and expected results are shown in Figure 4.31. The 
negative control (in the absence of protein and AMP) and positive control (10 µM AMP 
in the absence of protein) results were similar to the expected values. The BaKynB 
sample was the same that was used for the structural analysis and confirmed there is no 
AMP bound (negative control). The BaKynB controls inform about anomalies in the 
sample preparation and assay performance such as chymotrypsin interfering with the 
assay or signal when no AMP was present in the protein sample. The results show the 
BpDdl sample has been purified with AMP bound and there is an AMP signal even 
without pre-treatment. This indicates there is some free AMP in the protein solution 
(around 0.4 µM) probably due to AMP exchange/release. The BpDdl-Ch sample 
presented an AMP concentration of about 2.1 µM that indicates 1.6 µM (14.8 nmol) 
AMP belongs to AMP bound to BpDdl. Taking into account that the concentration of 
BpDdl is 25 mg ml-1 (18.9 nmol in each well), the ratio AMP:BpDdl is close to 1. This 
is consistent with the structural data that shows one AMP per BpDdl subunit. 
 
Figure 4.31: AMP detection result. Neg is the negative control (without enzyme, 
without AMP). Pos is the positive control from the standard curve (without enzyme 
with 10 µM AMP). KynB is BaKynB sample. WT means no pre-treatment is 
performed. ΔT and ΔpH indicates variations in the temperature or pH were carried out. 
Ch indicates digestion with chymotrypsin was used and + is used when 2 µM AMP was 
added. The table indicates the values of the bars and the legend.  
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The presence of AMP in the purified enzyme has implications for the kinetic data, 
compound screens and crystallisation. The KATP determination and the assessment of 
the screening has been done with BpDdl:AMP instead of apo-BpDdl. Additionally, 
during the spectrophotometric assay, a retarded phase was observed during the first 
seconds of measurement (Figure 4.32). This could be due to the presence of AMP in the 
sample. Also, the fragment screen using BLI was carried out with the closed BpDdl 
conformation and might explain why a low ATP binding signal was measured.  
 
  
 
 
 
 
 
 
 
 
 
 
A BpDdl structure of the apo-form (PDB code 4EGQ) has been determined previously 
by the Seattle Structural Genomics Center for Infectious Disease (SSGCID). The ATP 
binding site was inspected to confirm it is indeed an apo-BpDdl. There was no evidence, 
in terms of electron density or difference peaks, to suggest the presence of the co-factor. 
The apo-crystal was grown in a condition of a basic pH (0.1 M Ches pH 9.5, 1 M Na-K 
tartrate and 0.2 M Li2SO4) while the crystals obtained in this work were obtained at pH 
5.5. It is unclear why in our structures AMP is present yet in the PDB entry 4EGQ it is 
absent. However, this could be due to the different crystallisation conditions. 
 
4.3.5 BLI: Fragment library screen 
The DDU fragment library, around 700 compounds, was tested using a BLI binding 
assay. A control compound is required to check the sensor/protein integrity. In this case, 
D-Ala or DCS stripped the protein from the sensors, and background and binding 
Figure 4.32: Spectrophotometric 
assay. Absorbance at 340 nm against 
time (sec) plot. The circle indicates 
the retarded phase of the reaction.  
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signals decreased with increasing concentrations of the compounds. This might be due 
to competition of D-Ala/DCS for the bound Ni2+. Additionally, according to the 
manufacturer, these compounds are below the molecular weight edge of detection of the 
Octet (150 Da, BLI applications notes at www.fortebio.com). ATP was tested as a 
possible control compound. The binding signal was lower that expected and only at 
high concentrations of ATP was significant binding recorded. This can be explained by 
the fact that the sample contains AMP as a contaminant from the E. coli recombinant 
expression system. Fortunately, ATP also binds to TEV protease and provided an 
additional control.  
 
Once the screen was carried out, the hits were selected. A compound was considered a 
hit when a binding response was obtained for BpDdl sensors but not for TEV protease. 
The hits, together with their binding responses, are shown in Table 4.9. From the 11 
selected hits two gave a negative binding response, which could indicate a large 
conformational change, unfolding of the protein or aggregation. The 11 hits were tested 
at 500 µM for inhibitory properties. Only compound #3 gave some inhibitory effect. A 
similar Ki determination experiment to Ki,DCS was carried out. After analysing the data, 
the Ki,#3 was 10 mM, too high for a good candidate. However, the inhibitory effect 
might be due to the DMSO rather than the presence of #3. When the concentration of 
DMSO reaches 6%, the activity is decreased by 2%. At the highest #3 concentration 
tested, 5% of DMSO was also present in the reaction so this might be the cause of 
inhibition. A co-crystallisation trail with #3 was set up and crystals obtained. They 
diffracted at 1.7 Å (at Diamond Light Source beamline I04) but the difference map did 
not show the presence of the compound. This would be consistent with the DMSO 
inhibitory effect. 
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Table 4.9: Fragment screening hit compounds and their binding signal (Δλ against time 
in seconds). Two binding curves are represented; one from TEV protease (showing no 
binding) and other showing BpDdl binding. 
# Structure / Spectrogram # Structure / Spectrogram 
1 
 
4 
 
 
2 
 
5 
 
 
 
3 
 
6 
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Table 4.9: Continuation. 
# Structure / Spectrogram # Structure / Spectrogram 
7 
 
10 
 
 
8 
 
11 
 
 
 
9 
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4.3.6 HTP screens 
An HTP enzymatic assay measures activity which provides a direct tool to search for 
inhibitors targeting the active site. Therefore, it reduces the probability of finding false 
positive inhibitors.  
The ELF proposed criteria that every protein should fulfil in order to assess compound 
library screening. The criteria includes: homogenous assay available for a 384-well 
plate format, in a maximum volume of 30 µl, maximum protein concentration of 100 
µM, signal-to-noise ratio higher than three, a Z’ score greater than 0.6, DMSO tolerance 
of 0.5%, read out stability for at least 1 hour and proteins not affected by freeze-thaw 
process. The HTP BpDdl assay satisfied these criteria. 
 
4.3.6.1 EFL library screening 
The HTP assay had to be optimised. Firstly, a test to check the protein activity and 
signal at different enzyme concentrations was performed (Figure 4.33). A concentration 
of about 0.2 nM was chosen for further experiments. In Figure 4.33, the data 
corresponding to 0.14 nM of BpDdl is the closest to the chosen concentration and it is 
linear for 5 minutes. To get a robust assay, the signal-to-noise ratio needs to be higher 
than 3. In the case of 0.023 nM of enzyme, this is achieved only after 20 min of reaction 
while for 0.138 nM, it is close to 3 after 5 minutes. Additionally, this assay was 
performed at saturating concentrations of D-Ala and ATP. The HTP screening was 
developed to target the substrate and co-factor pockets so D-Ala and ATP 
concentrations needed to be close to their Km values. This implies the signal-to-noise 
ratio will be lowered. 
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Once the enzyme concentration was chosen, the Km experiments reported Km values of 
4 mM and 130 µM for D-Ala and ATP respectively (Table 4.8, section 4.3.4). Vmax 
values have not been calculated as nmol of phosphate formed per minute because for 
every plate it was necessary to create a standard curve and there was no space in the 
plates for performing this experiment.  
 
A DMSO tolerance experiment was performed (Figure 4.34) and the protein displayed a 
tolerance of 6% DMSO (only 2% inhibition of the enzyme activity). The final DMSO 
concentration during screening reached 0.075% so the assay has not been compromised. 
Figure 4.33: Enzyme 
titration experiment. 
The graph shows 
absorbance units (AU) 
against time (min). 
The different lines 
correspond to different 
enzyme concentrations 
(nM). 
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Figure 4.34: (A) DMSO dose-response curve to determine DMSO tolerance. (B) DCS 
dose-response curve.	
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A library of 6775 compounds was obtained from the ELF. This library is used by the 
ELF for HTP assay validation as it includes well known drugs, active compounds and 
aggregators. In each screening plate negative and positive controls are required. Ideally, 
the negative control should be the total inhibition of the enzyme by a known inhibitor. 
However, DCS did not show 100% inhibition (Figure 4.34). Instead, the negative 
control was performed without protein. Initially, the experiments were run in the 
absence of TCEP and Tween-20. To target the substrate and co-factor binding sites, a 
concentration of D-Ala and ATP close to the Km were used. To confirm that these assay 
conditions were favourable, a time course experiment was performed to check for 
linearity. It was performed for 92 minutes and the reaction was still linear at 80 minutes. 
The Z’ score at this time point was 0.8 and the ratio signal-to-noise 5. These matched 
the ELF criteria and the assay was ready for use. The results are summarised in Figure 
4.35. 
 
After screening the ELF library, 74 probable hits were selected (Figure 4.35) and re-
tested using the BIOMOL Green assay. To check that compounds were not interfering 
with the BIOMOL Green assay mixture two additional tests were done. The same 74 
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Figure 4.35: (A) Result of the ELF library screening represented as the percentage of 
inhibitory effect against the plate number. Compounds from different libraries are 
coloured in blue (Selleck), orange (NCC) and green (BioAscent), and hits are marked 
in purple. (B) Result of the ELF library as the compounds distribution along the 
percentage of effect. 
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compounds were subject to the BIOMOL Green assay in the absence of enzyme or 
substrates, and separately, in the presence of BIOMOL Green and 70 µM of phosphate. 
For these two plates, the positive controls contained assay buffer and 70 µM of 
phosphate and negative control assay buffer without any supplemented phosphate. 
Results showed no interference by any of the compounds with the BIOMOL reaction. 
From the 74 hits, 61 were false positives leaving 13 compounds for further testing. 
 
Compound ID Compound concentration (µM) IC50 
30 10 3.33 1.11 0.37 0.12 0.04 
BCC0038183 24.10 -1.85      - 
BCC0125015 30.23 2.12      - 
BCC0112154 41.76 2.84      - 
BCC0115825 48.60 30.59      - 
BCC0013632 8.60 4.28      - 
BCC0028871 42.12 8.24      - 
BCC0032689 14.73 12.93      - 
BCC0047923 44.64 35.27      - 
S4059 82.48 41.40 9.68 4.28 1.76 2.84 8.24 12.88 
SAM001247071 97.61 96.53 98.69 81.04 7.16 11.85 2.84 0.98 
SAM001247083 85.00 58.33 26.98 5.72 8.24 -2.21 4.64 7.59 
SAM002264651 36.35 16.53 -2.57 -2.21 -0.41 5.72 3.92 44.71 
SAM002554903 87.16 75.27 15.81 -4.01 1.40 1.40 0.32 5.89 
 
The dose-response experiment was performed in the absence and presence of 1 mM 
TCEP and 0.01% (w/v) Tween-20. In the first case, IC50 values were calculated for five 
of the compounds. The other eight had a low stock volume and only two concentrations 
(20 and 30 µM) were tested. However, at the maximum concentration (30 µM) the 
percentage effect was less than 50% indicating they are not good candidates. Indeed, 
from the other five, four presented inhibition greater than 80%. The dose-response 
curves and the compound structures are in Figure 4.36. The IC50 and the results are 
shown in Table 4.10. When the same experiment was carried out in the presence of 1 
mM TCEP and 0.01% (w/v) Tween-20, no inhibition was observed. This suggests the 
redox environment affects the stability of the compounds and/or they are protein 
Table 4.10: Results from the 
dose-response experiment 
for 13 hit compounds. 
Compound IDs for NCC 
(BCC0XXXXXX), Selleck 
(SXXXX) and BioAscent 
(SAM00XXXXXXX) 
libraries. 
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aggregators. Looking at the structure of the compounds in Figure 4.36, it is very likely 
they are aggregators (Baell and Holloway, 2010). The dose-response profile from 
SAM001247071 is also characteristic of an aggregator dose-response (Shoichet, 2006). 
Due to these results, it is concluded that no leads were obtained from this screen. 
Results provide confirmation of the reliability of the assay since aggregators were found 
in the screening. 
 
4.3.6.2 DDU small diversity set screening 
The optimisation carried out at the ELF provided a reliable HTP assay but no good 
inhibitors were found using their library. To check whether the D-Ala binding pocket is 
druggable, the DDU diversity set screen was selected. Prior to the realisation of this 
screening, a peer review of the HTP assay was performed with the screening team at the 
S4059 
IC50 = 13 µM 
SAM001247071 
IC50 = 0.98 µM 
SAM001247083 
IC50 = 7.6 µM 
SAM002554903 
IC50 = 5.9 µM 
SAM002264651 
IC50 = 44.7 µM 
Figure 4.36: Dose-response curves and 
structures of hit compounds for the ELF 
screen. 
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DDU. Some changes were made and a new optimisation of the HTP assay was carried 
out to set up new screening conditions. 
 
The starting point was the performance of the assay at higher enzyme concentration and 
a pH closer to the physiological condition (pH 7.4). At this pH, using 0.2 nM enzyme, 
Km calculations for ATP and D-Ala were carried out (Table 4.8). In the case of the 
diversity set, only the D-Ala pocket was prioritised as the library target. The initial 
assay conditions included Km concentration for D-Ala and saturating concentration of 
ATP. After performing the time course experiment at different enzyme concentrations 
(1, 2 and 3 nM), only the reaction with 1nM was linear for 10 minutes. In order to get a 
longer assay time scale, the concentration of D-Ala was decreased down to 1 mM. In 
this case, the reaction was linear for 20 minutes, the signal-to-noise ratio 6 and the Z’ 
score 0.8-0.9. 
 
The screen was then performed with 1 mM D-Ala, 500 µM ATP, and incubated for 12 
minutes. To minimize false positives (avoid aggregators) the assay was performed in the 
presence of TCEP and Tween-20. The screening results are represented in Figure 4.34. 
From the 15667 compounds tested four hits were selected (showing 30% inhibitory 
effect, Figure 4.37). A dose-response experiment was carried out for these compounds 
but none of them showed any inhibitory activity. 
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4.4 Conclusions 
 
Having selected Ddl as a potential drug target in B. pseudomallei and F. tularensis, and 
with the results of the Dstl labs showing essentiality for B. pseudomallei growth, we 
prioritised this enzyme for assessment for drug discovery. Firstly, protein production 
and purification of BpDdl and FtDdl were developed and optimised. Well diffracting 
BpDdl crystals were obtained in the presence of various ligands and structures 
determined at 1.3 and 1.5 Å resolution in the presence of AMP and AMP+D-Ala—D-
Ala respectively. These structures were used as a template for druggability assessment 
and drug design. Additionally, the analysis of different BpDdl structures suggested the 
protein was being purified in the presence of AMP. This was confirmed using an AMP 
detection assay. This means kinetic parameter determination, screens and crystallisation 
were performed on the AMP-bound conformation of the protein instead of the apo-
form. This had not been reported previously and therefore we questioned whether this 
might also apply in other Ddl studies. So far, no information about co-purification with 
AMP has been noted. The BpDdl activity was measured using two different enzymatic 
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Figure 4.37: (A) Result of the DDU diversity set represented as the percentage of 
inhibitory effect against the compound ID. Hits are coloured in purple. (B) Result of 
the DDU diversity as the compounds distribution along the percentage of effect. 
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assays and showed similar kinetic parameters to other Ddl proteins. Considering the 
sample has already AMP bound, it is necessary to note that a retarded phase during the 
assay performance was observed, probably due to the presence of the ligand, and the 
Km,ATP examination and comparison with other enzymes needs to take into account 
these observations. 
 
HTP binding and enzymatic assays were developed to conduct DDU and ELF 
compound library screens. Despite screening more than 22500 compounds, no good 
inhibitors were identified. A team at AstraZeneca reported a compound library screen 
for Streptococcus mutants Ddl but no lead compounds were found (Tommasi et al., 
2015), which is consistent with our results. 
 
The overall assessment is that BpDdl is a challenging target and a HTP screen approach 
might not be the best strategy to identify new inhibitors for this protein. New strategies 
need to be developed for drug discovery for this target. A rational structure-based 
design of compounds targeting BpDdl might be carried out. This could include 
compounds targeting the D-Ala pocket but with an extension to the ATP pocket, or 
molecules disrupting or preventing the ω-loop conformational change. 
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PART FIVE 
CASEINOLYTIC PROTEASE SUBUNIT P 
 
5.1 Introduction 
 
The caseinolytic proteases (Clp) are present in all bacteria with orthologues in 
eukaryotes (Brötz-Oesterhelt and Sass, 2014). Their role is in maintaining protein 
homeostasis in the cell, especially under stress conditions. They can indirectly modulate 
gene expression, cell motility and cell division, and they are involved in pathogenesis 
by promoting virulence factor expression, removing stress-damaged proteins and 
contribute an important role in the production of exotoxins (Brötz-Oesterhelt and Sass, 
2014; Frees et al., 2014) 
 
The Clp protease complex displays a cylindrical shape with an internal chamber where 
the proteolysis of unfolded proteins is carried out (Brötz-Oesterhelt and Sass, 2014). 
Different Clp protease complexes are constructed of a core, formed by the protease 
ClpP, surrounded by accessory proteins (AAA+ chaperones ClpA, ClpX and ClpC) that 
regulate the specificity of the proteolysis (Alexopoulos et al., 2012). ClpP is an 
unspecific serine protease containing the catalytic triad Ser-His-Asp and forms seven-
subunit rings that associate to generate a tetradecamer structure. Each ClpP monomer 
displays proteolytic activity, which depends on the formation of the tetradecamer 
complex (Brötz-Oesterhelt and Sass, 2014). The complex presents two axial pores for 
the entrance of peptide substrates to the active site (Geiger et al., 2011). In the absence 
of the regulatory proteins ClpA/X/C, the axial pore size allows small unfolded peptides 
to access the catalytic chamber. To speed up the reaction and increase specificity, the 
regulatory proteins bind either directly to the targeted protein or to other chaperones 
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carrying the target. They unfold the proteins and induce the aperture of the proteolytic 
core (Brötz-Oesterhelt and Sass, 2014). Once the reaction has been carried out, the 
conformation of the ClpP core changes and generates pores in the equatorial plane to 
release the cleaved peptides (Figure 5.1, Geiger et al., 2011; Lee et al., 2011). The ClpP 
structure is highly conserved among different organisms, constituting the ClpP folding 
family (Yu and Houry, 2007; see section 5.3.3 for further details). 
 
Clp proteases have been studied as 
antibacterial drug targets and 
different compounds that alter 
ClpP function have been found 
(Brötz-Oesterhelt and Sass, 2014). 
Depending on the effect of the 
compounds they can be used as 
antivirulence or antibacterial 
agents. Inhibitors, such as lactone 
D3 and U1, prevent virulence of Staphylococcus aureus (Böttcher and Sieber, 2008) 
and Listeria monocytogenes (Böttcher and Sieber, 2009). On the other hand, activation 
of the complex leads to unspecific proteolysis and therefore, activators act as 
antibiotics. This is the case for acyldepsipeptides (ADEP) (Sowole et al., 2013).  
 
A total of 31 ClpP structures have been determined including apo and ligand-bound 
with resolutions from 1.8 to 2.4 Å. Two structures in the presence of the activator 
ADEP, from Bacillus subtilis (BsClpP, Lee et al., 2010) and E. coli ClpP (EcClpP, Li et 
al., 2010), one with the inhibitor diisopropyl phosphonate (BsClpP, Lee et al., 2011), 
and three bound to small peptides, from EcClpP (Szyk and Maurizi, 2006) and H. pylori 
Figure 5.1: Scheme of Clp protease function. The 
adaptors/chaperones ClpA/X/C (red) bind to the 
misfolded protein (black) for degradation. They 
interact with the ClpP complex (blue) and unfold 
the protein so it can be proteolysed. The 
conformation changes (yellow) and products are 
released from pores in the equatorial plane.  
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(HpClpP, Kim and Kim, 2008) have been characterised. The two different 
conformations for ClpP, open and compressed, have been structurally characterised for 
BsClpP (Lee et al., 2011), M. tuberculosis (MtClpP, Ingvarsson et al., 2007) and S. 
aureus (SaClpP, Geiger et al., 2011; Zhang et al., 2011). An apo structure of F. 
tularensis ClpP (FtClpP, open conformation, 3P2L, 2.3 Å resolution) has been 
determined.  
 
ClpP was selected as a potential target for F. tularensis and validation studies initiated. 
Two structures presenting the open and compressed conformations have been 
determined.  
 
5.2 Experimental procedures 
 
5.2.1 Recombinant protein production 
The codon optimised gene encoding FtClpP (UniProt: Q5NH47) was purchased from 
GeneWiz and cloned into the pET15bTEV vector. Recombinant expression was carried 
out in E. coli BL21(DE3), using 1 mM IPTG for induction of expression and incubating 
the culture overnight at 20ºC. The first Ni-NTA column for the purification of FtClpP 
was performed using buffer A (20 mM Tris-HCl pH 7.4 and 200 mM NaCl) and buffer 
B (buffer A with 0.8 M imidazole). The His6-tag was cleaved using TEV protease (1 mg 
per 10 mg of FtClpP) by incubating the samples at room temperature for 2h or at 4ºC 
overnight. Then a second Ni-NTA chromatography step was performed after dialysis 
into buffer A to separate the His6-tagged and non-tagged proteins. To determine the 
quaternary structure, SEC using a HiLoad 16/60 superdex 200 prep grade column (GE 
Healthcare) and native-PAGE (Invitrogen) were performed in buffer A, with and 
without 10% glycerol. Calibration of the SEC column was carried out as in Part Three 
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using buffer A with and without 10% glycerol. Protein purity was assessed using SDS-
PAGE (with Coomassie Blue stain) and MALDI-TOF-MS analysis. Protein 
concentration was determined using the predicted ε(FtClpP) = 8940 M-1cm-1 (value 
obtained from PROTPARAM, Gasteiger et al., 2003) and the Lambert-Beer equation. 
 
5.2.2 Crystallographic analysis 
5.2.2.1 Crystallisation 
FtClpP samples were concentrated to 20 mg ml-1 and commercially available 
crystallisation conditions were tested. These included The Classics Suite from Qiagen, 
JSCG plus and PEGs screen from Molecular Dimensions. Conditions were assessed 
using 1:1 and 1:2 protein solution:reservoir ratios (final drop volumes of 0.2 and 0.3 µl 
respectively) in sitting drop 96-well plates. Diffracting crystals were obtained from The 
Classics Suite A4 (5% (v/v) isopropanol and 2 M (NH4)2SO4) and B4 [0.2 M NaCl, 
30% (v/v) MPD (2-methyl-2,4-pentanediol) and 0.1 M sodium acetate pH 4.6] 
conditions. Optimisation was performed using 1:1 protein solution:reservoir ratio in a 
final drop volume of 4 µl and using hanging drop plates. 
 
5.2.2.2 Diffraction measurements and structure determination 
Crystals from the B4 condition diffracted to 2.8 Å resolution. Data were collected using 
the in-house X-ray generator (Rigaku M007HF X-ray generator with a Saturn 944HG+ 
CCD detector), a 10º θ offset, 10 seconds of exposure time and an oscillation range of 
0.5º (covering 115º collected). Data integration and analysis were performed using 
iMOSFLM (Leslie and Powell, 2007) and AIMLESS (Evans, 2011). The crystal has a 
space group P21212 and unit cell dimensions of a=113.5, b=125.9, c=96.95 Å. The 
Matthews coefficient calculated with the CCP4i suite (Winn et al., 2011) indicated there 
were seven monomers in the asymmetric (Vm value of 2.2 Å3 Da-1 and bulk solvent of 
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45%). The FtClpP structure 3P2L (2.3 Å resolution, space group P21212 and unit cell 
dimensions a=120.52, b=128.82, c=98.03 Å), also containing seven subunits in the 
asymmetric unit, was used as the search model for molecular replacement. Firstly, a 
monomer from 3P2L was employed and a partial solution was obtained using 
PhaserMR (McCoy et al., 2007). Only three subunits were found and clashes were 
noticed. Molecular replacement was then carried out with the heptamer but the high 
number of clashes for the probable solutions did not support the packing and no 
acceptable solutions were obtained. Analysing the electron density maps from the initial 
PhaserMR results, suggested a change in the conformation. Accordingly, the structure 
was solved using the subunit A from 3P2L without residues 128 to 149 as the model, 
and it was called FtClpP:Form-I. 
 
Diffraction data were also collected at ESRF beamline BM30-A. Crystals grown from 
an optimised The Classics Suite B4 condition, diffracted to 1.5-1.8 Å. Four crystals 
were used for data collection and then analysed using XDS (Kabsch, 2010) and 
AIMLESS. All crystals had the same space group (P21212) and two crystal forms can be 
identified with cell dimensions of a=98.49, b=128.23, c=355.18 or a=117.90, b=128.20, 
c=98.26 Å. Two data sets, containing fewer reflection overlaps, were chosen for 
structure characterisation and named FtClpP:Form-II and FtClpP:Form-III. Matthews 
coefficients were determined and suggested the presence of 7 (Vm of 2.41 Å3 Da-1 and 
bulk solvent 50%) and 21 (Vm of 2.43 Å3 Da-1 and bulk solvent 50%) subunits in the 
asymmetric unit in FtClpP:Form-II and FtClpP:Form-III, respectively. FtClpP:Form-II 
was solved using PhaserMR with subunit A from the 3P2L model. In the case of 
FtClpP:Form-III, monomer, heptamer and tetradecamer models of the refined 
FtClpP:Form-I and FtClpP:Form-II were tried as search models but no good solutions 
were found. This might indicate problems with the data or the presence of a different 
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conformation and further analysis is required. The general refinement procedure for 
FtClpP:Form-I and FtClpP:Form-II data sets started with a first round of rigid body 
refinement using REFMAC (Murshudov et al., 2011) followed by cycles of restrained 
refinement. Electron density and difference maps were inspected, and modifications to 
the model including addition of rotamers, waters and ligands were made using COOT 
(Emsley et al., 2010). Tight non-crystallographic symmetry restraints were used at the 
beginning of the refinement and removed gradually. When inspection of the maps 
suggested no more changes were justified, and no significant changes in the Rfree and 
Rwork were observed, the refinements were ended. The electron density in some areas of 
the models did not support a reliable addition of residues. Missing sections of the 
peptide chains are detailed in Table 5.1. 
  
 
 
5.2.2.3 Further structural analysis 
The models were analysed using MolProbity (Chen et al., 2010). The secondary 
structure was inspected with DSSP (Touw et al., 2015) and the search for structural 
homologues and comparisons were performed with the DALI server (Holm and 
Rosenstrom, 2010). Images were prepared using PyMol (www.pymol.org) and ALINE 
(Bond and Schüttelkopf, 2009). The interface surface area was calculated with PISA 
FtClpP:Form-I               
Subunit A B C D E F G 
N-terminus 1-4 1-5, 13-17 1-5, 12-15 1-4, 12-20 1-5, 12-20 1-4, 13-19 1-4, 13-18 
Handle region 132-139 131-141 133-141 133-141 132-142 131-141 133-141 
C-terminus 196-201 196-201 196-201 196-201 197-201 194-201 197-201 
        
FtClpP:Form-II               
Subunit A B C D E F G 
N-terminus 1-5 1-4, 11-19 1-3, 13-20 1-6, 11-20 1-5*, 11-19 1-4 1-4 
Handle region - - - - - - - 
C-terminus 199-201 200-201 - 299-201 - 189-201 199-201 
Table 5.1: Missing residues from models FtClpP:Form-I and FtClpP:Form-II. (*) In 
residue number 5, only density supporting the presence of the main chain is visible and 
Ala was placed instead of Asn. 
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(Krissinel and Henrick, 2007). Amino acid sequences were analysed with Clustal 
Omega (Sievers et al., 2011) and Jalview (Waterhouse et al., 2009), and structural 
alignments were performed using PyMol. 
 
5.3 Results and discussion 
 
5.3.1 Recombinant protein production 
The expression vector was sequenced and no mutations were found. Protein production 
was achieved and yielded 10 mg of FtClpP per liter of culture. FtClpP does not contain 
any tryptophan and therefore, the gels were stained with Coomassie Blue and showed 
FtClpP presented a high level of purity. The predicted molecular weight of the FtClpP 
subunit is 22.1 kDa and formation of heptamers or tetradecamers has been reported (Lee 
et al., 2010). During the characterisation of B. subtilis ClpP, formation of the 
tetradecamer was observed with SEC in the presence of 10% glycerol. In the absence of 
Figure 5.2: (A) SEC results in the absence (red) and presence (green) of 10% glycerol. 
The equilibration results, without (top) and with (bottom) glycerol, are shown in the 
graphs. Arrows indicate the expected value for a tetradecamer. (B) Native-PAGE 3-
12%. Molecular weight standards are in lane 1. FtClpP was loaded in lanes 2 and 3 (7 
and 5 ng of protein respectively). 
1 2 3 
A B 
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glycerol, a peak corresponding to the molecular weight of a heptamer was observed 
(Lee et al., 2010). The FtClpP quaternary structure determination was first investigated 
using SEC in the absence and presence of 10% glycerol (Figure 5.2A). In the first case, 
a peak corresponding with 245 kDa was obtained and used for crystallisation 
experiments. When glycerol was present, a peak of 286 kDa was identified. In both 
cases, these values suggested FtClpP is present as a tetradecamer in solution. Results 
from the native-PAGE (Figure 5.2B) showed bands of 292 kDa and 170 kDa which 
correspond with the formation of tetradecamers and heptamers. The differences in the 
molecular weight shown by SEC and native-PAGE can be due to limitations on the 
techniques, the complex shape and size, precision of the native-PAGE and errors in the 
SEC column calibration. 
 
E. coli ClpP (EcClpP) is synthesized as a propeptide and cleavage of the first 14 
residues has been described (Maurizi et al., 1990). MALDI-TOF MS analysis was used 
to check whether FtClpP was also present as a propeptide. The result showed a 
molecular weight of 21.6 kDa (only 0.5 kDa lower than expected) and no degradation 
products are noticed (Figure 5.3). Also, a high level of purity of the purified FtClpP can 
be observed.  
  
Figure 5.3: MALDI-TOF mass spectrometry result for FtClpP. The plots show the 
intensity of the signal (a.u.) against the mass:ion charge relation ship (m/z). On the left 
a run comprising molecular weights 4-20 kDa and on the right the results from 20-180 
kDa run. Note the differences in the scales. The red circle indicates FtClpP peak. 
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5.3.2 Crystallisation and diffraction 
Diffracting crystals were obtained from The Classics Suit condition B4 (Figure 5.4). 
The first structure (FtClpP:Form-I) was obtained from one of these crystals. Data were 
collected in-house and the resolution was 2.8 Å. Further optimisation gave bigger 
crystals with improved resolution. Bigger crystals (average dimensions 600 x 200 x 400 
µm) grew from various optimisation conditions and two data sets were selected for 
structure determination and analysis (FtClpP:Form-II and FtClpP:Form-III). ClpP has 
been shown to have two conformational states; the open and compressed conformations. 
FtClpP:Form-I structure shows a compressed conformation while FtClpP:Form-II is the 
open form (like the molecular replacement model 3P2L). No information about the 
FtClpP:Form-III conformation is presented until the structure is solved. The 
crystallographic data for the three crystals are shown in Table 5.2.  
  
Figure 5.4: FtClpP crystals and diffraction patterns (A) The Classics Suite condition 
B4. (B) Result after the optimisation of condition (A).  
100 µm 
200 µm 
 In-house, 2.8 Å 
ESRF, 1.8 Å 
A 
B 
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Structure FtClpP:Form-I FtClpP: Form-II FtClpP: Form-III 
Space group P21212 P21212 P21212 
Wavelength (Å) 1.5418 0.9799 0.9799 
Unit cell dimensions    
a, b, c (Å) 113.5 125.9 96.9 117.9 128.2 98.3  98.5 128.2 355.2 
Resolution rangea (Å) 63.61 - 2.84 47.04 - 1.90 47.60 - 1.8 
No. reflections 90264 838386 2376413 
Unique reflections 32741 117661 405163 
Completeness (%) 97.8 (98.8) 100 (100) 97.9 (84.0) 
Rmergeb 0.098 (0.344) 0.085 (0.460) 0.061 (0.293) 
Redundancy 2.8 (2.0) 7.1 (7.1) 5.9 (3.3) 
< I/σ(I)> 5.9 (2.2) 18.5 (4.4) 16.3 (3.3) 
Wilson B (Å2) 15.6 10.8 10.1 
Mosaic spread (º) 0.9 0.2 0.2 
Rworkc/Rfreed 0.2437 / 0.3281 0.2008 / 0.2694 - 
DPIe (Å) 0.4936 0.1653 - 
R.m.s.d. bond lengths 
(Å) / anglesf (º) 0.006 / 1.150 0.018 / 1.875 - 
Average B-factors (Å2) 36.27 20.94 - 
Protein residues 1329 2436 - 
Water molecules - 1085 - 
Ligands - 5 MPD, 7 acetate - 
Ramachandran 
analyses   - 
Favoured regions (%) 90.4 96.9 - 
Allowed regions (%) 98.7 99.7 - 
Table 5.2: Crystallographic statistics. a. Values in parentheses refer to the highest 
resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i Ii(hkl); where Ii(hkl) is the 
intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean value of 
Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed 
structure factor and Fc is the calculated structure factor. d. Rfree is the same as Rwork 
except calculated with a subset, 5 %, of data that are excluded from the refinement 
calculations. e. Diffraction Precision Index (Cruickshank, 1999). f.(Engh and Huber, 
1991). 
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5.3.3 ClpP structure 
Analysis of the FtClpP structure has been carried out using FtClpP:Form-I and 
FtClpP:Form-II which both contain seven subunits (A, B, C, D, E, F and G) in the 
asymmetric unit.  
 
Each monomer presents the characteristic ClpP family fold consisting of eleven β-
strands and seven α-helices arranged in head and handle regions (Figure 5.5). The 
handle is formed by α5 and β9 and the active site, Ser101-His126-Asp175, is located at 
the edge of the head and handle regions (Figure 5.5B). The β-strands 1 and 2 are not 
ordered in subunit C (FtClpP:Form-I) and G (FtClpP:Form-II). A search of the bacterial 
ClpP sequences (excluding Francisella sp.) in UniProt revealed 405 reviewed/curated 
entries. The amino acid alignment showed 40-70% identity with FtClpP and 
conservation of the three active site residues in all sequences. The sequence regions 
corresponding with the secondary structure elements are also highly conserved with the 
exception of the C-terminal region of α5 (not shown). Figure 5.6 shows the alignment of 
FtClpP with three orthologues (BsClpP, EcClpP and M. tuberculosis ClpP). The 
sequence identity between FtClpP and BsClpP is 45% and about 60% in the case of 
EcClpP and MtClpP. Comparing the sequences with the human mitochondrial ClpP, 
residues are highly conserved sharing 38% identity with the FtClpP. This could present 
issues in developing a specific antibacterial drug.  
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Figure 5.5: (A) Cartoon representation of the Cα alignment of monomers from 
FtClpP:open (grey) and FtClpP:compressed (green). α-helixes and β-strands are named 
like in Figure 5.6. Catalytic triad is represented in sticks. (B) Active site pocket 
showing the catalytic triad residues. 
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Figure 5.6: Sequence alignment of FtClpP (UniProt code Q5NH47), BsClpP 
(P80244), EcClpP (P0A697) and MtClpP (P9WPC3). Secondary structure elements are 
represented as red cylinders (α-helices) and blue arrows (β-strands). Active site 
residues are marked with green triangles. 
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5.3.3.1 ClpP complex analysis 
The physiological arrangement of ClpP is a complex of 14 subunits by the association 
of two heptamer rings. FtClpP structures have the heptamer in the asymmetric unit and 
the tetradecamer is formed by a crystallographic two-fold rotation axis. The heptamer 
complex is formed by interactions of β-strands (3 and 4) and two loops (between β5 and 
β6, and β7 and β8) with α-helixes (α2, α3, α4 and α5) of the adjacent subunit. The 
tetradecamer formation occurs by the antiparallel hydrophobic interactions between the 
two α5, and hydrogen bonds between main chains of both β9 (Figure 5.7). The 14 active 
sites are located in the interface between the handle and the head region and the pockets 
form two grooves in the equatorial plate of the complex (Figure 5.7B). Two 
conformations have been described for ClpP; open (FtClpP:Form-II) and compressed 
(FtClpP:Form-I). The conformational change from open to compress allows the 
substrates to be released and is due to the disorganisation of the handle. This allows the 
head regions from one heptamer ring to approach the other, generating a more 
compressed conformation. The structural rearrangement produces changes at the active 
site pocket (Figure 5.5B) and the loss of the active site groove organisation (Figure 
5.7B). All this ultimately leads to the formation of equatorial pores where release of the 
products occurs (Lee et al., 2011). Analysis of the formation of these quaternary 
structures has been made using PISA. In the case of FtClpP:Form-I, 35 ± 2% of the 
monomer accessible surface area is involved in the tetradecamer formation and 43 ± 1% 
in FtClpP:Form-II. In the complex, the buried surface areas are about 47710 Å2 and 
46390 Å2, respectively which corresponds to a stable assembly (see Part Four).  
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Figure 5.7: Structural insights into FtClpP:Form-II (grey and blue), and FtClpP:Form-I 
(grey and green). The seventh subunit of the heptamer is coloured in red. (A) Ribbon 
representation of the complex top view, and surface overlaid with ribbon representation 
of the lateral view. The arrows and numbers indicate the dimensions of both 
conformations. (B) Surface representation of the catalytic chamber. The black arrow 
indicates one of the translocation sites for the substrates. The red arrows mark the 
active site grooves and the blue arrows the pores for the products release. The active 
site amino acids are coloured in yellow. (C) Ribbon representation of the interaction 
between subunits from different rings that forms the tetradecamer.  
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Structural Cα overlay of FtClpP:Form-I subunits indicates high similarity among 
subunits (r.m.s.d. average of 0.38 ± 0.04 Å). The same observation applies to 
FtClpP:Form-II subunits with an r.m.s.d. average of 0.21 ± 0.03 Å. Performing pairwise 
overlaps between FtClpP:Form-I and FtClpP:Form-II subunits (0.38 ± 0.04 Å), minor 
differences reside in β1, β2 and the C-terminus positions. Even when the heptamers are 
compared, there are no major structural differences (r.m.s.d. of 0.78 Å). However, the 
overlay of the tetradecamer complexes shows an r.m.s.d. value of 4.29 Å what is 
consistent with the large conformational change observed. A search for structural 
homologues among published structures showed a high homology with all the ClpP 
proteins structurally characterised (30-70% identity, r.m.s.d. 0.5-2.5 Å), and shares a 
similar monomer conformation with enoyl-CoA-hydratase from Mycobacterium 
smegmatis (18% identity, r.m.s.d. 2.1 Å, Baugh et al., 2015), and naphthoate synthase 
from Synechocystis sp (12% identity, 2.6 Å, Sun et al., 2012).  
 
5.4 Conclusions 
 
ClpP was considered as a potential drug target for F. tularensis. In contrast to other 
systems, the search of an activator to generate unspecific proteolysis, rather than an 
inhibitor, was the chosen strategy. Production of highly pure FtClpP samples has been 
achieved and crystallisation optimised. Structures of FtClpP in the open and 
compressed stage were obtained and indicated the conformational changes that FtClpP 
undergoes is similar to that previously described for other orthologues (Lee et al., 
2011). Work on FtClpP to find activators was not carried out due to time constraints 
and prioritisation of Ddl. Several enzymatic assays can be used for determining serine 
protease activity (Zhang, 2006). These include fluorescence the use of dyes (e.g. 7-
amino-4-methylcoumarin and 7-amino-4(trifluoromethyl) coumarin) chemically 
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quenched with a peptide, fluorescence resonance energy transfer (FRET) and 
fluorescence polarisation using peptides labelled with a large size dye. The first is the 
most promising approach towards the development of a FtClpP high-throughput assay 
to screen compound libraries and search for activators.  
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PART SIX 
DIHYDROFOLATE SYNTHASE:FOLYL-POLY-GLUTAMATE SYNTHASE  
 
6.1 Introduction 
 
Reduced folate derivates are essential nutrients in bacteria and eukaryotes. They are 
involved in one-carbon metabolism (Young et al., 2008), for example the pathways for 
methionine, purine nucleotide and thymidylate biosynthesis (Kwon et al., 2008). Folate, 
or vitamin B, can be synthesized de novo in most bacteria and plants but in mammals 
folate is generally obtained from extracellular sources and actively transported 
(Bermingham and Derrick, 2002). In bacteria, the folate biosynthesis pathway (Figure 
6.1) involves several enzymes. The first four generate the intermediate 6-
hydroxymethyl-7,8-dihydropterin pyrophosphate (DHPPP) from GTP. The second part 
of the pathway uses DHPPP to synthetize active folate forms. Here, dihydropteroate 
synthase (DHPS, EC 2.5.1.15) generates dihydropteroate (H2Pte). This is then used by 
dihydrofolate synthase (DHFS, EC 6.3.2.12) to form dihydrofolate (DHF). 
Dihydrofolate reductase (DHFR, EC 1.5.1.3) reduces DHF and generates 
tetrahydrofolate (THF) that can be poly-glutamated by folyl-poly-glutamate synthase 
(FPGS, EC 6.3.2.17). Folate can also be reduced by DHFR to form DHF, which can 
then proceed to poly-glutamation (Bognar and Shane, 1986; Sheng et al., 2003). It has 
been shown that the poly-glutamated forms of the vitamin are essential in bacteria and 
eukaryotes, and that FPGS activity is present in both cases (Young et al., 2008). Poly-
glutamation provides a way to accumulate folic acid (Sheng et al., 2002). Most folate-
dependent proteins have higher affinity for the poly-glutamated forms (Young et al., 
2008). Indeed, even antifolate inhibitors can be poly-glutamated by FPGS activity 
(Sheng et al., 2002). An example of this is methotrexate (MTX), a DHFR inhibitor 
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(Barnes et al., 1999), where poly-glutamation facilitates retention inside the cell 
(Galivan et al., 1985). The number of glutamates that are added to the folate derivatives 
is different between species, so that FPGS adds three glutamates in E. coli and up to 
nine in the case of Lactobacillus casei and mammals (Wang et al., 2010). 
 
In most bacteria, a single protein presents DHFS and FPGS activities. This is the 
bifunctional protein FolC. In fungi and some bacteria, these enzymes exist as separate 
proteins. In the case of mammals, DHFS activity is not present which suggests this 
might be a selective antibacterial target (Sheng et al., 2008; Wang et al., 2010). Fifteen 
FolC structures have been determined; two E. coli FolC in the presence of ADP or 
Figure 6.1: Schematic of the folyl-poly-glutamate biosynthesis pathway. Enzymes are 
colored in blue. Green arrows indicate the folate biosynthesis pathway in bacteria. 
Dashed green arrows represent the first four enzyme reactions that generate DHPPP. 
Black arrows mark the part of the pathway present in both prokaryotes and eukaryotes.  
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phosphorylated dihydropteroate+ADP (Mathieu et al., 2005), two M. tuberculosis FolC 
structures with ADP or AMPPCP (Young et al., 2008), seven Lactobacillus casei FolC 
apo-form mutants, in the presence of AMPPCP, AMPCP+5,10-methylene-6-
hydrofolate, or pyrophosphate (Sun et al., 1998; Sun et al., 2001; Smith et al., 2006), 
and four Y. pestis FolC, two without ligands (3NRS, 3N2A) and two in the presence of 
AMPPNP+Glu or AMPPNP (3QCZ, 3PYZ). FolC proteins contain two distinct α/β C-
terminal and N-terminal domains. The ATP binding site is formed by residues from 
both domains and the substrate binding sites are located in the N-terminal domain. Two 
loops at the N-terminal domain undergo a conformational change when ATP and DHF 
bind and the overall FolC structure shows a more closed confirmation. From the 
structures, the co-factor pocket and active site have strong similarities with the Mur 
ligase superfamily, suggesting they undergo a similar reaction mechanism (Mathieu et 
al., 2005). It has been proposed that both FolC reactions are carried out in an ordered 
sequential manner. First, ATP binds followed by the H2Pte, or poly-glutamated folate, 
and then L-glutamate. The substrate is phosphorylated and this favours the 
incorporation of L-glutamate to form DHF. The first products to be released are ADP 
and phosphate followed by the ligation product (Sheng et al., 2002; Mathieu et al., 
2005). 
 
Inhibition of folyl-poly-glutamate biosynthesis has been achieved by targeting DHPS 
and DHFR but little has been done for inhibition of DHFS (Nzila, 2006; Wang et al., 
2010). Two inhibitors, mimicking the acyl-phosphate intermediates of both DHFS and 
FPGS, have been reported against Plasmodium falciparum FolC (PfFolC) DHFS 
activity (Wang et al., 2010). The studies showed selective inhibition towards DHFS is 
feasible and suggest PfFolC could be used as a new drug target for malaria. 
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FolC was identified as a potential target for B. anthracis (BaFolC), B. pseudomallei 
(BpFolC) and Y. pestis (YpFolC) as explained in Part Two. Initial studies for the 
assessment of FolC chemical validation involved the investigation of crystallisation 
conditions and enzymatic assays. 
 
6.2 Experimental procedures 
 
6.2.1 Recombinant protein production 
Genes encoding BaFolC (UniProt code Q81LD4, expected molecular mass 48.9 kDa), 
BpFolC (Q63JM2, 47.1 kDa) and YpFolC (Q0WDC2, 47.2 kDa) proteins were 
purchased from GeneScript and cloned into the pET15bTEV vector using the restriction 
enzymes NdeI (at the 3’ DNA end) and BamHI (5’ end). The inserts were 1311 
(YpFolC), 1316 (BaFolC) and 1360 bp (BpFolC). Expression vectors were sequenced 
and no mutations were found. 
 
Heterologous expression using E. coli strain BL21(DE3) was obtained after the addition 
of 1 mM IPTG and cultures incubated at 20ºC overnight. The first affinity 
chromatography column (Ni-NTA) was carried out using buffer A1 (20 mM Tris-HCl 
pH 7.5, 20 mM NaCl and 10 mM MgCl2) or A2 (20 mM HEPES pH 7.5, 200 mM NaCl 
and 10 mM MgCl2) and buffer B (buffer A1/A2 with 800 M imidazole). Next, the His6-
tag was cleaved, during dialysis into buffer A1/A2, using 1 mg of TEV protease per 10 
mg of protein overnight at 4ºC. A second Ni-NTA chromatography step was carried out 
to separate the His6-tagged and non-His6-tagged proteins. A high level of purity was 
confirmed with SDS-PAGE and MALDI-TOF MS analysis. The quaternary structure 
was studied with SEC, using a superdex 200 HiLoad 26/60 prep grade column (GE 
Heathcare), and native-PAGE (Invitrogen). Protein concentrations were determined 
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using the predicted ε(BaFolC) = 44600 M-1cm-1, ε(BpFolC) = 37150 M-1cm-1, 
ε(YpFolC) = 52285 M-1cm-1 (values obtained from PROTPARAM, Gasteiger et al., 
2003) and the Lambert-Beer equation. 
 
6.2.2 Differential scanning fluorimetry 
Differential scanning fluorimetry (DSF), also called Thermofluor, is a technique for 
measuring protein denaturation. The dye SYPRO Orange binds to unfolded proteins by 
interaction with hydrophobic areas. This generates an increase in the fluorescence of the 
dye (Lo et al., 2004). In this project, DSF has been used to check FolC stability in the 
presence of different buffers to select a protein storage solution distinct to buffer A1. 
Protein unfolding was performed using increasing temperatures and the melting 
temperature (Tm) of each sample was determined.  
 
The assay was carried out in a 96-well plate. The protein concentration used in each 
well was 4 µM, and SYPRO orange 1000 times diluted (stock purchased from 
Invitrogen). BaFolC and YpFolC samples were incubated for 30 minutes with 24 
different buffers with different pH and salt concentrations. These involved Bicine, 
CAPS, CHES, HEPES, imidazole, MOPS, sodium-cacodylate, sodium-acetate, Tricine, 
Tris-HCl, and NaCl or KCl as the salt component. The increase in temperature and the 
fluorescence recordings were made using the real-time PCR system MX3005P from 
Stratagene. 
 
6.2.3 Crystallisation and diffraction 
BaFolC, BpFolC and YpFolC were concentrated to 15 mg ml-1. Prior to crystallisation 
TCEP at a final concentration of 1 mM was added. Initial crystallisation experiments 
were carried out using proteins in buffer A1 and samples were also incubated with 10 
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mM AMPPNP and L-glutamate. The screens tested were The PEGs Suite, The MPD 
Suite and The Classics Suite from Qiagen, and PGA, PROPLEX, JCSG plus and 
MIDAS from Molecular Dimensions. Drops were set up using 1:1 and 1:2 protein 
solution:reservoir ratios in final volumes of 0.2 and 0.3 µl. There were no positive hits 
from these screenings and only salt crystals grew in various conditions, and so the 
crystallisation trials were repeated using a different protein storage buffer. DSF gave 
information about the stability of the protein under various conditions; it identified 
buffers for which the protein was unstable and showed that higher NaCl concentration 
(0.5 M) provided an increase in YpFolC stability.  Due to the salt crystal growth in the 
first crystallisation experiments, the salt concentration was not increased and, since 
Mg2+ or Mn2+ is required for ATP hydrolysis, MgCl2 was included. The resulting buffer 
contains 0.02 M HEPES, 0.2 M NaCl and 0.01 M of MgCl2 (buffer A2). Based on the 
crystallisation conditions reported for PDB entries 3N2A and 3QCZ (YpFolC in the 
presence of ADP and ANPPNP+Glu, respectively), a screen was designed containing 
0.5-3 M sodium-formate, 20%-40% PEG 3350 and 0.1/0.2 M HEPES pH 7.0. Co-
crystallisation of YpFolC (in buffer A2) with 10 mM AMPPNP and L-glutamate was 
carried out and resulted in diffracting crystals. This crystallisation experiment was not 
performed with BaFolC and BpFolC proteins and might be considered for future work. 
 
Data were collected using the in-house X-ray generator (Rigaku M007HF X-ray 
generator with a Saturn 944HG+ CCD detector). Data reduction and analysis were 
performed with XDS (Kabsch, 2009) and AIMLESS (Evans, 2011). The structure was 
solved using PhaserMR (McCoy et al., 2007) and 3QCZ, a YpFolC structure with 
AMPPNP and L-glutamate bound, as the search model. Ligands and waters were 
removed prior to molecular replacement. The space group of 3QCZ and the crystal of 
YpFolC grown here is P212121 and they have similar unit cell parameters (a=62.9 
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b=83.24 c=127.0 and a=62.0 b=78.0 c=131.0 Å, respectively). The Matthews 
coefficient determination using the CCP4i suite (Winn et al., 2011) suggested the 
presence of one subunit in the asymmetric unit (Vm value of 3.4 Å3 Da-1 and bulk 
solvent of 64%).  A round of rigid body refinement using REFMAC (Murshudov at al. 
2011) was carried out. It showed the presence of a positive density peak (5 σ) in the 
ATP binding site. The structure did not offer new information about YpFolC so no 
further refinement was pursued.   
 
6.2.4 Enzyme kinetics 
Different enzymatic assays were tested with YpFolC. Two coupled enzyme systems can 
be used (Figure 6.2); the formation of DHF can be measured using DHFR, and ATP 
hydrolysis to ADP can be recorded using the pyruvate kinase/lactate dehydrogenase 
(PK/LDH) system. An additional assay, BIOMOL Green, was used to measure the 
release of phosphate.  
THF FPG 
DHFR 
NADPH 
NADP+ NADPH 
NADP+ Folate 
FolC 
DHFR 
H2Pte DHF 
L-Glu 
FolC 
ATP 
ADP + Pi 
PK/LDH 
NAD+ 
NADH 
ATP, Lactate 
PEP 
Malachite green assay 
Abs340nm 
Abs340nm 
Abs620nm 
Abs340nm 
Figure 6.2: Scheme of assays tested for measuring FolC activity (blue circles). 
Coupling enzymes are shown in bold. The assay described by Bognar et al. (1985) is 
coloured in turquoise, and the modification of the assay in purple. The PK/LDH 
coupled assay is coloured in orange. The dashed orange arrow indicates a two-step 
reaction. The BIOMOL Green assay is marked in green and the dashed green arrow 
indicates non-enzymatic reactions. The expected effect in the absorbance at 340 or 620 
nm is indicated with up (increase) and down (decrease) black arrows inside coloured 
squares. H2Pte is dihydropteroate, FPG folyl-poly-glutamate, DHR dihydrofolate, 
THF tetrahydrofolate and PEP phospho-enol pyruvate. 
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6.2.4.1 Coupled spectrophotometric assays 
DHFR coupled assay 
Firstly, the activity of DHFR (human enzyme purchased from SIGMA) was checked. 
The reaction mixture contained 50 mM Tris-HCl pH 9, 100 µM NADPH, 25 µM DHF, 
1 mM TCEP, 10 mM MgCl2 and 50 mM KCl in a final volume of 1 ml. A negative 
control involved the reaction mixture without the addition of DHFR. Activity was 
measured at 5 and 10 mU ml-1 enzyme concentration for 10 minutes at 37ºC. The 
decrease in absorbance at 340 nm was recorded by a UV-2450 Shimadzu 
spectrophotometer. To determine YpFolC activity, the assay mixture contained 50 mM 
Tris-HCl pH 9, 50 mM KCl, 1 mM TCEP, 10 mM MgCl2, 100 µM NADPH, 5 mU ml-1 
of DHFR, 25 µM H2Pte, 5 mM ATP and 10 mM L-glutamate (1 ml final volume) 
(Bognar et al., 1985). Tests at 37ºC for 30 minutes with different YpFolC concentrations 
(from 10 to 200 µM) were carried out. Activity was also checked using an assay 
variation. Instead of using NADPH, 100 µM NADP+ was used to promote the formation 
of folate and avoid the generation of THF, as this is also a substrate of YpFolC (Figure 
6.2). However, the folate formed might be transformed to DHF, thereby complicating 
the analysis, and this assay was used as an attempt to confirm whether YpFolC was 
active. Same positive and negative controls were used in this assay variation. All 
controls showed the expected result. 
 
PK/LDH coupled assay 
The same procedure and assay buffer was used for the PK/LDH coupled system but 
instead of DHFR and NADPH, 5 µl ml-1 PK/LDH mixture from SIGMA and 70 µM 
NADH were used. Additionally, 1 mM phopho-enol pyruvate was added.  
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6.2.4.2 Malachite green assay 
A malachite green assay was tested as a potential HTP assay, as wavelength distinct to 
340 nm is required to avoid interference due to compounds. An enzyme titration 
experiment was carried out using the BIOMOL Green assay procedure shown in Part 
Four. The assay conditions included 50 mM Tris-HCl pH 9, 50 mM KCl, 1 mM TCEP, 
10 mM MgCl2, 100 µM H2Pte, 500 µM ATP and 10 mM L-glutamate in a final volume 
of 30 µl in a clear bottom 384 well plate. The starting protein concentration used was 10 
µM and serial 1/2 dilutions were made in every row. The absorbance at 620 nm was 
measured using the EnVision plate reader from PerkinElmer at 0, 2, 5, 10 and 20 
minutes.  
 
6.2.5 Tryptophan fluorescence 
Tryptophan fluorescence was performed using a buffer containing 50 mM Tris-HCl pH 
9, 50 mM KCl, 1 mM TCEP and 10 mM MgCl2. Different concentrations of H2Pte (0.3, 
0.45, 0.6, 0.75, 0.9, 3, 4.5, 6, 7.5, 9, 30, 60, 90 µM) and L-glutamate (same 
concentrations) were tested in the presence and absence of 5 µM YpFolC. Samples were 
exited at 280 nm and the emitted fluorescence recorded at 340 nm using the FLUOstar 
OPTIMA from BMG Labtech. The negative control was the buffer in the absence of 
protein or substrates, and the positive control was buffer and 5 µM YpFolC. The assay 
was run in triplicate and a curve for measuring the fluorescence emission from H2Pte 
was performed (same H2Pte concentrations in the absence of YpFolC). The 
corresponding H2Pte signal was removed from the assay signal to determine the binding 
specific fluorescence. The Kd for H2Pte was determined using the saturation binding 
equation from GraphPad (www.graphpad.com). 
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6.3 Results and discussion 
 
6.3.1 Recombinant protein production 
Heterologous expression was obtained with yields of 10, 80 and 90 mg per liter of 
culture of BpFolC, BaFolC and YpFolC respectively. Purification was achieved with 
different buffers and the high levels of purity of the samples was confirmed with SDS-
PAGE gels and MALDI-TOF MS analysis, which showed peaks corresponding to 49.03 
(BaFolC), 47.37 (BpFolC) and 47.34 (YpFolC) kDa being consistent with the expected 
protein masses. 
 
The quaternary structure of FolC was investigated. All proteins eluted as monomers in 
SEC but the native-PAGE showed the presence of dimers and monomers. From the 
structures, monomers are expected but dimer formation has been suggested for DHFS 
activity (Bermingham and Derrick, 2002). Further analysis involving enzymatic assays 
will follow. 
 
6.3.2 Differential scanning fluorimetry 
The first crystallisation screens did not yield any crystal hits. This could be due to the 
buffer used for protein purification and storage. To investigate a more suitable protein 
buffer, DSF was carried out. The results for YpFolC (Figure 6.3) showed good stability 
of the protein in various buffers and pH values. The Tm for YpFolC in buffer A1 is 51ºC 
and no significant improvements in protein stability were observed. The protein had the 
highest Tm value in the solution containing 50 mM Tris-HCl and 500 mM NaCl (52ºC). 
DSF results also showed decreasing protein stability with imidazole (46ºC), MES 
(43ºC), sodium-acetate (37ºC) and sodium-cacodylate (46ºC). In the case of BaFolC, no 
increase in the fluorescence signal was detected for reasons that are unclear. 
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6.3.3 Crystallisation and diffraction 
Four YpFolC structures with different ligand combinations have been already solved by 
the Center for Structural Genomics of Infectious Diseases of Seattle, although no 
publications are available. The aim in this work for crystallisation of FolC was to find a 
condition that can be used for inhibitor:protein binding studies. Good quality crystals 
were obtained only in the case of YpFolC (Figure 6.4A-B). These crystals diffracted to a 
resolution of 2.5 Å and the structure was determined. Positive density corresponding to 
AMPPNP was observed (Figure 6.4C). YpFolC crystals could be further optimised for 
co-crystallisation and resolution improved at a synchrotron source. Due to the 
difficulties for determining the enzymatic activity of the protein (section 6.3.4), work in 
Figure 6.3: Results of YpFolC DSF represented by the Tm (ºC). The dashed red line 
marks the Tm value of the protein in the presence of buffer A. 
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crystal optimisation was stopped until an assay for inhibition validation could be 
developed, and some inhibitory hits found.  
The crystallographic statistics are shown in Table 6.1. 
 
 
 
 
  
Structure YpFolC:AMPPNP 
Space group P212121 
Wavelength (Å) 1.54178 
Unit cell dimensions    
a, b, c (Å) 62.0, 78.0, 131.0 
Resolution rangea (Å) 45.5 - 2.5 
No. reflections 79069 
Unique reflections 22627 
Completeness (%) 99.8 (99.5) 
Rmergeb 0.264 (0.450) 
Redundancy 3.5 (3.3) 
< I/σ(I)> 3.2 (2.1) 
Wilson B (Å2) 17.6 
Rworkc/Rfreed 0.3660 / 0.3974* 
Mosaic spread 0.5 
Figure 6.4: (A) YpFolC optimised crystal in the presence of 10 mM AMPPNP, 10 mM 
L-Glu, 1 M sodium-formate, 0.1 M HEPES pH 7.5 and 20% (w/v) PEG 3350. (B) 
Diffraction pattern from collected data on the in-house X-ray generator. (C) Electron 
density (blue, 1.4 σ) and difference maps (in green, 3 σ) for AMPPNP at the ATP 
binding pocket of YpFolC.  
200 µm  
A C B 
Table 6.1: Crystallographic statistics.  
a. Values in parentheses refer to the 
highest resolution shell. b. Rmerge = 
∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i Ii(hkl); 
where Ii(hkl) is the intensity of the ith 
measurement of reflection hkl and 
<I(hkl)> is the mean value of Ii(hkl) for 
all i measurements. c. Rwork = ∑hkl||Fo|-
|Fc||/∑|Fo|, where Fo is the observed 
structure factor and Fc is the calculated 
structure factor. d. Rfree is the same as 
Rwork except calculated with a subset, 5 
%, of data that are excluded from the 
refinement calculations. (*) Refinement 
not complete; values after one cycle of 
restraint refinement. 
Part Six: Dihydrofolate synthase:folyl-poly-glutamate synthase   	
	
157 
6.3.4 Enzyme kinetics 
As indicated in the introduction, the next enzyme in folyl-poly-glutamate biosynthesis 
after the first FolC reaction is DHFR. This enzyme oxidizes NADPH which can be 
measured as a decrease in the absorbance at 340 nm. Bognar et al. (1985) published an 
assay for determining enzyme kinetics parameters of L. casei and Corinebacterium sp. 
FolC using DHFR as a coupled enzyme. In this work, it was not possible to observe 
FolC activity using this assay. DHFR might not be useful for measuring FolC activity 
since the product THF is also a FolC substrate. Even using the variation of Bognar et al. 
(1985) assay, DHFR could form THF using DHF synthesised by FolC compromising 
the assay performance. To avoid using DHFR, another coupled assay involving PK and 
LDH was tested but no activity was detected, although binding of the substrate, H2Pte, 
to FolC was confirmed using tryptophan fluorescence (see section 6.3.5). Other groups 
have carried out enzyme kinetic studies for various FolC orthologues using radioactivity 
(Murata et al., 2000; Garrow et al., 2004; Wang et al., 2010) or HPLC (high 
performance liquid chromatography, Sybesma et al., 2003; Mathieu et al., 2005) instead 
of the coupled assay previously described. This may be indicative of an issue with the 
assay, probably due to interference of the substrate at the measured wavelength and/or 
the DHFR product. As a last check, the BIOMOL Green assay was used to measure the 
phosphate release and YpFolC activity was detected (Figure 6.5). Further experiments 
are required to determine the Km values of H2Pte, L-glutamate and ATP and to study the 
reaction mechanism.  
 
The result of the enzyme titration experiment is shown in Figure 6.5. Once the Km 
values have been determined, this could be used for developing a high-throughput 
assay. 
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6.3.5 Tryptophan fluorescence 
Tryptophan fluorescence was used to 
measure the binding constant (Kd) of H2Pte 
and L-glutamate. In the first case, the 
results showed a Kd of 24 µM (Figure 6.6). 
For L-glutamate, variations in the 
tryptophan fluorescence were not observed. 
Fluorescence changes may be due to the 
presence of two tryptophan residues in a 
loop that changes its conformation when ATP and H2Pte bind. L-glutamate binding 
might not be involved in the re-organization of this loop, and so has no effect on 
tryptophan fluorescence.  
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Figure 6.6: YpFolC tryptophan 
fluorescence result. The plot represents 
the percentage of saturation against the 
substrate concentration. 
B 
Figure 6.5: (A) Result from YpFolC enzyme titration experiment using the BIOMOL 
Green assay. (B) Plot representation of YpFolC results in A. Absorbance at 620 nm at 
different time points (min) and YpFolC concentrations (nM).  
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The results confirmed H2Pte binding. From the previously described sequential ordered 
mechanism (Mathieu et al., 2005) ATP is the first compound to bind FolC. In this 
experiment, binding of H2Pte to YpFolC is observed in the absence of ATP which might 
suggest the binding of the substrates is not necessarily ordered. This has to be 
confirmed with enzyme activity characterisation. 
 
6.4 Conclusions 
 
Bifunctional FolC is a potential selective antibacterial drug target as mammals lack 
DHFS activity. YpFolC crystals have been obtained and optimisation can be conducted 
for ligand co-crystallisation. Other techniques for ligand binding studies are BLI or SPR 
(Surface Plasmon Resonance), but it would be necessary to test difference ligand bound 
states of the enzyme. The search for an enzymatic assay has been pursued and a new 
DHFS assay based on the detection of released phosphate was found. Future work 
should focus on the optimisation of this assay to perform biochemical characterisation 
and develop a HTP assay to support a compound screening campaign.  
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PART SEVEN 
CONCLUSIONS 
 
This project aimed to evaluate and carry out initial validation of several potential 
antibacterial drug targets. Ten different enzymes in the biowarfare agents B. anthracis, 
Y. pestis, B. pseudomallei and F. tularensis were selected on the basis of the genome-
scale transposon knock-out sequencing data and previous work from the Dstl and 
Hunter labs. Structural and biochemical studies were initiated on four of these, KynB, 
Ddl, FolC and ClpP, and the targets were then prioritised based on the empirical results.  
− Structures were determined for three bacterial KynB examples. The structures 
show a distinct amidase fold and binuclear Zn2+ catalytic site, unrelated to the 
eukaryote kynurenine formamidase. This indicates that specificity towards 
bacteria might be feasible. However, genetic analysis showed no essentiality and 
work was directed to other targets, highlighting the importance of the genetic 
validation of potential targets. Nevertheless, should KynB be proven essential 
for other organisms, studies carried out during this project give information and 
tools for further validation. There is some evidence to suggest KynB is involved 
in virulence of B. pseudomallei, so inhibitors for KynB might be used in 
combinatorial therapies. 
− Research on B. pseudomallei Ddl provided structural and kinetic data. An 
optimised high-throughput (HTP) assay was developed and used to screen 
compound libraries. Despite testing a large number of compounds, no inhibitors 
were found suggesting other approaches, such as structure-based rational drug 
design, might be used for assessing this challenging target. In this case, 
inhibitors have been developed by others since 1988 but no information about 
the follow up has been described suggesting problems with the characterised 
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compounds. The optimised high-throughput assay can be used to screen new 
compound libraries that might be developed in the future. 
− Well ordered crystals have been obtained for Y. pestis FolC and can be further 
optimised to develop ligand-bound studies. Problems were encountered towards 
the development of an enzymatic assay for Y. pestis FolC, and a new assay has 
been found for measuring dihydrofolate synthase activity. Future work could be 
focused on the assay optimisation to characterise the enzyme and perform HTP 
compound library screens. 
− Pure F. tularensis ClpP was obtained and used for crystallisation. Two 
structures were determined showing the compressed and the open 
conformations. These data can be used for the development of compounds 
targeting this protein, or once activators are found, characterising the ligand 
binding modes. 
 
The project has generated data on the assessment of several potential drug targets. 
Complete early-stage chemical validation was not achieved. Nevertheless, only Ddl 
could be suggested as a target in B. pseudomallei taking into account the need for new 
inhibitors.  
 
Different therapies are being developed and improved to combat (multi)drug resistant 
bacteria. These include the use of conventional antibiotics, phage therapy (for which 
several clinical trials are being held for E. coli, P. aeruginosa and multidrug resistance 
S. aureus infections, Kingwell, 2015) and RNA interference (Dyawanapelly et al., 
2014). Despite the technology and the information available for the development of 
antibacterial drugs, the rate of success in drug discovery remains low and the process 
should be improved. On one hand, the report of negative results from protein 
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characterisation, target assessment and inhibitors follow up projects, as performed in 
this thesis, could be key for improving the rate of success by designing more 
appropriate strategies to validate targets. On the other hand, it has been shown that 
antibiotics and neuroactive compounds have different chemical properties (O’Shea and 
Moser, 2007; Payne et al., 2007). Regarding this, and the low success rate of HTP 
(Payne et al., 2007; Gwynn et al., 2010; Chopra 2013; Tommasi et al., 2015), it seems 
libraries still need to be improved. In this context, the re-evaluation of current 
compound libraries to become more antibiotic-specific might help towards a more 
effective antibiotic search. Therefore, it is reasonable to think that bacteria type and 
niche will require compounds with distinct chemical properties. For example, the cell 
membrane and peptidoglycan layers are different between Gram-positive and Gram-
negative bacteria, the presence of external capsules, formation of biofilms, the location 
of the infection or if bacterial cell division occurs inside another cell-type (e.g. B. 
pseudomallei, F. tularensis and Y. pestis, see Part Two), are also indicative that drugs 
may require different chemical properties. Screening current libraries in a phenotypic 
manner against different bacteria types could identify compounds that could overcame 
barriers and those that do not. This could help to create a collection of chemical 
properties specific to each bacterial type/species. This information could then be used to 
generate new bacteria-specific libraries for either phenotypic or single-target screens. 
Additionally, the identification of biologically active chemical scaffolds could be used 
for structure-based drug design to improve compound permeability. Combinatorial 
therapies involving the use of several drugs should be further studied as this may 
decrease the probability of drug resistance development. Additionally, drugs already in 
the market could be combined with newly developed compounds (e.g. efflux pumps 
inhibitors) to re-purpose existing drugs. Finally, the search of potential essential genes 
and candidate selection could be accompanied by performing genome-scale transposon 
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knock-outs in the presence of antibiotics to identify genes involved in drug resistance or 
that are essential under drug stress conditions. 
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Appendix A 
Results from TraDIS and the target selection criteria analysis for the 75 considered 
candidates. 
 
Table A.1: Target selection criteria and traffic light score. Bacteria abbreviations are: 
Bacillus anthracis (Ba), Burkholderia pseudomallei (Bp), Bombyx mori (Bm), Bos 
taurus (Bt), Escherichia coli (Ec), Helicobacter pylori (Hp), Homo sapiens (Hs), 
Microcuccus luteus (Ml), Mycobacterium tuberculosis (Mt), Neisseria gonorrhoeae 
(Ng), Pseudomonas aeruginosa (Pa), Plasmodium falciparum (Pf), Rattus norveqieus 
(Rn), Saccharomyces cerevisiae (Sc), Salmonella enterica (Se), Streptococcus 
pneumoniae (Sp), and Yersinia pestis (Yp). E indicates the gene is essential for cell 
growth/viability, P probable essential and N non-essential. When a human homologue 
was present, the percentage of sequence identity was included in the table. In the 
ChEMBL column the first values corresponds to the number of ChEMBL homologues 
and the second the number of ChEMBL targets. The Size column indicates the number 
of amino acids (AA) for the P. aeruginosa protein. Targets selected for further study are 
marked in blue. XtalPred score ranges from 1 (optimal crystallisation) to 5 (challenging 
crystallisation). See Part Two for traffic light score definitions. 
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APPENDIX B 
Structural comparisons of KynB monomers and dimers. 
 
Table B.1: Results of the Cα overlay between BaKyB and BcKynB subunits. The 
number of atoms used are: 206 for BaKynB (subunits A and B), 207 for BaKynB 
(subunit C and D), and 207 for BcKynB subunits. 
 
BaKynB BcKynB 
A B C D A B C D 
BaKynB 
A - 0.387 0.130 0.370 1.172 1.195 1.223 1.217 
B   - 0.348 0.100 1.195 1.252 1.222 1.278 
C    - 0.343 1.206 1.234 1.193 1.258 
D       - 1.165 1.221 1.258 1.246 
BcKynB 
A         - 0.269 0.178 0.301 
B        - 0.210 0.129 
C         - 0.255 
D               - 
 
 
Table B.2: Results of the Cα overlay between PaKynB, BaKyB and BcKynB subunits. 
The number of atoms used are: 206 for PaKynB (BaKynB and BcKynB as indicated in 
Table B.1). 
	 	
PaKynB 
	 	
A B 
BaKynB 
A 1.183 1.178 
B 1.212 1.172 
C 1.203 1.210 
D 1.153 1.167 
BcKynB 
A 0.694 0.622 
B 0.704 0.630 
C 0.684 0.605 
D 0.739 0.664 
PaKynB 
A - 0.324 
B   - 
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Table B.3: Results of the Cα overlay between PaKynB, BaKyB and BcKynB dimers. 
The number of atoms used are indicated in Tables B.1-2. 
 
 
BaKynB BcKynB PaKynB 
A/B C/D A/B C/D A/B 
BaKynB 
A/B - 0.156 1.255 1.217 1.195 
C/D   - 1.254 1.226 1.204 
BcKynB 
A/B     - 0.160 0.698 
C/D       - 0.714 
PaKynB A/B         - 
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APPENDIX C 
Resume of the work carried out with other potential targets; FabZ, FtsZ, MsbA, RsmH, 
PyrG and NorM. 
 
C.1 Introduction 
Additional targets were also included in the program. Only limited amount of work was 
carried out on them due to difficulties of expression, purification or crystallisation, and 
also the prioritisation of other proteins. 
 
C.1.1 FabZ 
Fatty acids are essential for membrane formation and its biophysical properties, which 
vary depending on the amount of saturated and unsaturated compounds. The fatty acid 
biosynthetic pathway type I (FASI) is present in mammals and it is carried out by one 
gene encoding for a multifunctional polypeptide. In bacteria, plants and parasites, the 
fatty acid synthesis type II (FASII) independent genes encode for mono-functional 
proteins (White et al., 2005). Due to these differences, proteins involved in the FASII 
have been proposed as selective potential antibacterial drug targets and inhibitors have 
been characterised for various FASII enzymes (Hiltunen et al., 2008; Yao and Rock, 
2015). FabZ is the 3-(R)-hydroxyacyl-[Acyl-Carrier-Protein] dehydratase from the 
FASII. It catalyses the dehydration of 3(R)-hydroxyacyl-ACP to trans-2-enoyl-ACP 
(Heath and Rock, 1996; White et al., 2005). The quaternary structure of FabZ is a trimer 
of dimers and inhibitors have been described for H. pylori, Plasmodium falciparum and 
P. aeruginosa (Tasdemir et al., 2006; Moynié et al., 2013). 
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C.1.2 FtsZ 
The tubulin homologue FtsZ is essential for cell division in bacteria (Errington et al., 
2003). It presents a similar secondary structure to tubulin and GTPase activity occurs at 
the N-terminal region. FtsZ, as well as tubulin, forms protofilaments with the GTP 
bound protein form. Differences are noted between these proteins; while tubulin has two 
distinct subunits (α and β) that associate longitudinally to form the filaments, there is 
only one FtsZ subunit that uses lateral association. This together with a sequence 
identity of only 20%, indicate selectivity towards the bacterial protein may be feasible 
(Ma and Ma, 2012). The FtsZ filament forms the Z-ring, an essential structure for 
cytokinesis in bacteria, at the equatorial plane of the cell that serves for the recruitment 
of at least 12 cell-division proteins to form what is termed the divisome. The GTPase 
activity of FtsZ is formed at the interface of two adjacent subunits and the monomers 
dissociate from the filaments by GTP hydrolysis to GDP (Oliva and Löwe, 2007; Ma 
and Ma, 2012). Good inhibitors have been characterised for FtsZ but none of them are 
optimised for clinical use (Ma and Ma, 2012; Blaauwen et al., 2014).  
 
C.1.3 MsbA 
Lipopolysaccharides are constituted of an O-polysaccharide and the lipid A core. The 
dimeric membrane protein MsbA is the lipid A export ATP-binding permease and 
belongs to the ABC transporter family. It mediates the translocation (or flipping) of 
lipid A-core from the cytoplasmic side of the inner membrane to the periplasmic space 
(Ghanei et al., 2007). MsbA lipid translocation is ATP-hydrolysis dependent, and the 
mechanism is still unclear (Kaul and Pattan, 2011). P. aeruginosa MsbA has been 
subject of study in the Hunter lab before and it was included in this work to gain 
experience in expression, purification and crystallisation of membrane proteins and to 
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assess its incorporation as a target for the biowarfare bacteria of interest. 
 
C.1.4 RsmH 
RsmH is the AdoMet-dependent 5-methyluridine methyltransferase. It catalyses the N4-
methylation of the ribosomal RNA (rRNA) Cys1402. Post-translational modifications 
of rRNA play important roles in protein synthesis quality control (Wei et al., 2012) but 
it is still unclear if it is essential or not (Kyuma et al., 2015). Preliminary data from Dstl 
(see Part Two) suggested RsmH is essential for the bacteria of interest. Additionally, 
inhibitors targeting RsmH have not been developed so it was included for 
characterisation of new antibacterial drug targets in Y. pestis, B. pseudomallei and B. 
anthracis. 
 
C.1.5 PyrG 
CTP synthase, also called PyrG, is the last enzyme involved in de novo CTP 
biosynthesis. Some bacteria and parasites present only one route for de novo CTP 
synthesis while in mammals there exists an additional salvage pathway (Huang and 
Graves, 2002). PyrG is an ammonia-dependent aminotransferase containing two 
differentiated domains. The N-terminal domain comprises the CTP synthase function 
and the C-terminal the glutaminase activity (Lunn and Bearne, 2004; Goto et al., 2004). 
The glutaminase domain hydrolyses L-glutamine to generate ammonia. This is 
transferred through a tunnel connecting both active sites to the N-terminal domain and 
the ammonia is transferred to the phosphorylated-UTP (Endrizzi et al., 2005). The 
reaction can also occur in the absence of L-glutamine but in the presence of free 
ammonia. PyrG activity is highly regulated. On one hand, ATP and CTP are allosteric 
activators of the CTP synthase activity while GTP induces the binding of L-glutamate. 
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On the other hand, GTP also inhibits PyrG when its concentration is greater than 0.15 
mM in E. coli. Additionally, product inhibition by CTP is also observed (Lunn and 
Bearne, 2004). PyrG can be present as monomer, dimer and tetramer depending on the 
protein concentration (Goto et al., 2004). Dimers and tetramers can also form fibrilar 
structures, called micro-cytoophidia, which can associate and generate macro-
cytoophidia structures (Liu, 2011). These macrostructures exist as a way of regulating 
PyrG activity as they are disassembled under high CTP demand situations (Noree et al., 
2014). The active form of PyrG is a tetramer and is formed when ATP and UTP bind to 
a dimer. Inhibitors of PyrG have been described for various species (Hofer et al., 2001; 
Endrizzi et al., 2005; Yoshida et al., 2012; Mori et al., 2015). 
 
C.1.6 NorM 
The last selected target is the membrane transporter NorM or PmpM. It is a multidrug 
resistance protein similar to MATE (multidrug and toxic compounds extrusion) efflux 
pump family (Su et al., 2008). Efflux pumps are known to be involved in drug 
resistance for various bacteria including B. pseudomallei (Schweizer, 2003; Biot et al., 
2011). This protein has been selected as a new strategy for a potential drug target for B. 
pseudomallei (BpNorM). BpNorM might be essential under the chemical stress 
conditions caused by drugs, so its inhibition might play an important role to avoid drug 
resistance. 
 
C.2 Experimental procedures 
Experimental details are shown in Table C.1.  
Genes encoding for the proteins in Table C.1 were cloned into a pET15bTEV vector 
using the restriction enzymes NdeI (at the 3’ DNA end) and BamHI (5’ end), and 
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sequenced to check gene integrity. Expression and purification protocols were similar to 
those detailed previously; 1) First Ni-NTA column, 2) His6-tag cleavage and 3) second 
Ni-NTA column. Cell lysis buffers and buffers A for Ni-NTA columns are detailed in 
Table C.1, and buffer B consisted of buffer A plus 0.8 M imidazole (0.3 M imidazole in 
the case of MsbA). To cleave His6-tags, 1 mg of TEV protease was added per 10 mg of 
protein and incubated at 4ºC O/N. Protein concentration was determined using the 
predicted molar extinction coefficient (ε, PROTPARAM, Gasteiger et al., 2003) and the 
Lambert-Beer equation. 
 
PaMsbA expression and purification protocols had been optimised previously by Dr. A. 
Dawson. Cell cultures were firstly centrifuged at 4,000 g for 40 minutes. Then pellets 
were resuspended in the lysis buffer. Cell lysis was carried out using the French Press, 
insoluble debris removed by centrifugation at 12,000 g, and then membrane isolation 
was obtained after centrifugation for 1 hour at 208,000 g. The pellet was then 
solubilised in buffer A, containing 0.02% n-dodecyl β-D-maltoside (DDM) detergent, 
and purification was pursued as indicated above.  
 
Fragile crystals were obtained for YpPyrG from condition D1 from The Classics Suite. 
Optimisation plates were prepared using different protein concentrations, temperature 
(4ºC, 20ºC and room temperature), including different concentrations of cryo-
protectants in the drops (ethylene glycol, PEG 400, glycerol and MPD), and different 
precipitants (tri-sodium citrate, tri-potassium citrate and ammonium sulfate) were also 
tested based on the commercial screening results. Severe aggregation or no crystals 
were observed in all cases. Hanging and sitting drop plates, as well as microbatch 
silicon oil plates were used. While mounting crystals, different cryo-protectants were 
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tested, including ethylene glycol, glucose, MPD, PEG 400 and glycerol but crystals 
dissolved or cracked. To minimize crystal manipulation, counter diffusion using 0.1 mm 
capillaries was carried out. Optimisation of a different condition (H11 from the PEGs 
Suite) was started and less fragile crystals obtained, however they were too small to be 
tested. Renata Reis, a visiting PhD student from the University of Sao Paulo, is carrying 
out further optimisation for the H11 condition. Improvements in the crystal size and 
diffraction to 9 Å has been obtained so far and further optimisation of this condition will 
follow. Ligands were also included for co-crystallisation. Different combinations of 10 
mM ATP, UTP, CTP and L-glutamine were tested. DSF was used to check protein 
stability of YpPyrG with and without His6-tag after a freeze-thaw process, and fresh 
YpPyrG (without His6-tag). DSF was carried out with 5 µM of protein in each well, in 
triplicate. SYPRO orange was added to the samples in buffer A. The temperature range 
tested goes from 25ºC to 94º, and data were analysed using the Boltzmann sigmoidal 
equation with GrapPad PRISM (www.graphpad.com) to determine the Tm values. 
Samples were also checked using SDS-PAGE. A DDU fragment library screening was 
carried out with YpPyrG enzyme. 
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C.3 Results 
Results are summarised in Table C.2. 
Protein Organism 
Expression, 
protein yield 
(mg L-1) 
Crystallisation Quaternary structure  
Fragment 
screening 
FabZ Ba Not soluble, possibly toxic - - - 
FtsZ 
Yp Aggregation - - - 
Bp Aggregation - - - 
Ba Aggregation - - - 
MsbA Pa 3 Poor diffracting crystals Dimer - 
RsmH 
Yp 10 No crystals - - 
Bp Aggregation - - - 
Ba Not soluble - - - 
PyrG Yp 30 Fragile crystals Dimer 32 hits Ba 5 Small needles Dimer - 
NorM Bp C43(DE3) - - - 
 
 
 
 
 
In the case of YpPyrG, variable crystal forms were observed depending on protein 
concentration. This may be due to the quaternary structure state in the protein solution 
as it has been described that formation of dimers and tetramers is concentration-
dependent (Goto et al., 2004). Crystals either too fragile or small (less than 10 µm) were 
obtained. During crystal optimisation, it was noticed that crystals grew solely from fresh 
protein. The SDS-PAGE for frozen-thawed protein (f-YpPyrG) and fresh samples 
(YpPyrG) did not show degradation or differences. Additionally, DSF results indicated 
the same stability with Tm of 66.5ºC (f-YpPyrG) and 64.3ºC (YpPyrG). These results 
suggested that the freezing process interferes in the crystallisation process by a 
mechanism that is not understood. In the case of BaPyrG, optimisation was carried out 
for different conditions but no improvement was made. No further optimisation was 
attempted. From the YpPyrG fragment screen, 32 potential hits were found but further 
validation has not being carried out. Hits are shown in Table C.3. 
Table C.2: Results resume from work carried out on FabZ, FtsZ, MsbA, RsmH, PyrG 
and NorM from B. anthracis (Ba), Y. pestis (Yp), B. pseudomallei (Bp) and P. 
aeruginosa (Pa). (-) Not carried out. 
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Structures of bacterial kynurenine formamidase reveal a crowded binuclear
zinc catalytic site primed to generate a potent nucleophile
Laura DI´AZ-SA´EZ*, Velupillai SRIKANNATHASAN*, Martin ZOLTNER* and William N. HUNTER*1
*Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, U.K.
Tryptophan is an important precursor for chemical entities that
ultimately support the biosynthesis of key metabolites. The
second stage of tryptophan catabolism is catalysed by kynurenine
formamidase, an enzyme that is different between eukaryotes and
prokaryotes. In the present study, we characterize the catalytic
properties and present the crystal structures of three bacterial
kynurenine formamidases. The structures reveal a new amidase
protein fold, a highly organized and distinctive binuclear Zn2 +
catalytic centre in a confined, hydrophobic and relatively rigid
active site. The structure of a complex with 2-aminoacetophenone
delineates aspects of molecular recognition extending to the
observation that the substrate itself may be conformationally
restricted to assist binding in the confined space of the active site
and for subsequent processing. The cations occupy a crowded
environment, and, unlike most Zn2 + -dependent enzymes, there is
little scope to increase co-ordination number during catalysis. We
propose that the presence of a bridging water/hydroxide ligand in
conjunction with the placement of an active site histidine supports
a distinctive amidation mechanism.
Key words: amidase, binuclear metal site, kynurenine
formamidase, tryptophan catabolism, X-ray crystallography, zinc
enzyme.
INTRODUCTION
Tryptophan catabolism via the kynurenine pathway supports
the biosynthesis of NAD+ , important neuroactive intermediates
in eukaryotes, then anthranilate, quinolate and antibiotics in
prokaryotes [1–4]. The proteins involved in tryptophan catabolism
are in general highly conserved across species, but with the notable
exception of the second enzyme in the pathway: kynurenine
formamidase. This enzyme catalyses the conversion of N-formyl-
L-kynurenine (NFK) into formate and L-kynurenine [2].
In eukaryotes, the enzyme is termed kynurenine formamidase
(KFase) and displays relatively low sequence conservation,
although the structure itself is well maintained. This is evident
from studies with Sacharyomyces cerevisiae and Drosophila
melanogaster KFase, which, although they only share 10%
sequence identity, are structurally conserved α/α hydrolases [5,6].
The KFase fold is dominated by a core eight-stranded α-sheet
decorated on either side with a number of α-helices. This creates
a well-defined cavity at one end of the sheet, leading to a catalytic
triad consisting of a serine, histidine and aspartate combination.
Overall, there are close structural similarities between KFase
and carboxylesterases, but also intriguingly to another enzyme
involved in kynurenine biology, namely a 5′-pyridoxyl phosphate-
dependent kynurenine aminotransferase [5,6].
The chemistry behind an amidation reaction involves either
acidic or basic hydrolysis. It is the latter that applies to these
metal-free amidases, which exploit the properties of reactive
cysteine or serine residues to create covalent acyl-intermediates
during catalysis. Cysteine-dependent amidases are exemplified by
trypanothione synthetase amidase [7], nicotinamidase [8] and the
nitrilases [9], whereas the eukaryotic KFases from S. cerevisiae
and D. melanogaster present examples of the serine-dependent
enzymes with a mechanism that correlates with known amidases
[5,6]. In KFase, an ordered mechanism results when the catalytic
triad positions histidine to activate serine into a nucleophile that
attacks the substrate carbonyl carbon. Subsequent engagement of
a water molecule then allows for completion of the reaction.
Our attention was drawn to the prokaryotic KFase KynB (EC
3.5.1.9). Analysis of KynB sequences indicated that they are
unrelated to KFase and indeed do not match any known amidase or
amidohydrolase. Clearly, KynB is different and so, intrigued, we
sought to investigate the structure–activity relationships in this
distinctive enzyme. We now report the preparation of efficient
recombinant expression systems for KynB from three bacterial
sources and their purification. The catalytic properties of the
enzymes are characterized and tryptophan fluorescence is used
to investigate ligand binding. High-resolution crystal structures
have been determined that allow us to describe the architecture
of the enzyme extending to the details of the active site, to
address metal ion identification and to investigate key features of
molecular recognition at the catalytic centre. Taken together, our
structural data then allow us to propose a plausible and distinctive
mechanism for KynB.
EXPERIMENTAL PROCEDURES
Expression plasmid preparation
Genes encoding KynB in Pseudomonas aeruginosa (PaKynB,
UniProt: Q9I234), Burkholderia cenocepacia (BcKynB, UniProt:
B4E9I9) and Bacillus anthracis (BaKynB, UniProt: Q81PP9)
were purchased (Genscript) having been codon optimized for
expression in Escherichia coli K12. PaKynB and BcKynB
encoding genes were cloned into the NdeI/XhoI and BaKynB into
the NdeI/BamHI site of a modified pET15b vector (Novagen)
Abbreviations: ACMSD, α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase; BaKynB, Bacillus anthracis KynB; BcKynB Burkholderia
cenocepacia KynB; CV, column volume; PaKynB, Pseudomonas aeruginosa KynB; KFase, kynurenine formamidase; NCS, non-crystallographic symmetry;
NFK, N-formyl-L-kynurenine; SEC, size-exclusion chromatography; TEV, tobacco etch virus; XANES, X-ray absorption near-edge structure.
1 To whom correspondence should be addressed (email w.n.hunter@dundee.ac.uk).
Atomic co-ordinates and structure factors have been deposited in the PDB under codes 4COG, 4COB, 4CO9 and 4CZ1.
c© The Authors Journal compilation c© 2014 Biochemical Society
B
io
ch
em
ic
al
 J
ou
rn
al
   
 w
w
w
.b
io
ch
em
j.o
rg
© 2014 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
582 L. Dı´az-Sa´ez and others
to create plasmids that produce an N-terminal hexahistidine-
tagged (His-tagged) protein and a tobacco etch virus (TEV)
protease cleavage site. All constructs were sequenced to check
their integrity.
Expression and protein purification
Gene expression and purification of the proteins started with
freshly transformed E. coli BL21(DE3)pLysS in the case of
PaKynB and BcKynB systems, and E. coli BL21(DE3) for
BaKynB. Bacteria were cultured at 37 ◦C in 10 ml of LB
broth containing 50 μg· ml− 1 carbenicillin and, for PaKynB and
BcKynB cultures, 20 μg· ml− 1 chloramphenicol was also present.
These cultures were used as inoculum for 1 litre of LB/antibiotic
mixtures. The bacteria were cultured at 37 ◦C until an attenuance
of 0.6–0.8 at λ= 600 nm was achieved. The temperature was
lowered to 16 ◦C in the case of PaKynB and BcKynB, and to
20 ◦C for BaKynB. Gene expression was induced with 1 mM
IPTG and cultures were incubated overnight. Cells were then
harvested by centrifugation (4000 g at 4 ◦C for 10 min). The
PaKynB and BcKynB cultures were resuspended in buffer A1
(25 mM Tris/HCl, pH 7.5, and 100 mM NaCl), and BaKynB in
buffer A2 (20 mM Tris/HCl, pH 7.4, and 200 mM NaCl) with
the addition of complete EDTA-free protease inhibitor cocktail
tablets from Roche. The cells were disrupted using a sonicator in
the case of PaKynB and BcKynB, and a French press for BaKynB,
and homogenates were centrifuged at 40000 g for 30 min at 4 ◦C.
The resulting supernatants were passed through a 0.45 μm filter,
and samples containing PaKynB and BcKynB were adjusted to
contain 5 mM imidazole. Proteins were loaded on a 5-ml HisTrap
HP column (GE Healthcare). After a 10-column volume (CV)
washing step using 90% buffers A1 or A2 and 10% of buffer B1
(25 mM Tris/HCl, pH 7.5, 100 mM NaCl and 0.5 M imidazole)
for PaKynB and BcKynB, or buffer B2 (20 mM Tris–HCl pH 7.4,
200 mM NaCl, 0.8 M imidazole) for BaKynB, the recombinant
proteins were eluted applying a linear imidazole gradient (50–
250 mM for PaKynB and BcKynB, and 80–400 mM for BaKynB
over 20 CV). The eluted proteins were dialysed into buffer A1
or A2 and incubated overnight with 1 mg of His-tagged TEV
protease per 20 mg of protein at 4 ◦C, then applied to a HisTrap
HP column equilibrated with buffer A1 or A2 to remove the
TEV protease, cleaved peptide and non-cleaved material. Initial
experiments indicated that the His-tag of PaKynB was not cleaved
efficiently by TEV protease, and protein aggregation/precipitation
was pronounced. We left the His-tag in place for further
experiments with that protein. The enzyme assay (see later)
indicated that the His-tagged PaKynB possessed a level of activity
comparable with that of other samples. Fractions containing
the proteins were collected, concentrated and applied to a size-
exclusion chromatography (SEC) column (HR 16/60, Superdex75
prep grade, GE Healthcare, CV = 120 ml) equilibrated with
buffer C (10 mM NaH2PO4/Na2HPO4, pH 7.8, 20 mM NaCl and
0.5 mM Tris/HCl) in the case of PaKynB and BcKynB, and buffer
A1 for BaKynB. The SEC columns had been calibrated with
molecular mass standards (thyroglobulin, 670 kDa; γ -globulin,
158 kDa; serum albumin, 67 kDa; ovalbumin, 44 kDa; myoglobin,
17 kDa; vitamin B12, 1 kDa). Protein purity and molecular
weight were assessed by SDS/PAGE and MALDI–TOF-MS
analyses performed at the University of Dundee ‘Fingerprints’
Proteomics Facility using an Applied Biosystems Voyager DE-
STR spectrometer. Protein quaternary structure was investigated
by native PAGE and SEC.
Protein concentration determination
Protein concentrations were measured by absorbance at 280 nm
using the predicted molar absorption coefficients by ExPASy
bioinformatics resource portal ProtParam [10]:
ε(PaKynB) = 28 210 M−1 · cm−1
ε(BcKynB) = 28 210 M−1 · cm−1
ε(BaKynB) = 20 970 M−1 · cm−1
Enzymatic assay and determination of catalytic parameters
A spectrophotometric assay was developed to obtain Km, Vmax
and kcat values for KynB. The assay is based on the increase
in absorbance due to L-kynurenine formation [11,12] which is
detected by measuring the absorbance at 365 nm with a UV-
2450 Shimadzu spectrophotometer over a period of 160 s. The
reactions were performed in triplicate using 1 ml final volume,
at 25 ◦C, using 0.025, 0.15, 0.25, 0.5, 0.7, 1, 1.5, 2 and 3 mM
NFK substrate (Dalton Pharma Services), and 500 ng of enzyme
(20 nM). The buffer used contained 0.1 M NaH2PO4/Na2HPO4,
pH 7.4, and 20 μM ZnCl2. Calculations of the initial velocity
for each substrate concentration were made by fitting a linear
equation to the data of the increase in L-kynurenine concentration
during 1 min, and data were analysed using the Michaelis–
Menten equation (SigmaPlot, Systat Software). L-Kynurenine
concentration was calculated using the Beer–Lambert law and
ε365 of 4220 M− 1 · cm− 1 [12].
Crystallization, diffraction and structure determinations
PaKynB and BcKynB were concentrated to 7.5 mg · ml− 1 in buffer
A1 and BaKynB to 4 mg· ml− 1 in buffer A2 to provide a stock
solution for crystallization experiments. The first crystallization
trials used commercial screening sets from Molecular Dimensions
and Qiagen and were set up in 96-well sitting drop plates with a
Phoenix liquid handling system (Rigaku-MSC) using a ratio of
1:1 for protein/reservoir and final volumes of 0.2 and 0.4 μl for
every condition. Plates were incubated at room temperature in
a Gallery DT plate hotel (Rigaku-MSC). PaKynB crystallization
occurred using the reservoir condition 0.1 M Hepes, pH 7.5, 20%
(w/v) PEG 4000 and 10% (v/v) propan-2-ol. Crystals grew to a
maximum dimension of approximately 0.25 mm, over 5 days. The
BcKynB crystal was obtained using a reservoir comprising 10–
16% (w/v) PEG 3350, 5 mM CoCl2, 5 mM CdCl2, 5 mM MgCl2
and 5 mM NiCl2. Before data collection, the crystals were soaked
for a few seconds in the reservoir liquid with added 25% (v/v)
glycerol and then flash frozen in liquid nitrogen. Diffraction data
for PaKynB and BcKynB were collected using the Diamond Light
Source beamline IO3 using a Pilatus 6M-F detector, indexed and
integrated using XDS [13], scaled and analysed with SCALA and
POINTLESS [14] from the CCP4 suite [15].
The initial crystallization conditions for BaKynB gave only
small mechanically twinned samples and optimization was carried
out in 24-well hanging drop plates using a ratio of 1:1 in final
volumes of 2 and 4 μl at 20 ◦C. BaKynB was incubated with
8 mM L-kynurenine for 10 min at room temperature, and a
structure was obtained from a crystal grown in a drop equilibrating
with a reservoir containing 100 mM Tris/HCl, pH 8.5, 150 mM
MgCl2, 30% (w/v) PEG 4000 and 1.5% (v/v) dioxane. The
presence of dioxane was crucial to improve the morphology
such that single-crystal blocks could be obtained. Crystals of
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BaKynB were flash frozen directly from the drops in which
they grew. Diffraction data were obtained using the in-house
X-ray facility (Rigaku M007HF X-ray generator with a Saturn
944HG + CCD detector). Data were indexed and integrated
using iMOSFLM [16] and scaled and analysed by AIMLESS
from the CCP4 suite [15]. To obtain crystals of the BaKynB–
2-aminoacetophenone complex, protein was incubated with 5%
(v/v) 2-aminoacetophenone before the crystallization plate was set
up. The ligand was previously dissolved to a final concentration
of 20% (v/v) into buffer A2 containing 20% (w/v) PEG 4000.
The reservoir contained 140 mM MgCl2, 30% (w/v) PEG 4000
and 100 mM Tris/HCl, pH 8.5. Diffraction data for the BaKynB–
2-aminoacetophene complex were obtained at the Diamond Light
Source using beamline IO3.
The structure of PaKynB was determined by molecular
replacement (MOLREP) [17] using a single polypeptide
(molecule A) for a putative metal-dependent hydrolase from
Geobacillus stearothermophilus (PDB code 1R61). All water
molecules and ions were removed from the model. The search
model, which shares 25% sequence identity with PaKynB,
is at 2.5 Å resolution, and although Zn2 + is assigned in the
possible active site, it is with low occupancy (0.5), with an
inflated thermal parameter (B-factor approximately 90 Å2) and
distances to potential co-ordinating groups that are more typical of
hydrogen-bonding interactions than metal ion ligand associations.
There is no information concerning why Zn2 + was assigned here,
and there are no publications on this structure. The BcKynB
structure was solved using a partially refined PaKynB as the
search model (64% sequence identity), and then the BaKynB
structure was solved using BcKynB (40% sequence identity)
as the search model. Similar protocols were applied in the
refinement of all structures. This involved first a rigid body
refinement as part of the molecular replacement calculations, then
iterative cycles of restrained refinement combining REFMAC5
[18] with electron and difference density map inspections, and
model manipulations in COOT [19]. The starting B-factors
for each model were derived from the Wilson B-factor. There
are multiple polypeptide chains in the asymmetric units (two
subunits for PaKynB and four subunits for BcKynB, BaKynB
and the BaKynB–2-aminoacetophenone complex), and tight non-
crystallographic symmetry (NCS) restraints were imposed at the
onset of refinement, which were gradually released during the
process. Although L-kynurenine was present in the crystallization
mixture used for BaKynB, there was no evidence for the enzyme
product in electron density maps. Even with a much greater
amount of 2-aminoacetophenone present, we only observed
ordered binding of ligand in one active site. Once the protein
models were complete, alternative side-chain conformers, water
molecules, metal ions and ligands were incorporated into the
models. A correction for a twinning component of 0.15, calculated
in REFMAC, was applied in refinement of the BaKynB–2-
aminoacetophenone complex. Refinements were terminated when
there were no significant changes in Rwork and Rfree values and
inspection of the difference density maps suggested that no further
corrections or additions were justified.
The presence of Zn2 + was first suggested by anomalous
difference Fourier maps (not shown) and subsequently
confirmed in the PaKynB and BaKynB crystals by X-ray
absorption near-edge structure (XANES) spectra measured at
Diamond Light Source on beamline IO3 using a Vortex
Silicon Drift detector and an excitation energy range
from 9626.7 to 9690.14 eV (Supplementary Figure S1 at
http://www.biochemj.org/bj/462/bj4620581add.htm). Since no
Zn2 + was added during protein production, purification or
crystallization, then it is most likely to be derived from the media
used to culture the E. coli.
The presence of Cd2 + and Zn2 + in the active site of BcKynB
was confirmed on the basis of the electron density and anomalous
scattering. Positive density in a difference Fourier map calculated
for the 12 sulfur atoms in the asymmetric unit gave 1.1 σ per
electron. The average B-factor for these 12 atoms is 16.4 Å2.
This was used for the determination of the number of electrons
present at the BcKynB metal ion sites. The difference Fourier
map revealed peaks with heights of 46.5 and 68.4 σ , respectively.
These height values and the difference between them are constant
within the four active sites in the asymmetric unit, and indicate the
presence of two different metal atoms per active site. Comparing
atomic numbers between the different metals present in the
crystallization condition, one Cd2 + and one Zn2 + were added
to these positions. The average B-factors refined to 11.4 and
10.1 Å2, respectively. A B-factor-adjusted calculation suggests
that one site is occupied by an ion consisting of approximately
28 e− and the other about 48 e− . Values of 28 and 46 e− would
be expected for Zn2 + and Cd2 + , respectively. An anomalous
dispersion difference Fourier calculation provided a further
check. At the wavelength used for diffraction measurements,
λ= 0.9795 Å, the theoretical f ′′ values for zinc and cadmium
are 2.480 and 2.132 e− [20]. In an anomalous difference
Fourier a slightly larger signal should therefore occur at the
Zn2 + . Indeed this is observed in all four active sites of the
asymmetric unit. The average heights of the peaks are 24.2 σ
at Zn2 + and 22.5 σ at Cd2 + (Supplementary Figure S2 at
http://www.biochemj.org/bj/462/bj4620581add.htm).
MolProbity [21] was used to assess geometry of all models.
Secondary-structure determination involved use of DSSP [22] and
visual inspection, and subunit interface surface area calculations
were carried out with PISA [23]. Figures were prepared using
ALINE [24] and PyMOL (http://www.pymol.org). The DALI
server [26] was used to search the PDB for structural homologues,
whereas superpositions were calculated using DALILITE [27].
Relevant crystallographic statistics and geometric details of the
refined models are reported in Table 1.
Fluorescence spectroscopy with BaKynB
Fluorescence measurements for BaKynB were performed
using a LS-55 PerkinElmer spectrometer to investigate ligand
association/disassociation. To determine the peak of maximum
emission due to tryptophan, the excitation wavelength used was
280 nm and the emission wavelength detection ranged from 300
to 400 nm. The sensitivity of the detector was fixed to 800 V, and
the peak of maximum emission was experimentally determined
at 337 nm.
The sample (2 ml) contained 20 μg of BaKynB (400 nM),
0.02 M Tris/HCl, pH 7.4, buffer and 0.2 M NaCl. The two
products of the KynB catalysed reaction, L-kynurenine and
formate, and 2-aminoacetophenone were investigated separately.
Concentrations ranged from 0 to 800 μM in the case of L-
kynurenine and 2-aminoacetophenone and from 0 to 500 μM
for formate. No fluorescence emission from either L-kynurenine
or 2-aminoacetophenone was observed under the experimental
conditions. In the presence of increasing concentrations of L-
kynurenine and 2-aminoacetophenone, a decrease and shift of
the maximum fluorescence intensity was observed. In the case of
formate, no variation in the fluorescence intensity was detected.
Data are represented as percentage of active site saturation
within the different compound concentrations (Supplementary
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Table 1 Crystallographic statistics
Structure PaKynB BcKynB BaKynB BaKynB–ligand
PDB code 4COB 4COG 4CO9 4CZ1
Space group P3121 P21 P21 P21
Wavelength (A˚) 0.9795 0.9795 1.5418 0.9791
Unit cell dimensions a, b, c (A˚) 112.7, 112.7, 90.76 76.86, 50.12, 35.2, β = 94.14◦ 73.17, 66.02, 83.76, β = 90.32◦ 73.69, 66.56, 84.06, β = 90.24◦
Resolution range* (A˚) 28.90–2.37 28.37–1.60 42.48–1.95 42.64–2.25
Number of reflections 133546 479924 202165 104599
Unique reflections 27365 134904 58336 38046
Completeness (%) 99.2 (94.5) 99.3 (99.8) 99.4 (94.1) 98.1 (97.7)
Rmerge† 0.057 (0.571) 0.068 (0.477) 0.063 (0.166) 0.164 (0.551)
Redundancy 4.9 3.6 3.5 2.7
<I/σ (I)> 16.8 (2.4) 12.8 (3) 11.1 (4.3) 4.8 (2.2)
Wilson B (A˚2) 43.87 14.97 11.84 15.33
Rwork‡/R free§ 0.1519/0.1945 0.1489/0.1842 0.1715/0.2066 0.1837/0.2241
Number of residues/waters/ligands and metals 412/181/6 831/1068/38 829/906/18 825/793/1/11
Diffraction precision indicator‖ (A˚) 0.198 0.068 0.137 0.086
Bond lengths (A˚)/angles¶ (◦) 0.018/1.890 0.025/2.429 0.008/1.322 0.017/1.684
Average B-factors (A˚2) 51.4 16.4 15.3 20.9
Protein atoms 3207 6533 6658 6521
Water molecules 181 1068 906 411
Metal ions 4 Zn2 + 4 Zn2 + , 4 Cd2 + , 8 Mg2 + 8 Zn2 + , 5 Mg2 + 8 Zn2 + , 3 Mg2 +
Ligands 12 Glycerol, 10 1,2-ethanediol,
1 PEG
2 Dioxane, 3 1,2-ethanediol 2-Aminoacetophenone
Ramachandran analyses
Favoured regions (%) 96.1 96.1 97.2 96.5
Allowed regions (%) 100 100 100 100
*Values in parentheses refer to the highest resolution shell.
†Rmerge =hkl i|Ii(hkl) − <I(hkl)>|/hkl i Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean value of Ii(hkl) for all i measurements.
‡Rwork =hkl‖F o| − |F c‖/|F o|, where F o is the observed structure factor and F c is the calculated structure factor.
§Rfree is the same as Rwork except calculated with a subset, 5 %, of data that are excluded from the refinement calculations.
‖Diffraction Precision Index [42].
¶[43].
Table 2 Catalytic parameters
V max, maximum catalytic velocity; K m, Michaelis-Menten constant; specific activity (SA), amount of active enzyme from the total protein quantity; k cat , number of substrate molecules that are
transformed per active site and per time unit. k cat/K m defines the catalytic efficiency.
Enzyme V max (nmol · min− 1) K m (mM) k cat (s− 1) k cat/K m (M− 1 · s− 1) × 104 SA (μM · min− 1 · mg− 1)
BaKynB 65.41 +− 2.64 0.40 +− 0.05 50.56 12.64 130.82
BcKynB 58.15 +− 0.98 0.57 +− 0.02 43.94 7.71 116.30
PaKynB-His 147.99 +− 8.42 0.98 +− 0.13 114.21 11.65 295.98
Figures S3 and S4 at http://www.biochemj.org/bj/462/
bj4620581add.htm), and disassociation constants were determ-
ined.
RESULTS AND DISCUSSION
Enzyme purification and quaternary structure
Highly efficient recombinant protein expression systems for the
enzymes from B. anthracis (BaKynB), B. cenocepacia (BcKynB)
and P. aeruginosa (PaKynB) were prepared. The total protein
yields, after purification, from the bacterial cultures were about
10 mg· l− 1 for PaKynB and BcKynB, and 50 mg· l− 1 for BaKynB.
The theoretical polypeptide mass of KynB is about 23 kDa. During
the final chromatography step of purification, i.e. SEC, all three
proteins were eluted as a single species with approximate mass of
40 kDa and native gels also identified that a single dimeric species
was observed in each case.
Enzyme assays
The kinetic properties of the enzymes were determined using a
spectrophotometric assay and are reported in Table 2. The assays
confirmed that active bone fide KFases had been purified; for
example, in the case of BaKynB, approximate values for Km
0.4 μM, Vmax 65 nmol· min− 1, kcat 50 s− 1 and specific activity
130 μM min− 1· mg− 1 were derived. No substrate inhibition was
observed under the assay conditions and NFK concentrations
that were used. In the case of PaKynB, assays were carried
out using protein still carrying the His-tag due to aggregation
problems when removal of the tag was attempted. The kinetic
parameters for PaKynB, BaKynB and BcKynB are similar to
each other. Comparisons of kinetic properties of enzymes is
often complicated by the use of different assay conditions and
this applies to studies with KynB from Streptomyces parvulus
[11] and Ralstonia metallidurans [1] which were conducted at
30 ◦C and 37 ◦C, respectively. In these cases, the activities are
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Figure 1 Sequence alignments and assignment of secondary structure for BaKynB
Protein sequence alignment from BaKynB, PaKynB and BcKynB. Blue arrows (β-sheets) and red cylinders (α-helixes) indicate the secondary structure of BaKynB. Triangles mark the metal-binding
amino acids. Circles mark amino acids in the active site. The star marks a key amino acid for the reaction, His60. The diamond marks the tryptophan located at the active site pocket.
lower than we report with reduced specific activities of about
27 and 4 units· mg− 1 noted. A more similar room-temperature
assay was reported for KynB from Bacillus cereus [12] and this
gave a specific activity of 68.5 μM min− 1· mg− 1 with kcat/Km
of 18.3 × 104 M− 1· s− 1, values comparable with those from our
observations.
Comments on crystallographic analyses and metal ion
identification
The crystal structures of all three enzymes were determined
(Table 1). The first analysis, PaKynB at about 2.4 Å resolution
identified two cations in the active site, tentatively assigned as
a binuclear Zn2 + site. A more accurate model was sought, and
the structure of BcKynB was determined at 1.6 Å resolution.
However, these highly ordered crystals could only by obtained
in the presence of different transition metal cations including
Co2 + , Ni2 + and Cd2 + . In addition, glycerol, the optimized cryo-
protectant, was bound to the metal ions, blocking the active site,
so preventing ligand studies. A structure was required without
Cd2 + being present, or indeed any transition metal ions other than
Zn2 + and for which we could obtain data to inform on substrate
recognition. Highly ordered structures of BaKynB and a complex
with 2-aminoacetophenone at resolutions of 1.9 and 2.3 Å resulted
and confirmed the binuclear Zn2 + environment. XANES scans
confirmed the presence of Zn2 + in crystals of PaKynB and in
BaKynB (Supplementary Figure S1).
The overall structure of KynB
The secondary and subunit structure of KynB, NCS of the dimer
and detailed architecture of the active site are all highly conserved
for the three enzymes. The average NCS values for overlay of
Cα atoms range from 0.22 Å, for BcKynB, to 0.32 Å for both
BaKynB and PaKynB. The Gram-negative KynB structures are
more similar to each other (rmsd overlay of Cα atoms is 0.70 Å)
than to the Gram-positive BaKynB (rmsd 1.25 Å in each case).
This maps to sequence identities of about 64% for the enzymes
from the Gram-negative organisms to 40% when compared with
Gram-positive KynB (Figure 1). The structures are, however, so
similar, particularly the detail in the active site which is highly
conserved (see below), that we primarily detail BaKynB mainly
because for that example we also have data that inform on the
molecular recognition of ligands in the active site.
The KynB subunit, approximate mass 23 kDa, comprises just
over 200 residues with about 50% in 12 β-strands and 15%
in four α-helices (Figures 1 and 2). Three short segments of
310-helix occur between β4 and β5. The molecule gives the
appearance of a distorted eight-stranded β-barrel by treating β1
and β4 as a single strand. Three α-helices cluster on one side
of the β-barrel, and on the other side is the dimer interface.
The fold is not common and a search of the PDB reveals a
significant similarity to only three other proteins for which there
are little or no published biochemical data. These orthologues
are a putative metal-dependent hydrolase/cyclase (PDB codes
3KRV and 1R61, Z-scores 27, 26, sequence identity 25%), isatin
hydrolase carrying a single Mn2 + (PDB code 4J0N, Z-score 23,
sequence identity 23%) and a hypothetical protein with no metal
ion present (PDB code 2B0A, Z-score 20, sequence identity
23%).
The KynB dimer (Figure 2) displays comparatively high values,
between 22% and 27%, for the accessible surface area of
subunits that interact with the partner. This is consistent with
the observation of only dimeric species in SEC and native gels.
The dimer is stabilized by hydrophobic interactions primarily
involving side chains from strands β1, β11 and β12, together
with a contribution from short helical segments between residues
68 and 74. The formation of an antiparallel four-stranded β-sheet
involving β2–β3 from each subunit is a pronounced feature of the
dimer. The N-terminal segment of β3 contributes to formation of
the active site, which is mainly created by the partner subunit. In
the dimer, the two catalytic sites are separated by about 30 Å.
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Figure 2 Ribbon diagram of the BaKynB and location of the active site,
orthogonal views
Zn2 + ions are shown as grey spheres. For one subunit, the terminal positions of the polypeptide
are labelled N and C, helices are labelled and β-strands numbered. (A) Top view, (B) side view.
The active site of KynB
The enzyme active site is a narrow cavity approximately
7 Å × 12 Å and 10 Å in depth, lined by hydrophobic walls
composed of Trp20, His60 and Leu158 from one subunit, and Val40
and Val42 from the partner (Figure 3). Four of these residues
are strictly conserved in BcKynB and PaKynB, whereas Leu158
corresponds to Met157 in BcKynB (Figure 1). At the base of the
cavity is a polar floor, where two Zn2 + ions, separated by a
distance of 3.1 Å, are bound. This separation is unusually close
for a binuclear site when compared with other systems [28].
The co-ordination environment at the binuclear Zn2 + site is
highly organized (Figure 3). One Zn2 + is co-ordinated by Asp56,
His161, Glu173 and a water molecule/hydroxide ion in a tetrahedral
fashion with distances less than 2.3 Å. The water/hydroxide
co-ordinates with the other cation and acts as a bridge for the
binuclear site. A water molecule and the other oxygen of the side
chain of Glu173 are about 2.5 Å from the cation, and together
with the adjacent metal ion crowd around this Zn2 + to provide a
distorted octahedral environment. In a similar fashion, the other
cation also has four ligands co-ordinating with distances less than
2.3 Å. These are His50, His54, Asp56 and the bridging water/
hydroxide. Then, another water and OE1 of Glu173 are 2.4 Å
distant from this Zn2 + . The water molecules that co-ordinate the
metal ions also interact by hydrogen-bond formation with the
enzyme. This involves interactions with the main chain carbonyl
of Pro148 and NE1 of Trp20 in one case and the side chain of
Ser149 in the other. The bridging water or hydroxide forms a
hydrogen bond with NE2 His60. Such interactions may help to
stabilize the active site configuration. In similar fashion, the three
co-ordinating histidine side chains are held in place by hydrogen
bonds that link Asp151, Asp198 with His161 and His50, respectively,
then His54 interacts with the carbonyl group of Gly52. All of these
residues and their contributions to the organization of the active
site are highly conserved in the three types of KynB structures
characterized (Figures 1 and 4).
There are 380 unique sequences annotated as a bacterial KFase
in UniProt [29]. The list is reduced to 336 entries when filtered
for those with 30% sequence identity with BaKynB using the
NCBI BLAST server [30]. The sequences were aligned (Clustal
Omega) [31,32] and the conservation of key active site residues
investigated. His54, Asp56 and His60 are strictly conserved in
all sequences, whereas His50, His161 and Glu173 are maintained
in 99.7% of the entries. Trp20, which contributes a significant
hydrophobic character to the substrate-binding site, is strictly
conserved in 81% of the entries. Conservative substitutions for
phenylalanine and tyrosine account for a further 17.8% of the
entries, confirming the importance of an aromatic group at this
position.
Tryptophan fluorescence
Having identified Trp20 in the active site, we used fluorescence
spectroscopy to investigate binding of L-kynurenine and
formate, the products of the formamidase reaction. We also
investigated 2-aminoacetophenone given chemical similarities
to part of L-kynurenine. This ligand provides the aromatic
component of substrate and product and primarily lacks
only the 2-amino-4-oxobutanoic acid moiety. Formate did
not elicit any spectroscopic change but L-kynurenine and 2-
aminoacetophenone gave comparable Kd values of approximately
60 and 50 μM, respectively (Supplementary Figures S3
and S4). A BaKynB–2-aminoacetophenone complex structure
then revealed aspects of molecular recognition in the
active site (Figure 3 and Supplementary Figure S5 at
http://www.biochemj.org/bj/462/bj4620581add.htm). As we will
show, this is consistent with the ligands binding in the vicinity of
the active site tryptophan with comparable affinity and suggests
that 2-aminoacetophenone represents a suitable molecule from
which we can derive information on aspects of substrate
recognition. Formic acid did not elicit any change in tryptophan
fluorescence, suggesting that this moiety of substrate and one
product of the KynB-catalysed reaction does not interact with the
active site tryptophan.
Recognition of a conformationally restricted substrate is implied
We were unable to obtain the structure of a complex of KynB
with the products of catalysis, formate or kynurenine. However,
the characterization of a BaKynB–2-aminoacetophenone complex
structure at 2.25 Å resolution provides a suitable template to
inform on aspects of molecular recognition in the active site
(Figure 3). Key to ligand, and by implication substrate, binding
is the interaction with Trp20. There are also van der Waals
associations with Val40 from the partner subunit. The 2-amino
group forms a hydrogen bond to the Zn2 + bridging water or
hydroxide. In this respect, the complex derived may closely mimic
the configuration at the completion of the catalytic reaction and
immediately prior to the replacement of product by the incoming
substrate for another round of catalysis. An intramolecular
hydrogen bond between the amine and carbonyl groups of 2-
aminoacetophenone appeared to be significant. A 3D search of the
Cambridge Structural Database [33] using 2-aminoacetophenone
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Figure 3 Active site of the BaKynB–2-aminoacetophenone complex
Zn2 + is a grey sphere, grey broken lines mark co-ordination to amino acid side chains and waters/hydroxide (red spheres). Amino acid atomic positions are coloured with C in grey or yellow
depending on subunit, N in blue, O in red, and 2-aminoacetophenone is shown with C in black, N in cyan and O in red. Blue broken lines represent potential hydrogen bonds and a single red broken
line indicates the intramolecular interaction in the ligand.
Figure 4 The active site of KynB is highly conserved
(A) Superimposition of BaKynB (violet), BcKynB (blue) and PaKynB (yellow) active site structures. (B) The BaKynB active site with difference density for the three water molecules (red spheres) in
the active site depicted as dark green chicken wire and contoured at 5σ . (C) The BcKynB active site with glycerol bound to the metal ions. (D) The PaKynB active site. Continuous lines represent
co-ordinating contacts to the Zn2 + ions (grey spheres).
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Figure 5 A proposed mechanism for the amidase KynB
(S)-2-Amino-4-(2-formamidophenyl)-4-oxobutanoic acid (N-formylkynurenine) is converted into (S)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid (kynurenine).
as the template identified 28 similar compounds with structures
determined at atomic resolution and all of which display the same
interaction. Therefore, such an intramolecular hydrogen bond
probably defines or constrains the substrate conformation, and
orients the scissile bond such that the formyl moiety would be
directed over between His60 and Ser149. These are two strictly
conserved residues in KynB sequences. The complex structure
suggests then that when substrate binds the oxygen of the formyl
substituent could displace a water that binds Zn2 + weakly and
perhaps also interact directly with Ser149. The orientation or
alignment is then fixed for nucleophilic attack to occur at carbon
as is described further below.
Mechanistic considerations and comparisons with
metallohydrolases
Although the enzyme fold is different, the binuclear Zn2 + catalytic
centre of KynB suggests some similarity to mononuclear and
binuclear metalloenzymes in the amidohydrolase superfamily.
Such enzymes exploit the Lewis acid properties of the cation,
decrease the pKa of water and generate a hydroxide nucleophile
to initiate catalysis [34,35]. They bind and polarize substrate
during an intermediate state in the catalytic cycle and generally,
then use an acidic glutamate or aspartate to donate a solvent-
acquired proton as the intermediate collapses to release products.
Examples of such metallohydrolases include type B β-lactamases
[28,36], phosphotriesterases [37], leucine aminopeptidases [38]
and dihydro-orotases [39]. Constant features of this superfamily
[34] include using an acidic component as proton donor and
the presence of flexible loops to engage with substrate are in
particular noted in the (β/α)8 triose phosphate isomerase-type
barrel structures. A relevant example actually occurs further
down in the kynurenine pathway, it is the enzyme α-amino-
β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD)
[40,41]. ACMSD possess a single Zn2 + ion co-ordinated by three
histidine residues and an aspartate. Other (β/α)8 barrel enzymes
such as specific phosphodiesterases and dihydro-orotases also
possess a carboxylated lysine, which binds two metal ions,
typically Zn2 + , holding them about 3.5–4.0 Å apart and with
enough room around the metal ions to allow for a co-ordination
increase from four to five or six in the intermediate state of
catalysis [34,35].
KynB immediately struck us as distinct with a binuclear Zn2 +
site, cations only 3.1 Å apart, which is closer than in other
cases, in a more crowded environment and with little scope to
increase the co-ordination number given that six co-ordinating
groups already surround each ion. This suggests then that
straightforward replacement of a co-ordinating water ligand might
be important. Furthermore, unlike other metallohydrolases where
conformational flexibility appears to be important [34,36,37], the
catalytic site of KynB is relatively rigid with an average thermal
parameter (B-factor) of 9.6 Å2 compared with an overall average
of 15.1 Å2 in BaKynB.
Based on the structural data and consistency with the
fluorescence measurements, we can now suggest a plausible and
distinctive mechanism (Figure 5). The fixed conformation of a
planar substrate would assist binding in the small rigid active
site cavity. His60, a strictly conserved active site residue, in
conjunction with the powerful Lewis acid activating binuclear
Zn2 + environment, is ideally positioned to acquire a proton
from the bridging water to generate a potent nucleophilic
hydroxide for attack at the carbonyl component of substrate.
Direct interaction between the substrate and Zn2 + as a catalytic
intermediate is formed would probably involve replacement of
weakly co-ordinated water assisted by interaction with Ser149.
The intermediate would collapse as His60, which in the complex is
3.6 Å from the 2-amino group of the ligand, donates the proton to
form the amine. The C–N bond breaks and products are released.
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Structures of bacterial kynurenine formamidase reveal a crowded binuclear
zinc catalytic site primed to generate a potent nucleophile
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Figure S1 XANES spectra
K -edge XANES spectra from BaKynB (A) and PaKynB (B) showing the anomalous scattering
factor f ′ and f ′′ values within a range of X-ray energy (from 9626.7 to 9690.14 eV).
Figure S2 Anomalous difference Fourier map for BcKynB
The map, blue chicken wire, is contoured at 6σ . Zn2 + and Cd2 + are shown as grey and purple
spheres respectively. Water molecules and glycerol have been omitted for the purpose of clarity.
1 To whom correspondence should be addressed (email w.n.hunter@dundee.ac.uk).
Atomic co-ordinates and structure factors have been deposited in the PDB under codes 4COG, 4COB, 4CO9 and 4CZ1.
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Figure S3 L-Kynurenine binding
Plot derived from fluorescence spectroscopy showing the percentage of active site saturation at different L-kynurenine concentrations.
Figure S4 2-Aminoacetophenone binding
Plot derived from fluorescence spectroscopy showing the percentage of active site saturation at different 2-aminoacetophenone concentrations.
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Figure S5 Omit difference density for 2-aminoacetophenone
The F o − F c omit map is shown as green chicken wire and contoured at 1.5σ .
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